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The Thirtieth Annual Meeting of the British Association for Cancer
Research and the Fourth Annual Meeting of the Association of Cancer
Physicians, 10-12 April 1989
Held at the University of Glasgow, UK.
Abstracts of Invited Papers
Symposium on 'Current Approaches to Cancer
Treatment and Patient Management' (ACP)
Intrahepatic arterial chemotherapy with cytotoxic drug
containing microspheres
D.J. Kerr
CRC Dept of Medical Oncology, University of Glasgow, UK.
Given the relative paucity of novel, active cytotoxic drugs, it
behoves us to optimise clinical usage of the currently avail-
able agents. The concept underlying regional chemotherapy
depends on the genesis of high drug concentrations in the
organ harbouring tumour deposits with a potential for
decreased systemic concentrations and hence toxicity. If the
drug was administered into an artery in microcapsular form,
there could be an additional arterial embolic effect. In
association with N. Willmott (Dept of Pharmacy, Strathclyde
University), C. McArdle and J. Goldberg (Dept of Surgery,
Glasgow Royal Infirmary) I have conducted a series of
pharmacokinetic studies of intrahepatic arterial 5-fluorou-
racil (5-FU) in combination with adriamycin loaded albumin
microspheres (1% drug w/w) in patients with colorectal
hepatic metastases. Treatment was administered via an intra-
hepatic arterial portacath with a subcutaneous administ-
ration port. Using 99TcN-labelled albumin microspheres it
has been possible to demonstrate that co-infusion of the
vasoconstrictor angiotensin II (10 Ig min-1 for 4 min)
significantly increases the delivery of microspheres to tumour
relative to normal tissue. Peripheral venous plasma concen-
trations of 5-FU are similar following bolus administration
by intravenous or intrahepatic arterial (+ microspheres and
angiotensin II) routes. There is a significant inverse corre-
lation between systemic clearance of 5-FU and white cell/
platelet nadirs. Subsequent studies showed that infusing
5-FU over 2h significantly reduced systemic concentrations
comparing lV and IA routes. The main problem with
albumin microspheres is the small drug payload (1% w/w)
and therefore we are continuing our studies with ethyl-
cellulose microspheres containing mitomycin C (60% w/w).
The principle of 'targeted' radiotherapy as illustrated by
experience with meta-iodobenzylguanidine
L.S. Lashford
The Imperial Cancer Research Fund & The Hospital for Sick
Children, London, UK.
The iodinated benzylguanidine mlBG is actively transported
into tissue of sympathetic origin, creating an opportunity for
selective radiation delivery to chromaffin tumours. The
success of this approach is dependent on differential dose
delivery to tumour sites and normal organs. Detailed
pharmacokinetic data has been obtained from studies in the
sub-human primate, the common marmoset, and children
with neuroblastoma. These studies demonstrate that the
compound undergoes a period of rapid renal excretion,
accounting for a mean of 13% -of the dose in the first 3h.
Uptake is invariably noted in myocardium, liver, and saliv-
ary tissue, resulting in an estimated mean whole body dose
of 0.4-0.5mGyMBq-1 (range 0.2-0.5) and.hepatic dose of
1.5mGyMBq-1 (range 0.2-4.6). Animal studies suggest that
whole body radiation dose delivery can be predicted within
+30 to -20% by tracer scintigraphy. This hypothesis is
currently being tested in the UKCCSG phase 1 of mIBG in
chemoresistant neuroblastoma. However, animal studies also
suggest that whole body radiation dose delivery may signifi-
cantly increase with repeat administrations of mIBG
(P=0.003). Mathematical modelling of these data, in combi-
nation with information on levels of isotope in resected
tumour, indicates that tumoricidal doses may be delivered in
some patients without marrow rescue. Strategies for improv-
ing tumour dose delivery are under investigation, and
include changing the isotope to Auger electron emitters (121I)
and alpha emitters (21'At) and by manipulating tumour
storage of the compound (e.g. calcium channel blockade).
These strategies will be discussed.
Intraperitoneal chemotherapy for minimal residual ovarian
cancer. Experience with cisplatin and carboplatin
W.W. ten Bokkel Huinink, R. Dubbelman, A. van Wijk,
E. Aartsen, J.G. McVie, H. Franklin, S. Rodenhuis &
W. v.d. Vijgh
The Netherlands Cancer Institute, Amsterdam; Free University
of Amsterdam, The Netherlands.
Intraperitoneal (i.p.) chemotherapy for cancer confined to
the abdominal space may have a pharmacological advantage
if, as has been shown in animal models, an increased dose
may indeed overcome secondary resistance, e.g. of ovarian
cancer to cisplatin. In order to test this hypothesis we treated
32 patients (pts) with i.p. cisplatin with doses of 60-
150mgm2 i.p. in 21 dialysis fluid. After a phase I study
with carboplatin which defined the maximum tolerated dose
as 700mgm 2, 28 pts were treated with 6 courses at a dose
of 650mgm 2. A Tenckhoff catheter was installed by
laparoscopy for the i.p. chemotherapy and fluid distribution
in the abdominal cavity was assessed after 6-10 days.
Pharmacokinetic studies revealed that indeed cisplatin and
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carboplatin given i.p. may reach 2-10-fold higher concent-
rations in the abdominal space than when given intra-
venously. The AUC-uf.p./AUC-uf.pr is 17%. The peritoneal
clearance of carboplatin is 3.3mlmin-1m .2 In patients
with minimal residual disease ovarian cancer, all having
undergone heavy pretreatment with cisplatin based chemo-
therapy, 10 out of 32 pts evaluable for response, who had
been treated with escalated doses of cisplatin i.p., reached a
complete remission (CR). Of 28 pts treated with carboplatin
only 3 reached a CR.
In conclusion, i.p. chemotherapy for tumours confined to
the abdominal space may indeed offer a pharmacological
advantage and have an increased therapeutic ratio. However,
this kind of treatment is cumbersome and should be still
regarded as experimental' Randomised studies for final proof
of the advantage of i.p. chemotherapy above continued
systemic treatment are in progress.
The role of growth factors in patient management
N. Thatcher
Christie and Wythenshaw Hospitals, Manchester, UK.
Haemopoietic growth factors (colony stimulating factors -
CSFs) have been known for many years to exert critical
effects on bone marrow precursor cells. Only recently with
the advent of recombinant DNA technology have sufficient
quantities of these factors - erythropoietin (EPO)
granulocyte-macrophage CSF (GM-CSF), granulocyte CSF
(G-CSF), macrophage CSF (M-CSF), interleukin-2 (IL-2)
and 3 (IL-3) - become available for preclinical testing. Some
of these EPO (GM-CSF, G-CSF, IL-2) have recently entered
clinical evaluation.
The myeloid CSFs, by increasing the number and func-
tional activity of granulocytes and macrophages in patients,
would be expected to counter infection and possibly have an
anti-neoplastic effect. Infusions of rG-CSF (without any
toxic side-effects) have been shown to restore functional
neutrophils in patients undergoing myelosuppressive chemo-
therapy for small cell lung cancer with consequent reduction
in severe infective episodes (Bronchud et al., Br. J. Cancer,
1987, 57, 809). Significant increases in total leucocyte, neu-
trophil and eosinophils have also been obtained with rGM-
CSF infusions with stabilisation and response of previously
progressing metastatic solid tumours (Steward et al., Br. J.
Cancer, 1989). However, GM-CSF in this study was asso-
ciated with pyrexia, bone pain and pruritus. Other clinical
applications of CSFs include: EPO, stimulating red cell
production in end stage renal failure, in chronic disease, e.g.
Rh, arthritis and in neoplasia; also at high dose, stimulation
of platelet production in marrow failure after chemotherapy.
The myeloid CSFs could be of use in marrow failure
(idiopathic, neoplastic, iatrogenic), improve host defence
after major trauma (burns), and also in the treatment of
established infections associated with leucopenia and/or
reduced myeloid function, e.g. in AIDS, post-chemotherapy
patients. Myeloid CSFs may also augment marrow recovery
after transplantation.
The therapeutic use of IL-2, the T-cell growth factor was
established by Rosenberg et al. (NEJM, 1987, 316, 889). The
use of high dose rIL-2 with or without LAK (lymphokine
activated killer) cells obtained by multiple leucophoresis, in
vitro incubation with rIL-2 and subsequent reinfusion,
resulted in tumour responses particularly in resistant meta-
static tumours, e.g. hypernephroma and malignant mela-
noma. Other schedules of rIL-2 (constant infusions, alternate
day administration without LAK cells) have been developed.
Tumour responses with rIL-2 have been confirmed by our-
selves and others in malignant melanoma and hyperne-
phroma.
This new era of oncology in which there is immuno-
therapy and the abrogation of chemotherapeutic induced
bone marrow suppression is one of the most exciting
developments in recent years.
The Bagshawe Lecture
(Sponsored by Upjohn UK Ltd)
While waiting for the human genome to be mapped
K.D. Bagshawe
Cancer Research Campaign Laboratories, Dept of Medical
Oncology, Charing Cross Hospital, Fulham Palace Road,
London W6 8RF, UK.
See full paper in this issue.
Symposium on 'The biological basis for breast
cancer treatment' (BACR/ACP)
Epidemiology of breast cancer as a guide to biological
understanding
P. Boyle
Unit of Analytical Epidemiology, International Agency for
Research on Cancer, 150 Cours Albert-Thomas F-69372 Lyon,
France.
Breast cancer is the commonest form of cancer occurring in
women throughout the world apart from skin cancers.
Although traditionally considered as a disease of advanced
lifestyle and affluence, developing countries are not spared
breast cancer, where it is estimated that over 14% of the
total cancer burden in 1980 comprised tumours in the breast.
In developed countries there are apparent inconsistencies
between incidence and mortality rates which could point to
important biological aspects of breast cancer which remain
to be unmasked by closer study. The suggestion from several
countries of downward tumours or stabilisations in breast
cancer risk among younger groups of women is one that
defies current knowledge of risk factors and requires close
surveillance. It is generally agreed that nulliparous women
have about a 50% excess of breast cancer over parous
women. An early age at first birth appears to confer
protection, while breast cancer risk appears to be increased
by an early age at menarche and a later age at menopause.
The risk of breast cancer seems to be increased by having
had a previous cancer in the contralateral breast or in the
ovary and seems to be reduced by having had a surgical
menopause at an earlier age. There is still lack of concor-
dance regarding the role of risk factors such as lactation,
oral contraception usage, first trimester abortion, dietary
consumption and alcohol use in the aetiology of cancer of
the breast. Hitherto, research for breast cancer risk factors
has almost exclusively focused on the function of the ovary
and related phenomena. The risk factors mentioned above
are almost certainly some proxy for the mechanism which
leads to the appearance of a clinical cancer. Despite exten-
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aetiology of breast cancer is unclear. Recent analyses of
breast cancer case-control studies reveal clearly that some of
the risk factors for breast cancer affect breast cancer arising
at different ages differentially. This will be illustrated by
recent data relating to age at first birth, parity and obesity.
Biological environment of the cancerous breast
D.P. Rose
Division of Nutrition and Endocrinology, American Health
Foundation, New York, USA.
The microenvironment of the breast cancer cell is derived
from contributions by the host, and by the tumour itself.
Nutrients are delivered via the circulation, together with
steroid and protein hormones, thyronines and other growth
factors. Fatty acids are metabolised 'on-site', including lino-
leic acid, which serves as a precursor for prostaglandin
synthesis, and influence cancer cell membrane fluidity, recep-
tor sites and cell proliferation. Although dietary fats may
promote breast cancer growth, those rich in omega-3 fatty
acids appear to have an inhibitory effect, perhaps because
they are inhibitors of the enzyme prostaglandin synthetase.
Adipose tissue is a major sjte for the conversion of Clg
steroids to oestrogens, and production of these mammary
cancer-stimulating hormones is increased in obesity, itself a
recognised risk factor for post-menopausal breast cancer,
and may also be enhanced in the cancer-bearing breast.
Breast cancer cells are frequently capable of performing the
metabolic interconversion of steroids, including both oestro-
gen synthesis and deconjugation to produce the biologically
active hormone. The synthesis of polyamines from ornithine
appears essential for the growth of cancer cells, at least in
rat mammary tumour models, perhaps because the poly-
amines regulate the production of tumour-derived protein
growth factors. The complexity of polypeptide growth
factors synthesised within tumour cells, and secreted into the
microenvironment, includes the transforming growth factor
(TGF)-a family, which are structurally related to epidermal
growth factor and bind to the EGF receptor, TGF-/, the
insulin-like growth factors, and platelet-derived growth
factor. As a clearer understanding of the biochemical inter-
relationships which create the biological environment of the
cancerous breast emerges, it offers exciting new approaches
to breast cancer therapy.
Growth factor receptor expression in human tumours
W.J. Gullick, F.J. Lofts, N.L. Tuzi, D.M. Barnes &
P. Quirke
ICRF Oncology Group, 3rdfloor, MRC Cyclotron Building,
Hammersmith Hospital, Du Cane Rd, London W12; ICRF
Oncology Unit, Guys Hospital, London SE]; Dept of
Pathology, University of Leeds, Leeds LS2, UK.
Examination of the mechanisms by which normal cells
regulate their growth, and comparison of these with those of
cancer cells, has revealed molecular changes which may
represent some of the fundamental causes of malignant
transformation. Tumour cells frequently produce polypeptide
growth factors in an apparently unregulated way which may
stimulate their own, or adjacent cells to grow. The receptors
for such factors are also frequently affected, either by
mutation or by greatly elevated levels of protein expression.
We have investigated the level of expression of one such
molecule, the c-erbB-2 protein, in a variety of human normal
and malignant tissues using immunohistological staining.
The c-erbB-2 protein is expressed on many normal tissues
including those derived from all three germ layers. Elevated
expression, generally as a consequence of gene amplification,
has been found in 10-30% of breast and stomach adeno-
carcinomas. The c-erbB-2 protein is also expressed in greater
than 90% of comedo type ductal carcinoma in situ but not
in other histological types of CIS. One consequence of this
change may be to accelerate the growth of such cells. This
event may have implications in diagnosis of early stage
disease, in prediction of disease progression and in tumour
response to drug treatment or radiotherapy.
An additional biochemical consequence of overexpression
of c-erbB-2 is reduction of gap junctional permeability which
could affect the response of such cells to other oncogenic
changes.
A model for the mechanism of growth factor receptor
activation will be presented.
Biological indices of progression in breast cancer
R. Leake
Department of Biochemistry, University of Glasgow, Glasgow
G12 8QQ, UK.
Several clinical features of breast cancer are known to give
good prognostic information (e.g. node involvement, disease-
free interval). Biological indices of prognosis have been
disappointing. Soluble oestrogen receptor (ER) status gives
some information about total survival but a proportion of
ER+ still relapse and die quickly. Combining soluble and
nuclear oestrogen receptor status gives much better prognos-
tic discrimination. Assessment of the heterogeneity of recep-
tor distribution further improves the discrimination. How-
ever, because of this heterogeneity, no one biological feature
is able to give a complete description of the growth potential
of an individual tumour. Presence of epidermal growth
factor receptor (EGF-R) is a positive indication of poor
prognosis though not all laboratories find the same prognos-
tic significance. Elevated levels of a-TGF are found in some
breast cancers and combining a-TGF levels with EGF-R
concentration may improve the prognostic discrimination.
Increased aneuploidy is associated with poorer prognosis.
Increased expression of the neu (erb B2) gene is observed in
a large proportion of ductal carcinoma in situ. This may be
an indication of those tumours which are likely to become
invasive. Amplification of the myc gene is also reported in
some breast cancers and may have significant prognostic
value. Overall, biological markers of prognosis are most
likely to be accurate when several independent markers are
measured on each tumour. Quantitation of markers should
include some measure of heterogeneity. Ideal markers will
work on paraffin embedded, fixed tissue or on representative
fine needle aspirates.
The 1989 Walter Hubert Lecture
Does biological understanding influence surgical practice?
R.W. Blamey
City Hospital, Nottingham, UK.
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Symposium on 'The molecular and cellular
biology of cell-cell interaction' (BACR;
sponsored by Bristol Myers Oncology UK
Ltd)
Junctional communication and cellular differentiation
J.D. Pitts, M.E. Finbow & E. Kam
Beatson Institute for Cancer Research, Garscube Estate,
Bearsden, Glasgow G61 JBD, UK.
Cytoplasmic continuity between adjacent cells in the tissues
of metazoan animals is provided by the aqueous channels of
gap junctions, sieve-like structures which are freely perm-
eable to small ions and molecules (Mr> 1000). Coupled cells
surrender independence through the coordinating effects of
shared intracellular pools of ions, metabolites, cofactors,
second messengers, etc., while retaining individuality through
the expression of different macromolecules. The junctional
channels are made of a tissue invariant, evolutionarily
conserved 16k protein but the formation and maintenance of
active coupling also requires one or more connexins, a family
of tissue-specific proteins ranging in size from 21k to 75k.
The connexins may interact with tissue-specific proteoglycans
and account for specificity of junction formation. Such
specificity leads to the production of communication com-
partments, groups of cells joined by junctions but separated
by reduced trans-boundary coupling from cells in adjacent
compartments. Such compartmentation occurs during
embryonic development, probably to allow the necessary
expression of cellular differentiation. The patterns of com-
munication have been mapped in detail in mouse skin, in
normal, in hyperplastic conditions and in tumours. The
results suggest that in small compartments, like those of the
epidermis, where only a proportion of the cells responds to a
systemic stimulus (e.g. growth factor) which affects activity
through second messengers, homeostatic pressure through loss
of second messengers into non-responding cells, produces a
modulating control related to compartment size. Such cell
interactions, within compartments and also between com-
partments, may provide a growth restraint for maintaining
the required cell numbers in different parts of a tissue.
Oncogene and growth factor activity in tumour initiation
promotion and progression
A. Balmain, B. Bailleul, S. White, A. Surani & J. Jorcano
carcinogen-specific mutations in the cellular H-ras gene. In
this case treatment with a tumour promoting agent is
necessary for the development of papillomas, but if the
mutant ras gene is present in all epidermal cells, as in
transgenic mice, the papillomas appear spontaneously. This
is compatible with models which suggest that tumour pro-
moters remove the growth inhibitory effects of normal cells.
The additional events required for progression to carcinomas
are unknown, but experiments using hybrid mice show that
progression is frequently accompanied by loss of alleles on
mouse chromosome 7. This may be associated with the
development of homozygosity at mutant ras alleles or the
loss of tumour suppressor genes.
Epithelial mesenchymal interactions in growth and
differentiation of normal and transformed skin keratinocytes
N.E. Fusenig, D. Breitkreutz & P. Boukamp
German Cancer Research Center, D-6900 Heidelberg, FRG.
Epithelial mesenchymal interactions are important regulators
in embryonic development and responsible for maintenance
of tissue homeostasis as well as its loss in carcinogenesis.
Differentiation and malignancy are complex tissue pheno-
mena which cannot be fully understood at the single cell
level. Model systems for mouse and human skin keratino-
cytes have been developed to analyse both processes under in
vivo and in vitro conditions providing also direct (cellular)
and indirect (factor-mediated) mesenchymal influence.
Normal epidermal differentiation strictly depends on mesen-
chymal signals irrespective of whether cell-cell contact is
permitted. But also malignantly transformed mouse keratino-
cytes can still be induced to re-express rather normal kerati-
nisation although subtle changes in the co-ordination of the
differentiation programme become apparent. These alter-
ations increase concomitantly with continued growth of
cancer cells in vivo leading to a dysplastic and eventually
invasive epithelium. These altered growth and differentiation
phenomena occur independently of direct epithelial mesen-
chymal contact and thus are most probably mediated by
diffusible factors. During early growth phases of malignant
keratinocytes these factors may still be competent for con-
trolling epithelial cell homeostasis comparable to the situa-
tion with benign tumour cells. Carcinoma cells, however, are
obviously capable of modulating these mesenchymal interac-
tions, leading to disturbances of tissue homeostasis and
eventually to invasion and progressive tumour growth.
Beatson Institute, Glasgow; IAPGR, Cambridge and Univ. of
Madrid, Madrid, Spain.
Among the most frequent molecular changes which have
been detected in human tumours are the activation of ras
genes by point mutations and the loss of heterozygosity at a
number of different chromosomal loci. It is extremely diffi-
cult with human tumours to evaluate the causal nature of
these events in tumour development, or to determine the
stage of carcinogenesis at which they occur. Mouse skin
carcinogenesis has been a valuable model system for the
study of these questions. It has previously been shown that
initiation of carcinogenesis can be induced by rare
The effect of surrounding normal cells on the growth and
behaviour of cells transformed by viral oncogenes
F. Tato
Dipartimento di Biologia Cgllulare e dello Sviluppo, Universita'
di Roma, 'La Sapienza', Roma, Italy.
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inhibited in vitro by surrounding normal cells, as long as the
latter display a high degree of contact inhibition and density-
dependent growth arrest. Cells transformed by v-ras and v-
src are insensitive to this inhibition. Tumorigenicity in nude
mice parallels this in vitro behaviour: v-myc transformed cells
do not produce tumours, whereas v-src and v-ras trans-
formed cells are strongly tumorigenic. When v-myc trans-
formed muscle cells are co-cultivated with appropriate
normal cells their growth is also inhibited and, furthermore,
there is re-expression of the myogenic differentiation
programme.
The behaviour of v-myc transformed cells thus resembles
that of hybrids between tumorigenic and normal human
cells. In these hybrids, studied by a number of groups,
abnormal in vitro growth persists but tumorigenicity is lost,
apparently in association with expression of the differen-
tiation programme of the normal parent. The two sets of
data suggest that an interaction with adjacent normal cells is
important in inhibiting the expression of the transformed
phenotype, both in vitro and in vivo.
The generation of invasiveness in transformed cells represents
an essential step of tumour progression
W. Birchmeier
Institut fur Zellbiologie, Universitdtsklinikum
Essen-Westdeutsches Tumorzentrum, Essen D-4300, FRG.
The generation of invasiveness in transformed cells repre-
sents an essential step of tumour progression. We show first,
that non-transformed MDCK epithelial cells become invasive
when intercellular adhesion is specifically inhibited by the
addition of antibodies against the cell-cell adhesion molecule
Arc-1/uvormorulin; the separated cells then invade collagen
gels and embryonal heart tissue. Second, MDCK cells trans-
formed with Harvey and Moloney sarcoma viruses are
constitutively invasive, and they were found not to express
Arc-i/uvormorulin at their cell surface. These data suggest
that the loss of adhesive function of Arc-l/uvormorulin
(which is identical to L-CAM or E-cadherin) is a critical step
in the promotion of epithelial cells to a more malignant, i.e.
invasive phenotype. Similar modulation of intercellular adhe-
sion might also occur during invasion of carcinoma cells in
vivo.
Role of proteoglycans and cell contact in stromal cell
interaction in haemopoiesis
M.Y. Gordon
The Leukaemia Research Fund Centre, Institute of Cancer
Research, 237 Fulhqm Road, London SW3 6JB, UK.
The idea that stromal cells are essential for the control of
normal haemopoiesis is generally accepted but poorly under-
stood. We have exploited the finding that blast colony-
forming cells (BI-CFC) in human marrow adhere to pre-
formed marrow-derived stromal layers in vitro and are
stimulated to divide. This allows investigation of binding
interactions between haemopoietic cells and stromal cells in
the haemopoietic microenvironment; and of any growth
factors that may be required for the proliferative response by
BI-CFC. The BI-CFC are primitive cells that are ancestral to
lineage-committed haemopoietic progenitors (Gordon et al.,
J. Cell Physiol., 1987, 130, 150). They bind to stroma via a
haemopoietic progenitor cell-adhesion molecule (HP-CAM)
which does not require serum or divalent cations but does
require heparan sulphate in the extracellular matrix (ECM)
produced by the stromal cells. The minimal integrin recogni-
tion sequence (RGD) is not necessary. HP-CAM is masked
by sialic acid or not expressed by more mature lineage-
committed cells. Proliferation by immobilised Bl-CFC might
be stimulated by growth factors sequestered by the ECM.
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) binds to glycosaminoglycans (Gordon et al., Nature,
1987, 326, 403) but not to heparin-sepharose to differing
extents. The different binding properties of haemopoietic
progenitor cells and of their corresponding growth factors
suggests that the ECM produced by stromal cells can present
growth factors to immobilised target cells. Binding interac-
tions with stroma are disrupted in leukaemia (Gordon et al.,
Nature, 1987, 328, 342). This abnormality may be related to
the accelerated release of malignant cells into the blood and
facilitate extramedullary haemopoiesis.
Abstracts of members' proffered papers
ACP-oral presentations
The natural history of low grade non-Hodgkin's lymphoma
(LG NHL) development of discrete prognostic groups
R. Leonard, L. Hayward, R. Prescott, N. Allan, S. Das,
A. Davison, H. Lucraft, J. MacGillviray, M. Mackie,
A. Parker, S. Proctor, G. Ritchie & T. Sarkar
Scotland and Newcastle Lymphoma Group (SNLG),
Edinburgh EH8 9AG, UK.
463 patients (pts) with working formulation LGNHL,
managed with conventional chemo and/or radiotherapy were
registered with the SNLG between 1979 and 1987. With a
median available follow-up of 4.5 years detailed analysis was
performed on pts aged <70 years with the aim of identifying
poor and good prognostic groups. A model was developed
using clinical haematological and pathological presentation
data. A test group (118 Edinburgh pts <70 years) was
excluded from the model and used to confirm its value.
Using Cox's proportional hazard model best survival was
confirmed to be in females aged 40 years with clinical stage I
disease and ECOG performance status (PS) 0. Risk of death
was increased by a factor of 5.8 for PS 3/4; by 3.8 for stage
III/IV; by 2.4 for stage II; by 2.3 for PS 1/2 and by 1.8 for
male sex. The age effect was complex, being worse by 2.16-
fold for each decade >40 and by 1.63 for each decade <40.446 THIRTIETH BACR AND FOURTH ACP MEETINGS
Thus using simple multiples of PS, stage, age and sex a
patient can be assigned to one of three prognostic categories
with very different median and long-term survivals. Tested
on the Edinburgh pts the best cohort of 25% have not
reached median survival (25% dead at 65 months, actuarial
5-year 83%). The worst cohort of 25% have median survival
37 months, actuarial 5-year 42%. Simple clinical features can
be appropriately weighted to provide valuable information
for the selection of patients with LG NHL for novel or
intensive therapies.
Recurrence with low grade follicular (LGF) histology in
patients previously treated for high grade (HG) non-Hodgkin's
lymphoma (NHL)
C.G.A. Price, J. Matthews, A.G. Stansfeld & T.A. Lister
ICRF, Department of Medical Oncology and Department of
Histopathology, St Bartholomew's Hospital, London ECIA,
UK.
A total of 1170 patients have been treated for NHL in this
department since 1972. A policy of rebiopsy before retreat-
ment in relapsing patients has been adhered to whenever
appropriate. This has enabled the identification of a group
of 7 patients in whom LGF histology has been found after
successful treatment of HG NHL. Six of these had presented
de novo with HG disease; they represented 7% of a total of
88 patients who relapsed after achieving remission of prim-
ary HG NHL. A single patient changed from HG to LGF
histology whose HG disease reflected blastic transformation
of previously treated LGF lymphoma.
These patients are important clinically because their
prognosis appears to be better than that of the majority of
patients relapsing after treatment of HG NHL, and may do
well with 'mild' chemotherapy. In this group 5/7 responded
to single agent chlorambucil and a further patient responded
to an adriamycin containing regimen. 4/7 survive 5 months,
1 year, 2 years and 4 years after diagnosis of LG disease. 3/7
died 9 months, 5 years and 8 years thereafter. They under-
line the value of rechecking histology at each relapse of
NHL.
That LGF disease can persist after elimination of a HG
component with intensive chemotherapy reflects the relative
'incurability' of the former histological subtype with conven-
tional treatment. Further investigation of this phenomenon
with cytogenetic and molecular techniques may throw light
on the mechanisms of histological progression in NHL
bearing the 14;18 translocation.
A comparative study of the nodular and diffuse variants of
lymphocyte predominant Hodgkin's disease
A. Borg-Grech, J.A. Radford, D. Crowther, R. Swindell
& M. Harris
Dept of Pathology, CRC Dept of Medical Oncology & Dept
of Medical Statistics, Christie Hospital, Manchester, UK.
Recent evidence has suggested immunophenotypic differences
between the nodular and diffuse variants of lymphocyte
predominant Hodgkin's disease (HD-LP). To see if these
differences are reflected in clinical behaviour we have studied
104 cases of HD-LP treated at this institute. At review, 69
cases had a nodular or mixed (N/M) histological pattern and
35 were diffuse (D). Gender was evenly distributed between
the two groups and median age was virtually identical (N/M
39 years, D 38 years). The majority of cases had stage I or II
disease (N/M 72%, D 65%), and a peripheral pattern of
nodal involvement with 90% of N/M cases and 94% of D
cases having cervical and/or axillary adenopathy at presen-
tation. 89% of patients achieved complete remission (CR)
and with a median follow up of 89 mths, overall survival
(OS) was 80% at 5 years and 75% at 10 years. For those
achieving CR, relapse-free survival (RFS) was 88% at 5
years and 78% at 10 years. No difference was observed
between the N/M and D subgroups for either OS (P=0.43)
or RFS (P=0.40), results which differ from those of the
Stanford Group (Regula et al., N. Engl. J. Med., 1988, 318,
214), who found that the N and D cases behaved differently,
with the former pursuing a chronic relapsing course akin to
low grade non-Hodgkin's lymphoma. Moreover, no signifi-
cant differences in either OS or RFS were observed when the
LP cases were compared with 134 cases of nodular sclerosing
and mixed cellularity histology matched for stage.
We conclude that the nodular and diffuse variants of HD-
LP have a similar natural history and, unlike Regula et al.,
we have not found histological pattern to be a strong
predictor of RFS.
Extended follow-up of the first UK Wellferon (WFN) study in
hairy cell leukaemia (HCL)
A.B.W. Nethersell, P. Bedford, D.A. Jones, M.K. Small,
J.M. Bottomley, J. Cawley, D. Catovsky & P. Bevan
(for the UK Group)
Wellcome Research Laboratories, Beckenham BR3 3BS, UK.
The first 50 consecutive evaluable HCL patients given WFN
(3MU daily or thrice weekly according to response and
tolerance) have now been followed up for median 122 (31-
160) weeks. They received a median WFN dose of 660 (42-
1900) MU over a median 67 (2-143) weeks. Overall res-
ponses according to international criteria (Golomb et al., J.
Clin. Oncol., 1986, 4, 900) were: CR 8, PR 31, PR (haemato-
logical) 7, MR 4. Kaplan-Meier estimates for achieving
stated peripheral blood indices on therapy and maintaining
these off therapy are shown in the table.
Probability of achieving or
maintaining level
On therapy Off therapy
(n=50) (n=39)
t=O t-= year t=O t=I year
HC=0 16% 96% 86% 29%
Hb)12gdl-1 14% 92% 90% 67%
Pl> 100+ 109l1-1 50% 98% 100% 91%
N > 1.5 x 109 1-' 12% 85% 89% 21%
MW0.1 x 1091-1 17% 88% 91% 20%
The high overall response was followed by clear evidence
of progressive relapse off therapy. Reinduction has, to date,
always been successful.
Sera from HCL patients in this (n=23) and a subsequent
(n= 12) study have been tested for neutralising antibodies by
bioassay. The median dose of WFN was 700 (24-2688) MU
over a median duration of 56 (1-174) weeks in these 35
patients, none of whom developed neutralising activity.THIRTIETH BACR AND FOURTH ACP MEETINGS 447
PCR used to detect dissemination in gastric lymphoma-
implications for treatment
D. Cunningham, T. Hickish, D. Rosin, P. Sauven, H. Baron,
P.J. Farrell & P. Isaacson
Ludwig Institute for Cancer Research, St Mary's Hospital,
London W2; Department of Histopathology, UCH and
Middlesex School of Medicine, London WI; St Mary's
Hospital, London, UK.
The polymerase chain reaction (PCR) permits the enzymatic
amplification of a target sequence of DNA and by the
selection of the appropriate oligonucleotides the method
should be sensitive enough to detect at least 1 in 105 cells
with the target sequence. In lymphoma, a target sequence for
PCR is the rearranged Bcl-2 gene which results from a
translocation between chromosomes 14 and 18 (tl4;18). This
translocation is found in over 90% of cases of low grade
non-Hodgkin's lymphoma (NHL) and up to 30% of inter-
mediate grade diffuse B-cell NHL. The incidence of the
translocation in gastric lymphoma is unknown. The gastro-
intestinal tract is the most common site of primary extra-
nodal lymphoma and prognosis is most closely related to the
stage of disease. The break-point in a patient with a stage I
gastric lymphoma was determined by restriction enzyme
digestion. Based on this localisation, oligonucleotide primers
were prepared which would permit PCR across break point.
Using PCR, malignant lymphoma cells with the Bcl-2 gene
rearrangement were found in the peritoneal washings taken 2
weeks after surgery and bone marrow of a patient who had
an apparently localised gastric lymphoma. Bone marrow and
peritoneal washings were cytologically normal. Following
four courses of cytotoxic drug therapy the cells could no
longer be demonstrated in either site.
This is the first time PCR has been used to demonstrate
malignant cells in peritoneal washings. PCR is a useful
addition to the staging investigations of non-Hodgkin's
lymphoma and can also be used to monitor response to
treatment.
Use of the polymerase chain reaction (PCR) in the diagnosis
of extra-nodal progression of follicular non-Hodgkin's
lymphoma (F-NHL)
C.G.A. Price, B.D. Young & T.A. Lister
ICRF Department of Medical Oncology, St Bartholomew's
Hospital, London ECJ, UK.
The technique of amplification of short segments of DNA by
means of the PCR is rapidly finding applications in the
investigation of genetic, neoplastic and viral diseases. In F-
NHL, which is associated with the 14;18 translocation in the
majority of cases, amplification of the 14;18 breakpoint
region can be used to demonstrate occult tumour cells within
pathological samples. A direct clinical application of this is
in the rapid diagnosis of F-NHL in situations where material
for morphological examination is unavailable or difficult to
interpret. Two illustrative cases are described. (1) A woman
of 48 with a 14 year history of recurrent F-NHL presented
with a pleural effusion. Pleural biopsy and cytology were
non-diagnostic. DNA from pleural mononuclear cells was
amplified using Taq polymerase and primers from JH region
of chromosome 14 and Bcl-2 gene on chromosome 18. A
single amplified product was identified by electrophoresis;
that this was the 14;18 breakpoint region was confirmed by
probing with a second JH region oligonucleotide. (2) A man
of 65 with persistent F-NHL confined to the bone marrow
developed raised red truncal skin lesions. Immuno-
phenotyping of skin biopsy showed aggregates of Bi positive
cells, but a definite morphological diagnosis of F-NHL was
not possible. PCR amplification of DNA was once again
positive; different primers were required in this case, indicat-
ing that the breakpoint occurred at a different site in the
major breakpoint region (mbr) of the Bcl-2 gene. The
rapidity of this technique (e.g. in comparison with gene
rearrangement studies), its sensitivity and the specific genetic
information obtained suggest that it will be of value in the
investigation of occult F-NHL.
A successful treatment for chemotherapy induced anticipatory
nausea and vomiting
M.A. Ratcliffe, L.G. Walker, A.A. Dawson, S.M. Pollet,
L. Hamilton & J. Lolley
Dept of Medicine and Dept of Mental Health, Royal
Infirmary, Aberdeen AB9 2ZB, UK.
In a previous retrospective study in Aberdeen of 84 patients
with lymphoma or teratoma the incidence of conditioned
nausea and/or vomiting was 41%.
Eighteen patients having cytotoxic chemotherapy who had,
despite anti-emetics, developed severe anticipatory symp-
toms, particularly nausea and vomiting, were treated by
nausea management training (NMT) during hypnotherapy
and relaxation sessions. This training, a form of behavioural
psychotherapy, involved helping patients to experience
nausea by appropriate imagery, then using direct suggestion
and gentle abdominal self massage to eliminate the nausea.
Symptoms were assessed sytematically by the physician at
the time of referral for NMT and at completion of chemo-
therapy and in all patients were found to have improved.
A prospective study was initiated with 69 newly diagnosed
lymphoma or teratoma patients about to have cytotoxic
chemotherapy. Using an 8 point scale each patient graded
the severity of their anticipatory and pharmacological symp-
toms after each pulse of treatment. Following the third pulse
patients were randomly allocated to three sessions of NMT
with hypnotherapy or relaxation, or to a control group.
Results recorded a low incidence of anticipatory symptoms,
at 14%, and there was poor compliance with NMT. Prophy-
lactic NMT was thus not evaluable. It is possible that the
intervention in undertaking the study influenced the inci-
dence of conditioning.
However, for these patients with anticipatory problems
hypnotherapy or relaxation with NMT has been proved to
be of benefit.
Efficacy and safety of three 6-hourly i.v. doses of 40pg kg-1
of granisetron in cytotoxic induced emesis
V. Raina, J. Cassidy, S. Kaye, M. Soukop & S. Thompson
Depts of Medical Oncology, Royal Infirmary/Western
Infirmary, Glasgow; Beecham Pharmaceuticals Ltd,
Research Division, Essex, UK.
Previous studies on granisetron, a new selective 5HT3 anta-
gonist, have demonstrated significant efficacy of a single i.v.
dose of 40 ig kg-1 for cytotoxic (including cisplatin)
induced emesis (Cassidy et al., Br. J. Cancer, 1988, 58, 651;
Carmichael et al., BMJ, 1988, 297, 110). The optimum dose
and scheduling of granisetron has not, however, been estab-
lished. This pilot study was undertaken to assess the efficacy
and safety of 3 doses of 40 ig kg 1 granisetron given i.v. at
6 hourly intervals, each by 30 min infusion. Chemotherapy
was started at the end of the first infusion. 23 of 25 patients
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drugs (6 platinum) completed treatment. Two patients deve-
loped rigors and pyrexia after the first dose of granisetron
and were withdrawn. Nine patients were naive to chemo-
therapy. Subjective and objective assessments of nausea,
vomiting and symptoms were done 6 hourly for the first 24
hours after the start of granisetron treatment. Subjective
assessment of efficacy continued for up to 6 more days.
Using subjective rating scales, 14 (1 cisplatin) out of 23
assessable patients recorded no vomiting during the first 24
hours. This was confirmed by objective assessment of vomit-
ing incidence. Of 19 patients assessable for nausea during the
same period, no nausea was seen in 9 (1 cisplatin), mild in 6
(2 cisplatin), moderate in 2 (2 cisplatin) and severe in 2 (0
cisplatin). Only 3 patients required a rescue antiemetic in the
first 24 hours. In a retrospective open comparison made
after the next chemotherapy session under conventional
antiemetic cover, 10 from 20 assessable patients (50%) (4
cisplatin) preferred granisetron, 3 (1 cisplatin) had no prefer-
ence and 7 (35%) (1 cisplatin) preferred a conventional
antiemetic. This study establishes the effectiveness of a total
of 120 jug kg-1 granisetron given in 3 divided doses in the
first 24 hours in cytotoxic induced emesis. Due to the
variation in time of onset of emesis with different cytotoxics,
the advantages of repeated dosing over single doses of
granisetron were not clear. One of the 2 patients who had
rigors had an infected Hickman line and the cause of the
untoward reaction in the other patient was not clear. The
safety of repeated dosing in 24 hours was also demonstrated.
A randomised trial of aminoglutethimide and hydrocortisone
(AG+ HC)Q aminohydroxypropylidene diphosphonate (APD)
in patients with advanced breast cancer
APD for the treatment of hypercalcaemia of malignancy
(HOM): a comparison of different doses and schedules of
administration
R.E. Coleman & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London SE1
9RT, UK.
APD is an effective treatment for HOM but the optimum
dose and schedule have not been defined. We have treated
43 patients with hypercalcaemia secondary to advanced
breast cancer with APD. Patients were hydrated with 4-6
litres of intravenous saline over 36-48 hours prior to treat-
ment with APD. 21 received a single 30 mg dose (study A)
but were randomised between a short (2 hours, 11 patients)
and long (24 hours, 10 patients) infusion time. 23 patients
received a single 15 mg dose over 2 hours (study B).
Additional doses of APD were permissible if the serum
calcium had not improved at 48 hours.
Thirty-seven patients (84%) achieved normocalcaemia with
a nadir in serum calcium and urinary calcium excretion at
5-6 days. Two patients died within 24 hours of APD
(1 lymphangitis, 1 myocardial infarction). Five patients
remained hypercalcaemic (1 study A, 4 study B). The time to
control hypercalcaemia and duration of normocalcaemia
were similar in both studies and uninfluenced by the
duration of APD infusion. The nadirs in serum calcium were
lower in study A but were identical for urinary calcium
excretion suggesting equivalent inhibition of bone resorption.
Three patients in study B required a second 15 mg dose of
APD to control the serum calcium. Additional doses were
not given in study A.
These results suggest that, in breast cancer, there is no
clear evidence of either a dose-response relationship,
between 15 and 30 mg, or of improved efficacy with a long
schedule of administration.
B. Cantwell, K.A. Mannix, J. Carmichael & A.L. Harris
University Dept of Clinical Oncology, Newcastle General
Hospital, Newcastle-upon-Tyne NE4 6BE, UK.
Diphosphonates can induce healing of bone metastases in
breast cancer, with sclerosis of lytic bone metastases. To
investigate the value of APD with a standard hormone
therapy in breast cancer we have performed a randomised
trial of AG+HC + APD in post-menopausal women with
breast cancer and skeletal metastases. All patients received
AG 125 mg bd and HC 20 mg bd continuously. Those
randomised to receive APD in addition had i.v. infusion of
APD 30 mg at 21 day intervals to a total of 12 infusions (i.e.
to 36 weeks). Assessment included serial clinical, scan, X-ray
and biochemical evaluations. Of the first 25 women ran-
domised, 5 had rapid disease progression and early death
and 1 patient was withdrawn because of AG intolerance. Of
the 19 remaining patients, 10 received APD in addition to
AG/HC. Radiological assessment of bone metastases showed
objective response in 4 patients (40%) in the APD group and
3 (33%) in the AG/HC alone group after 12 weeks' treat-
ment. At 24 weeks, 3 (30%) APD patients and 2 (22%) AG/
HC alone patients maintained this response. At 36 weeks the
response was continued among APD patients (30%) but
there were no continuing responders among the AG/HC
alone group. After 1 year, 3 (30%) APD patients have
continuing response in bone. The response in non-skeletal
sites of disease in patients receiving APD compared with
AG/HC alone was 40% and 22% respectively at 36 weeks
and 30% and 0 at 1 year. Preliminary analysis suggests that
short out-patient infusions of APD 30 mg contributes to the
efficacy of low dose AG+HC for patients with advanced
breast cancer and predominantly bone metastases. This effect
may be an enhancement of duration rather than rate of
response in the combined modality treatment group.
Primary medical therapy in operable breast cancer
J.L. Mansi, I.E. Smith, G. Walsh, H.D. Sinnett &
J.A. McKinna
The Breast Unit, Royal Marsden Hospital, Fulham Road,
London SW3 6JJ, UK.
Fifty-seven patients with large but potentially operable pri-
mary breast cancer were treated with chemotherapy (15) or
endocrine therapy (42) with the tumour remaining in situ,
and with the aim of avoiding mastectomy. For patients
treated with chemotherapy, 1 (7%) achieved a complete
remission and 8 (53%) a partial response (overall response
60%). The rest had either a minor response (2) or stable
disease (3), and one progressed on chemotherapy. For
patients who received endocrine therapy one (2%) achieved a
complete response, and 19 (45%) a partial response. Four
(10%) patients had a minor response, 17 (38%) no change
and 2 (4%) progressed whilst on therapy. Only 10 patients
have so far had a subsequent mastectomy (18%), and 17
(30%) have had radiotherapy and/or conservative surgery.
The rest are still on medical therapy.
With a median follow-up of 19 months (range 6-42) no
patient has developed uncontrollable local disease and only 2
(4%) have had a local recurrence after being disease-free.
Eight (14%) patients have developed distant metastases and
4 (7%) have died of metastatic disease.
Primary medical therapy followed by radiotherapy may
offer an effective alternative to mastectomy for the majority
of patients with breast carcinomas inappropriate for
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Identification of patients with poor prognosis stage II breast
cancer
S.M. O'Reilly, R.S. Camplejohn, A. Howell, R.D. Rubens &
M.A. Richards
ICRF Clinical Oncology Unit, Guy's Hospital, Richard
Dimbleby Dept of Cancer Research, St Thomas' Hospital,
London SE; and Christie Hospital, Manchester, UK.
Adjuvant chemotherapy improves the 5 year survival of
patients with breast cancer by approximately 3.5% (N. Engl.
J. Med., 1988, 319, 1681). Intensification of treatment might
improve the outcome for some subgroups, but carries the
risk of early treatment related mortality. Such treatment
might be justified for patients ages <60 years at high risk of
early distant metastases. The outcome for 341 patients aged
, 60 years in the Guy's/Manchester adjuvant CMF study
was reviewed in order to identify a subgroup with a 2 year
distant metastasis free survival (DMFS) <20%. DNA flow
cytometry was performed on tissue from Guy's patients with
> 10 positive nodes.
In premenopausal control patients, the 2 year DMFS of
patients with 7 positive nodes was <20%. Further analy-
sis based on age, tumour size, histological grade or steroid
receptor status identified no similar group in patients with 1-
6 positive nodes. Among postmenopausal patients aged <60
years, only the combination of >10 positive nodes and an S
phase fraction > the median selected a similar group. The 5
year survival of the combined pre- and postmenopausal poor
prognosis group (29 patients) was <20%.
Thirty-one patients with the same 'poor prognosis' presen-
tation features received CMF. When compared with their
controls, a significant improvement in both DMFS
(P<0.001) and survival (P<0.001) was seen, but the
actuarial curves show little, if any, evidence that this treat-
ment is curative.
This study indicates that 60/341 (17%) of patients aged
, 60 years with stage II breast cancer may be suitable
candidates for intensification of adjuvant treatment.
Two weekly high-dose doxorubicin therapy with infusions of
granulocyte colony-stimulating factor in patients with advanced
breast and ovarian cancer
M.H. Bronchud, A. Howell, D. Crowther, P. Hopwood.
L. Souza & T.M. Dexter
Christie Hosptial, Manchester, UK.
Granulocyte colony stimulating factor (G-CSF) was given to
17 patients with advanced breast and ovarian cancer in order
to increase the intensity and effectiveness of chemotherapy.
Treatment with doxorubicin, at doses of 75 mg m-2 (n=4
patients), 100 mg m-2 (n=5), 125 mg m-2 (n=6) and 150
mg m-2 (n=2), was followed by infusion of G-CSF for 11
days. G-CSF administration resulted in a return of the
absolute neutrophil count to normal and above normal levels
within 12-14 days at all dose levels of doxorubicin used and
allowed the administration of up to three cycles of high dose
chemotherapy at 14 day intervals. An absolute neutrophil
count >2.5 x 109 1-I was not reached until days 19-21 after
75 mg m-2 of doxorubicin given without G-CSF. At doses
of doxorubicin of 125 mg m-2 and 150 mg m-2 all tumours
regressed rapidly and the response rate was significantly
higher that at the lower doses (P<0.036), although there
was marked epithelial toxicity. Two months after doxoru-
bicin G-CSF therapy there was a pronounced improvement
of symptoms compared with before treatment. Thus the
effectiveness of chemotherapy may be enhanced and treat-
ment duration shortened by the use of G-CSF infusions.
Further studies of this promising approach are warranted.
High-dose melphalan with granulocyte-macrophage
colony-stimulating factor (GM-CSF) in the treatment of
metastatic colorectal carcinoma
W.P. Steward, J.H. Scarffe, K. Borkett, E. Bonnem &
D. Crowther
Dept of Medical Oncology, Christie Hospital, Manchester,
UK; and Schering Corporation.
Nine patients (pts) with metastatic disease from primary
colorectal carcinoma were entered into a phase I/II study
using continuous intravenous (i.v.) infusions of GM-CSF
and high-dose melphalan (120 mg m-2). GM-CSF was given
alone during the phase I part of the study to determine a
dose that would produce a leucocyte count (WBC)
>50 x09 1-1 and was initially given at 3 jg kg-1 day-1
and escalated to 10 jg kg-1 day-1 after 10 days. The
infusion was discontinued at WBCk50 x 109 1-1 and 1 week
later melphalan was given i.v. over 30 minutes. GM-CSF
was recommenced 8 hours later at the endpoint dose deter-
mined from the phast I part of the study and was continued
until the neutrophil count recovered to >0.5 x 109 1-1 for 7
consecutive days.
One patient achieved a WBC>50 x 109 1-1 with GM-CSF
at 3 jg kg 1 day 1 in the phase I part of the study but the
other pts required 10 jg kg-1 day-1. No toxicity attribu-
table to GM-CSF was seen. After melphalan, the median
times to neutrophil and platelet counts <500 x 109 1-1 and
<20 x 109 1-1 respectively were 6 and 8 days. The median
durations of neutropenia (<500 x 109 1-1) and thrombo-
cytopenia (<20 x 109 1-1) were 15 and 10 days respectively.
All pts required intensive support with a median duration
inpatient stay of 28 days. There was 1 treatment related
death due to renal failure. One complete response and 2
partial remissions (33% response rate) were seen but these
were of short duration (median 2 months).
This study suggests that GM-CSF given by continuous i.v.
infusion is associated with no toxicity and produces signifi-
cant WBC increments at a dose of 10 jg kg- day-. The
duration of neutropenia and thrombocytopenia induced by
high-dose melphalan appear to be reduced by subsequent
administration of GM-CSF when the results of this study are
compared with the published literature.
A pilot study of high dose busulphan with autologous marrow
rescue in myeloma
M. Harding, C. Viner, I. Judson, M. Gore, B. Millar &
T. McElwain
Institute of Cancer Research, Royal Marsden Hospital,
Sutton, Surrey, UK.
We have initiated a pilot study of high dose busulphan with
autologous marrow rescue in myeloma, as in vitro data
suggest that lymphoplasmacytoid clonogenic cells are more
sensitive to busulphan than melphalan. To date, 7 pts have
been treated (median age 52 years, range 37-59). All had
previously responded to VAMP (vincristine 0.4 mg+adria-
mycin 9 mg m-2 infused over 24 hours for 4
days+methylprednisolone 1.5 g orally days 1-5: q 21 days)
with high dose melphalan (200 mg m-2) in 6 patients. At the
time of treatment 5 had disease refractory to
VAMP+cyclophosphamide, the other 2 had relapsed after
partial remissions of 2 and 4 months. Busulphan 1 mg kg-l
was given orally 6 hourly for 4 days with continuous
intravenous sodium bicarbonate and prophylactic phenytoin.
Cryopreserved bone marrow was returned on day 7. The
median duration of WHO grade IV leucopenia and
thrombocytopenia was 17 days (ranges 10-30 and 4-70 days
respectively); 1 pt died from intracranial haemorrhage on
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day 26. Oropharyngeal mucositis (grade II-IV) occurred in
all pts and CNS toxicity was common (1 grand mal convul-
sion, 3 severe motor restlessness and agitation).
Three pts had transient (<2 month) reduction in para-
protein and 1 had symptomatic improvement. Two have
partial remissions (PR: reduction in paraprotein to <50%,
clearing of Bence Jones proteinuria) and 1 had a late
paraprotein fall, insufficient as yet to qualify as PR. The
preliminary results are encouraging and accrual continues.
Treatment of advanced ovarian cancer using high-dose
melphalan with autologous bone marrow transplantation
R.J. Osborne, P.I. Clark, C. Price, M.L. Slevin &
T.J. McElwain
Imperial Cancer Research Fund Department of Medical
Oncology, Homerton and St Bartholomew's Hospitals,
London; and Royal Marsden Hospital, Sutton, UK.
For patients with ovarian cancer which is recurrent after or
refractory to first line chemotherapy, the outlook with
conventional chemotherapy is bleak. Accordingly we have
investigated the activity of high-dose chemotherapy with
melphalan, supported with autologous bone marrow
transplantation, in advanced ovarian cancer. Ten patients
were treated, with a mean age of 47.5 years (35-54) and
median Karnovsky status 80% (50-90%). One patient had
stage III disease and 9 stage IV. All patients had bulky (>2
cm) disease. Four patients had been previously treated with
high-dose cyclophosphamide and cisplatin, 3 with carbo-
platin, 1 with platinum, adriamycin and cyclophosphamide
and 2 patients had had no prior treatment.
Priming with 300 mg m-2 cyclophosphamide was followed
1 week later by intravenous high-dose melphalan 200 mg
m 2. Bone marrow, harvested immediately before high-dose
melphalan, was refrigerated and then reinfused 8 hours after
treatment.
Five of 10 patients (1 previously untreated) responded to
treatment (1 clinical CR, 4PR). Median duration of
remission was 4 months (4-11 months). Median survival
after high-dose melphalan was 8.5 months (0.5-26 months).
Two patients died within 1 month of treatment from infec-
tion. Haematological toxicity was severe. Patients had a
mean time of 18.8 days (12-41) with WCC<1 x 109 P1 and
23.5 days (16-61) with platelets <50 x 109 1-1. Nine patients
developed pyrexia >38.5°C requiring intravenous antibiotics.
Although high-dose melphalan with autologous bone
marrow transplantation achieves useful remissions in some
patients in this poor prognosis group, the short duration of
remission and marked toxicity renders it unsuitable for
general use in previously treated patients.
Randomised trial of oral verapamil with chemotherapy for
non-small cell lung cancer (NSCLC)
M.J. Millward, P.A. Corris, A.L. Harris & B.M.J. Cantwell
University Dept. of Clinical Oncology, Newcastle General
Hospital, Newcastle-upon-Tyne NE4 6BE; and Cardiothoracic
Centre, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN,
UK.
The calcium channel blocker Verapamil can reverse multi-
drug resistance (MDR) in vitro. To test the clinical value of
this concept we have treated 37 patients with locally
advanced or metastatic NSCLC who were chemotherapy
naive with Ifosfamide/Mesna 5 g m2 +Vindesine 7 mg total
and either oral verapamil 160 mg t.d.s. for 72 hours
commencing 24 hours prior to chemotherapy or no addi-
tional treatment. Vindesine was given by bolus intravenous
(i.v.) injection and Ifosfamide by 24 hour i.v. infusion with
concomitant Mesna. Courses were repeated every 3 weeks to
a maximum of 6. The response rate is 31% in the verapamil
arm and 22% in the no-verapamil arm (n.s.) and the median
survival 41 weeks versus 27 weeks. There was no significant
difference in survival between those who received verapamil
and those that did not (log-rank test P=0.14). In patients
with metastases or local recurrence (n= 13) there was a
trend toward better survival in patients who received
verapamil (log-rank test P=0.06). There was one probable
treatment related death (infection without myelo-
suppression). WHO grade 3 or 4 myelosuppression occurred
in 4 patients with one episode of sepsis. Reversible Ifosfa-
mide encephalopathy occurred in 4 patients. One patient
who received verapamil developed grade 4 ileus, and
asymptomatic first degree heart block was noted in one
patient receiving verapamil. The addition of verapamil to
chemotherapy in NSCLC does not appear to improve res-
ponse rates suggesting that verapamil, in the doses given
orally, does not circumvent MDR. However, a possible
positive effect on survival in patients with metastatic disease,
suggests that verapamil may have other effects in NSCLC.
Accrual of patients continues.
Intermittent high dose tamoxifen (HDT) with oral etoposide
(EPO): phase I and II clinical studies
B. Cantwell, J. Carmichael, M.J. Millward, M. Chatterjee &
A.L. Harris
University Dept of Clinical Oncology, Newcastle General
Hospital, Newcastle-upon-Tyne NE4 6BE, UK.
To circumvent multidrug resistance (MDR) in malignant
tumours, patients (pts) with progressive cancers poorly
responsive or resistant to conventional therapies were treated
with HDT 120 mg daily plus EPO 300 mg daily, both drugs
for 3 days, repeated at 21 day intervals. Of 18 pts so treated
1 pt with mesothelioma had a partial response (PR) and 3
others (2 with lung cancer and 1 with soft tissue sarcoma}
had stable disease (SD) >3 months. Broad phase II evalu-
ation has occurred in >60 pts with HDT 320 mg daily for 6
days plus EPO 300 mg daily on days 4, 5 and 6 only, and
cycles were repeated at 21 day intervals. Of 46 pts so far
evaluable for response there were 1 complete response (CR)
and 1 SD in 2 pts with gastric cancer, 1 CR, 1 PR and 1 SD
in 6 pts with soft tissue sarcoma, 1 PR in 3 pts with non-
small cell lung cancer, 1 PR in 3 pts with melanoma and 1
PR and 3 SD in 7 pts with platinum analogue resistant
ovary cancer. Six other patients had SD and 29 pts had PD.
Toxicity overall was mild with WHO grade 3 or 4 myelo-
suppression in only 4 pts, but alopecia was common. There
were 2 pts with marked visual disturbances and 3 with
thromboembolism, possibly therapy related. 2 pts disconti-
nued because of tamoxifen related emesis, and there was 1
possible allergic event. Parallel laboratory experiments using
tamoxifen to reverse resistance in MDR Chinese Hamster
ovary cell mutants and estimation of plasma tamoxifen levels
in patients have been performed and these laboratory corre-
lates will be presented. Continued tumour specific phase II
and also randomised studies are indicated in soft tissue
sarcoma, melanoma and gastric, non-small cell lung and
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A pilot study of epiruhicin and quinidine in advanced breast
cancer
R.D. Jones, E.M. Rankin, T. Habeshaw, A.N. Harnett,
S.B. Kaye, D.J. Kerr, J. Plumb, S. Rae, R. Rampling,
N.S. Reed & S. Stallard
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
Tumour cell resistance to anthracyclines limits the effective-
ness of these drugs in breast cancer. Quinidine at a concent-
ration of 6.6 pmol is capable of increasing by 10-fold the
sensitivity of the multidrug resistant breast cancer cell line
MCF-7 to adriamycin.
Twenty-five patients have entered a feasibility study com-
bining oral quinidine with epirubicin 100 mg m-2 as first
line chemotherapy for advanced breast cancer. A maximun
of 8 cycles were given, the first without quinidine. To
achieve steady state levels quinidine durules were given 4
days prior and continued 1 day following epirubicin admi-
nistration. Three patients received quinidine at a dose of 1 g.
b.d.:2 developed symptoms of cinchonism and 1 nausea and
vomiting. Of 8 patients treated with 500mg b.d., 2 exper-
ienced tiredness and nausea and 1 developed severe oral
toxicity with epirubicin. Quinidine 250 mg b.d. has been well
tolerated by 13 patients. Epirubicin induced toxicity was not
significantly increased. Mean nadir WBC with epirubicin was
1.5 x 109 1-1 (range 1.1-2.5) and with epirubicin/quinidine
was 1.5 x 109 1-1 (range 1.0-2.7). There was no evidence of
significant cardiac toxicity as judged by 12 lead ECG, 24
hour ambulatory monitoring and echocardiography. Plasma
quinidine levels were assayed at the time of epirubicin
infusion and the mean value was 7.4 imol 1-1 (range
3.5-14).
We conclude that at a dose of 150 mg b.d. quinidine
plasma levels similar to those active in vitro can be achieved
with minimal toxicity. A prospective randomised trial of
epirubicin vs epirubicin and quinidine in advanced breast
cancer will commence shortly.
The analgesic activity and pharmacokinetics of
morphine-6-glucuronide in man
R.J. Osborne, M.L. Slevin, S.P. Joel, D.M. Trew,
P.I. Thompson & J.S. Malpas
Imperial Cancer Research Fund Department of Medical
Oncology, St Bartholomew's and Homerton Hospitals,
London ECIA 7BE, UK.
Morphine-6-glucuronide (M6G), a natural morphine (M)
metabolite, posesses analgesic activjty in animals, its potency
exceeding that of M. We have investigated the clinical
activity and pharmacokinetics (PK) of synthetic M6G in
man to determine the likely contribution of this abundant
metabolite to the analgesia occurring after conventional M
treatment. Synthetic M6G (1 mg ml-1 in 0.9% saline) was
administered intravenously (i.v.) at a dose of 1 mg 70kg- 1 to
10 cancer patients with moderate to severe pain. Pain relief,
defined as a sustained improvement of 2 points or more on a
4 point pain scale (none =0, mild = 1, moderate =2,
severe=3) was assessed. Cardiorespiratory function and sub-
jective symptoms were monitored. 8/9 assessable patients
experienced pain relief, the median duration being 6 hours
(range 1-18 hours). There were no clinically significant
cardiorespiratory effects or other adverse effects. Plasma
M6G PK were examined using an HPLC method (J.
Chrom., 1988, 430, 394) in 6 patients.
Normal (n=4) Renal impairment (n=2)
Creat. cl.
(mlmin- 70kg-1) 76+15 24+9
M6G cl.
(mlmin 170kg1) 99+11 31+8
M6G AUCo.00
(nmol-I h-170kg-1) 346+40 1,106+301
Renal dysfunction impaired M6G elimination. No M or
M3G were identified in plasma or urine. The M6G AUCoG00
after 1 mg 70 kg 1 i.v. M6G was similar to that previously
observed after i.v. or oral M treatment at a dose 10 mg 70
kg-' (Proc. ASCO, 1987, 6, 1077). Six further patients
administered M6G at a dose of 2 mg 70 kg-' intravenously
also experienced pain relief. None of the patients studied at
the higher dose experienced any clinically significant cardio-
respiratory effects or other adverse effects. These findings
clearly indicate that M6G is a narcotic agonist in man, and
strongly suggest that the metabolite contributes considerably
to the clinical effects seen after M treatment.
The effect of age and obesity on the pharmacokinetics of
ifosfamide
M.J. Lind, J.M. Margison, T. Cerny, N. Thatcher &
P.M. Wilkinson
CRC Dept of Medical Oncology; Dept of Clinical
Pharmacology, Christie Hospital and Holt Radium Institute,
Manchester, M20 9BX, UK.
The pharmacokinetics single agent intravenous ifosfamide in
patients with carcinoma of the bronchus were studied to see
if they correlated with age or obesity. A positive correlation
between age and half life (tl/20) was demonstrated (r=0.48,
0.01 <P<0.054-. The increase in elimination half life was
attributed to an increase in the volume of distribution of
ifosfamide (Vd,B) with age (r=0.48, 0.01 <P<0.05).
Correspondingly total clearance and non-renal clearance of
ifosfamide did not alter with age. In obese patients the
terminal elimination half life (t1/2P) was found to be higher
than ih the control group (6.36 hours (range 5.77-7.45) vs
4.95 hours (range 1.82-6.48), P.<0.05). The volume of
distribution (Vd,B) in the obese group was 42.81 (range
35.49-51.90) vs 33.70 (range 17.76-50.62), P<0.05. There
was no significant difference in total plasma clearance
between the obese and normal groups. The volume of
distribution (Vd,B) correlated with both total body weight
and percentage of ideal body weight but not with ideal body
weight. When Vd,B was normalised for ideal body weight
there was a strong positive correlation with percentage ideal
body weight, suggesting that ifosfamide will distribute into
the total body weight in excess of the ideal body weight.
Carboplatin: what is the right dose?
E.M. Rankin & J. Paul
CRC Department of Medical Oncology, Beatson Oncology
Centre, Western Infirmary,for Scottish Ovarian Cancer Study
Group.
The dose limiting toxicity of carboplatin (JM8) is myelo-
suppression. We have compared JM8 400 mg m2 i.v. alone
(arm A) with a combination of JM8 300 mg m-2 and
chlorambucil 10 mg daily x 7 days (arm B) every 28 days for
6 courses as first line therapy for ovarian cancer. The dose
for each course was adjusted according to the nqdir count of
the previous course. If the nadir white count >4 x 109 1-1
and platelets > 120 x 109 1-1 dose of JM8 was increased to452 THIRTIETH BACR AND FOURTH ACP MEETINGS
500 mg m-2 arm A, and 375 mg m-2 in arm B. If the nadir
white cell count <l x 109 P1 or the platelets <25 x 109 1-I
JM8 was reduced to 300 mg m-2 in arm A and 225 mg m-2
in arm B and chlorambucil to 10 mg day-l for 5 days for all
subsequent courses. The dose received for the third course of
therapy (when the majority of dose adjustments had been
made) was compared with that calculated according to the
various formulae for JM8 which depend upon renal function
and pretreatment platelet count (Egorin et al., Cancer Res.,
1985, 45, 6502; Fish et al., Proc. ECCO, 1987, 215) or renal
function and AUC (Calvert et al., Proc. ASCO, 1987, 645).
We found substantial differences between dose given accord-
ing to our protocol and that indicated by the available
formulae. Up to 60% of patients received more than the
indicated dose; 41% arm A and 20% arm B received >100
mg more than indicated dose. Preceding myelosuppression
led to dose reduction, 34% arm A and 20% arm B received
> 100 mg less than indicated dose. Our data show there is
considerable inter-patient variability in the handling of JM8.
Provision for dose escalation as well as reduction allows
maximum safe dosing of JM8 alone or in combination. If
tumour response correlates with dose intensity of JM8 (as it
does fox cisplatin) then it will be important to optimise dose
in the individual patient.
Pharmacokinetics of repeated antibody therapy
R.H.J. Begent, J.A. Ledermann, A.J. Green, S.J. Riggs,
S.E. Dewhurst, A. Kelly, D.B. Smith, C. Massof,
M.G. Glaser, R.G. Dale & K.D. Bagshawe
Cancer Research Campaign Laboratories, Charing Cross and
Westminster Medical School, London W6 8RF, UK.
Antibody targeted therapy of cancer is limited to one or two
repeated doses because of production of human antibody
directed against xenogeneic antibody or the conjugated
therapeutic agent. Cyclosporin A has been shown to prevent
or delay anti-antibody production and permit repeated
therapy (Ledermann et al., Br. J. Cancer, 1988, 58, 654). The
purpose of this study was to investigate the distribution of
radiolabelled antitumour antibody in tumour and normal
tissues with repeated therapy. Six patients with carcino-
embryonic antigen (CEA) producting tumours received 2-4
(mean 3.3) doses each of 5-7.5 mg mouse monoclonal
antibody to CEA (A5B7) labelled with approximately 50
mCi iodine 131. Cyclosporin A 25 mg kg-l day 1 by mouth
for 6 days with each dose of antibody was given to 3
patients, the remainder had 15 mg kg-1 day-1 continuously.
Human antimouse antibody production was suppressed by
these regimens. Serial estimations of radioactivity were made
in tumour, blood, liver and lung by gamma camera imaging
with single photon emission tomography (Riggs et al., Int. J.
Cancer, 1988, Suppl. 2, 95). The percentage of injected
activity in tumour and normal tissues showed no significant
difference between the first and subsequent doses of anti-
body. The rates of clearance from tumour and normal
tissues did not vary significantly with each repeated dose.
The results suggest that the effect of antibody targeted
therapy can be augmented by repeated therapy provided that
anti-antibody production is prevented.
Use of CA125 to predict survival of patients with ovarian
carcinoma
G.J.S. Rustin, J.N. Gennings, A.E. Nelstrop,
H. Covarrubias, H.E. Lambert & K.D. Bagshawe
CRC Lab., Dept of Medical Oncology, Charing Cross
Hospital, London W6 8RF; and Dept of RTOP &
Oncology, Hammersmith Hospital & Mount Vernon Hospital,
London, UK.
The prognostic value of serum CA125 measurements was
assessed in 54 patients with advanced ovarian adeno-
carcinoma. They all received a minimum of two courses of
carboplatin as part of the North Thames Cooperati'e Group
Trial. With a minimum follow up 14 months, 37 (69%) have
clinical evidence of progressive disease. The absolute pre-
chemotherapy level of CA125 was of no value in predicting
those patients who have developed progressive disease. How-
ever, the change in CA125 levels from immediately prior to
chemotherapy to one month later, after one course of
carboplatin could be used to divide patients into different
prognostic groups. The best discrimination was found by
dividing the patients into those who showed a greater than
7-fold decrease in CA125 levels and those who showed a
smaller change. Eight of 14 (58%) patients with a greater
than 7-fold decrease in CA125 levels remain disease free
compared to 3 of 36 (9%) patients with a lesser fall
(P=0.0005). The change in CA125 levels during the first
month of chemotherapy may indicate which patients should
be offered alternative or symptomatic therapy and which
patients should continue with the currently available toxic
chemotherapy.
The use of early serum CA125 response in the management of
epithelial ovarian cancer
C.W.E. Redman, G. Blackledge, E.J. Buxton, D.M. Luesley
& K.K. Chan
West Midlands CRC Clinical Trials Unit, Queen Elizabeth
Medical Centre, Birmingham B15 2TH, UK.
Despite the advent of active chemotherapy in epithelial
ovarian cancer (EOC), not all patients respond to treatment
and in some responding patients the duration of response is
short-lived, failing to justify the toxicity and disruption in
the quality of life that such treatment can entail. The
monitoring and assessment of response in EOC can be
difficult, but serum CA125 may facilitate an early appraisal
of response and identify those patients unlikely to derive
benefit from continued intensive chemotherapy. Serum
CA125 levels were measured in 50 EOC patients, receiving
first-line cisplatinum based chemotherapy, prior to treatment
and after 2 cycles of treatment. Subject to response (assessed
by UICC criteria) and toxicity patients received up to 8
courses of treatment. The overall response rate was 76% and
median survival for the group was 16.4 (95% CI=9.8-23.0)
months. Median time on-study was 25 (95% CI =23-25)
months; range= 14-32 months. An initial univariate analysis
of prognostic variables, including serum CA125 levels before
treatment and after 2 courses, and % fall in serum CA125
levels was performed. In this analysis a cut-off point of 30 U
ml-' for CA125 values, and multiple cut-off points (25-90)
for % fall were used. On the basis of this analysis, residual
disease, and serum CA125, both prior to treatment and after
2 courses, were significant prognostic variables, of which the
second serum CA125 value was the most important. Patients
with a second serum CA125 <30 U ml-I were more likely to
achieve a complete remission (X% = 17.8; P<0.0001) and
survived significantly longer (X% = 11.1; P=0.0009) than
patients with elevated levels. Because of the potential inter-
relation of these and other factors, a stepwise discriminant
analysis was performed using a survival at 12 months after
primary surgery as the end point. Serum CA125 (loge
transformed) after 2 courses of treatment gave the greatest
discrimination between patients who were alive or dead at 12
months. No other variables could significantly improve
predictive accuracy. Using the classification function derived
from this analysis, it was possible to predict correctly 85%
of patients who would be dead at 12 months, and 96% of
survivors (an overall predictive accuracy of 93%). These
results indicate that serum CA125 levels after only 2 courses
of treatment can identify good and poor prognostic groups
of patients enabling timely and appropriate changes in
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Chemotherapy type and good performance status improve
response in patients with recurrent cervical cancer
J. Buxton, R. Coleman, K. Towlson, P. Harper,
E. Wiltshaw, J. Dunn, C. Redman & G. Blackledge
West Midlands CRC Clinical Trials Unit, Queen Elizabeth
Hospital, Birmingham; and Department of Medical Oncology,
Guy's Hospital, London, UK.
Response rates in phase II trials of chemotherapy regimens
in advanced and recurrent cervical cancer have varied con-
siderably. Despite the development of active regimens the
duration of response in the majority of patients is usually
short although useful palliation of disease related symptoms
may be achieved. In a small but significant group of
patients, who achieve a complete response, survival may be
improved. Chemotherapy also has potential for up-front use
in advanced and bulky early stage disease. High activity
chemotherapy is associated with considerable toxicity. A
method of identifying patients likely to respond to chemo-
therapy would be a considerable advance in the treatment of
this disease. To determine which if any factors predicted for
response and survival an analysis of 171 patients with
advanced or recurrent cervical cancer treated in five phase II
studies was carried out. The regimens were all based on
Ifosfamide (I) (5gm 2 over 24 hours or 7.5gm-2 over 5
days) either alone or in combination with bleomycin (30 mg)
and/or cisplatin (50mgm 2). Seventy-one patients had single
agent I, 49 had B, I and P, 44 had I and P and 7 had B and
I. Parameters included in the analysis included initial FIGO
stage, histological type and grade, chemotherapy regimen,
age, sites of disease, previous irradiation, performance status
and time to relapse. Univariate analysis revealed that the
likelihood of response to treatment was increased by good
performance status at study entry and chemotherapy type
(BIP>IP>I>BI) (P=0.0004 and P=0.006 (X2 for linear
trend)). Patients who responded survived significantly longer
than those with stable or progressive disease. The only other
factor associated with survival was performance status on
study entry (P<0.007). These data indicate that patients
with WHO performance status less than two on commencing
chemotherapy are significantly more likely to respond to
chemotherapy and survive longer than those with a poorer
performance status. The data also suggest that, in patients
with recurrent disease, combination chemotherapy does not
confer a survival benefit when compared to single agent
treatment.
Intensive weekly chemotherapy for good prognosis patients
with small cell lung cancer (SCLC)
D. Miles, P. Harper, H. Earl, R. Souhami, S. Spiro,
R. Rudd, J. Tobias, L. James & K. Ash
Guy's Hospital, London SEJ; University College Hospital,
London WCJ; The Brompton Hospital, London SW6; and
London Chest Hospital, London E2, UK.
In an attempt to increase the efficacy of chemotherapy in
SCLC we have adopted a weekly, intensive, alternating
regimen, similar in principle to that used in non-Hodgkin's
lymphoma (Klimo & Connors, Ann. Intern. Med., 1985, 102,
596). Treatment consisted of cisplatin 50 mg m2 i.v. DI
with Etoposide 75mgm-2 i.v. Dl +2 alternating weekly with
Ifosfamide 2 gm-2 i.v. x 1 and Adriamycin 25mgm-2
i.v. x 1, with six courses of each being given over a total of
12 weeks.
74 patients in the good prognosis category (normal bio-
chemistry, ECOG 0 or 1) have been entered onto the study.
42 patients have completed treatment and are assessable for
response and toxicity (31 limited disease, 11 extensive dis-
ease, median age 61 years, range 41 to 75). Overall response
rate is 38/42 (90%). CR is 23/42 (55%), PR 15/42 (35%).
Progression free interval is 46 weeks, median survival has
not been reached.
From a total of 467 courses given the number of indivi-
dual courses complicated by WHO grade 3 or 4 toxicity
were; nausea+vomiting, 26 (5.5%), mucositis, 1 (0.2%),
leucopenia 55 (12%), thrombocytopenia, 4 (1%), anaemia 16
(3.5%). 70% of patients required red cell transfusion.
Weekly myelosuppressive chemotherapy is possible in
SCLC. The overall and complete response rates are high. CI
toxicity is manageable and haematological toxicity is predict-
able. A randomised trial comparing this regimen with a 3
weekly alternating schedule has begun.
A randomised trial to examine the effect of more extended
scheduling of etoposide administration in small cell lung cancer
(SCLC)
P.I. Clark, M.L. Slevin, S.P. Joel, P. Thompson, D. Talbot,
C. Price & P.F.M. Wrigley
Imperial Cancer Research Fund Department of Medical
Oncology, St Bartholomew's and Homerton Hospitals,
London ECIA 7BE, UK.
Etoposide is a schedule-dependent drug, as clearly demon-
strated by the superiority of 5 consecutive daily infusions
over a 24-hour infusion in patients with SCLC (ASCO 1986,
5, 175). A randomised trial has therefore been conducted
comparing a more extended 8-day regimen with the 5-day
schedule. 77 patients with SCLC (50 ED, 27 LD) were
randomised to receive single-agent etoposide 500mgm 2,
either as 5 daily 2 hour infusions of 100mgm-2 day-I or as
8 daily 75-minute infusions of 62.5mgm-2 day -'. Both
regimens were repeated every 3 weeks for 6 cycles. Single
agent carboplatin was given at relapse in both arms of the
study. Patients were stratified at randomisation according to
their LD/ED status and Karnofsky performance score. No
patients have been excluded from analysis. Median follow up
time is 24 months. The high single-agent activity of etopo-
side in untreated patients with SCLC is confirmed. The 5-
day and 8-day regimens are equivalent in their activity in
SCLC. There was less bone marrow toxicity in the 8-day
regimen but more patients with CNS relapse.
5-day 8-day
Extensive disease (n) 25 25
Response rate (%) 72 80
Remission duration (months) 4.7 5.6
Survival duration (months) 7.0 9.1
Median Karnofsky status (%) 60 70
Limited disease (n) 14 13
Response rate (%) 85 93
Remission duration (months) 5.0 5.8
Survival duration (months) 12.5 11.5
All patients
Median day 14 neutrophils, 1st cycle
(1091-1) 0.8 P<0.05 1.7
CNS relapse 5 P<0.05 14
Planned versus as required chemotherapy: final report of a
randomised trial in small cell lung cancer (SCLC)
H.M Earl, R.L. Souhami, C.M. Ash, L.E. James, R. Rudd,
S.G. Spiro, D.M. Geddes, J.S. Tobias & P.G. Harper
Dept. of Oncology, Univ. Coll. & Middlesex School of
Medicine; Brompton Hospital; London Chest Hospital;
and Guy's Hospital London, UK.
Two different approaches to palliative chemotherapy were
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received the same chemotherapy (cyclophosphamide 1 gm-2
day 1, vincristine 2mgday 1, etoposide 120mgm 2 i.v. day
1, 100mg orally b.d. days 2, 3) but were randomised to
either planned chemotherapy every 3 weeks, or to as
required (PRN) chemotherapy, given only when there was
disease progression, or for symptomatic control. Both groups
of patients were assessed 3 weekly. A maximum of 8 cycles
were given.
300 patients were randomised up to September 1988. In
PRN patients the median treatment-free intervals were 42
days and did not decrease in those who continued to receive
chemotherapy. PRN patients received approximately half the
number of courses of chemotherapy as the planned patients.
Overall survival of the PRN patients was not significantly
worse than that of the planned patients. Patients with a
longer first treatment-free interval survived longer than those
with a short interval. Quality of life assessment was made
using daily diary cards. In the categories of sickness, appe-
tite, pain, sleep, mood and general 'well-being' the PRN
patients consistently scored themselves as having more severe
symptoms than the planned patients (P<0.001).
The policy of as required chemotherapy is shown to result
in less drug treatment for approximately equivalent survival.
However, it is not preferred by patients.
Bone marrow involvement (BMI) by small cell lung cancer
(SCLC) using magnetic resonance imaging (MRI)
D.N. Carney, 0. Redmond, P. Harford, J. Stack & J. Ennis
Departments of Medical Oncology & Radiology, Mater
Misericordiae Hospital, Eccles St., Dublin 7, Ireland.
We have used MR to image the BM of 38 patients with
SCLC. Coronal images were obtained of the femoral and
pelvic marrow with a 1.5 T Magnetom superconducting
magnet system using both Ti weighted (500/17) and T2
weighted (2000/80) spin echo sequences. Discrete foci or
patchy areas of altered signal intensity were indicative of
marrow abnormality. Results using MR were compared with
other staging procedures including CT scan chest and abdo-
men, radionuclide bone scan, chest X-ray and unilateral BM
aspirate and biopsy. BMI was detected using MRI in 19/38
(50%) of patients compared to 2/38 (5%) using standard
criteria: in no instance was pathology positive and MRI
negative. Among the 38 patients studied, 24 patients had
limited stage disease (LD) and 14 patients extensive stage
(ED) using standard staging procedures. However, when
MRI and BM was included, of the 24 patients with LD, 10
(41%) were now considered to have ED. With combination
chemotherapy, resolution of BMI was detectable with MRI.
Early CNS relapse was noted in 5/8 patients with LD but
who had positive BM MRI. These data suggest: (1) BMI by
SCLC can be detected with MRI; (2) the incidence of BMI
by SCLC is significantly greater when MRI is used; (3)
treatment responses in BM can be monitored using MRI; (4)
involvement detected by MRI may predict for early CNS
relapse in LD patients.
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Treatment of myeloma relapsing after high dose melphalan
with continuous infusion vincristine, adriamycin + wonal
methylprednisolone (VAMP) followed by a second.high
dose melphalan
M. Harding, M. Gore, I. Judson, C. Viner, P. Selby,
A. Nandi & T. McElwain
Institute of Cancer Research, Royal Marsden Hospital,
Sutton, Surrey, UK.
High dose melphalan (HDM: 140 mg m -2) produces
remission in 80% of patients (pts) with previously untreated
myeloma. On relapse, pts have received vincristine 0.4
mg+adriamycin 9 mg m-2 over 24 hours for 4 days with
methylprednisolone 1.5 g orally days 1-5 (VAMP: q 21 days)
with or without cyclophosphamide (c: 500 mg weekly)
followed by melphalan 180-200 mg m2 with autologous
marrow rescue. To date 23 pts have received a second
HDM, with an adequate bone marrow harvest (BMH) in 22
pts and ongoing myeloma precluding BMH in 1. Their
median age was 45 years (range 26-61). There was 1 fatal
septicaemia during 2nd HDM pancytopenia. Fourteen pts
responded to VAMP +C and a further 7 to HDM giving a
total response rate of 91%. HDM also converted 4 VAMP
±C partial to compelte remissions. Thus a minimum 48%
(11/23) of pts with HDM sensitive myeloma at presentation
relapse with HDM sensitive disease.
The median duration of first CR was 15 months (range 4-
51) and of PR was 20 months (8-42). Eleven patients have
relapsed following 2nd HDM and median duration of
second remission is currently 12 months. For patients in
whom direct comparison can be made between durations of
1st and 2nd remission, 50% (6/12) had a longer 2nd
remission: only 1 of these had VAMP + C resistant disease
whereas 5/6 pts with shorter 2nd remissions failed to respond
to VAMP + C. Thus, although dose escalation ofmelphalan
from 140 to 200 mg m-2 is feasible, the relative contribu-
tions of a melphalan dose response effect and VAMP + C
sensitivity to prolongation of 2nd remission remains to be
clarified.
Alfacalcidol as a treatment for low grade non-Hodgkin's
lymphoma
V. Raina, D. Cunningham, N. Gilchrist, R. Cowan
& M. Soukop
Department of Medical Oncology and Department of
Biochemistry, Glasgow Royal Infirmary, Glasgow G4 OSF,
UK.
Alfacalcidol has been shown to prolong survival in mouse
leukaemia induced by inoculation of leukaemic cells. Malig-
nant and activated T and B lymphocytes have alfacalcidol
receptors which are not found on resting lymphocytes. Many
malignant cell lines respond to alfacalcidol with inhibition of
replication and stimulation of differentiation. Thirty-four
patients with progressive low grade (28 follicular small
cleaved and 7 small lymphocytic) were treated with 1 ug of
oral alfacalcidol daily. Complete remission was seen in four
patients and partial remission in four more, the overall
response rate being 23.5%. Disease stabilised in ten patients
(29.4%). No response was seen in 16 patients (47%). Three
patients who relapsed after discontinuing alfacalcidol res-
ponded again after exposure to alfacalcidol. All patients who
had initially responded to alfacalcidol but relapsed later,
responded to chemotherapy subsequently. Four of the res-
ponders to alfacalcidol had previously received chemo-
therapy. 1,25 (CH)2D3 receptors were measured from lymph
nodes in 11 patients. No correlation was found between the
presence of receptors and response to alfacalcidol. Treatment
was well tolerated, apart from transient reversible hyper-
calcaemia in two patients.
Results suggest significant activity of alfacalcidol in a
selected group of low grade non-Hodgkin's lymphoma
patients with the additional advantage of absence of side
effects of chemotherapy. Further research is required to
define exactly the mechanism of action and to compare the
use of alfacalcidol with other presently available treatment
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Predicting survival in high and intermediate grade
non-Hodgkin's lymphoma (HIG NHL)
L. Hayward, R. Leonard, R. Prescott, N. Allan, S. Das,
A. Davison, H. Lucraft, J. MacGillivray, M. Mackie,
A. Parker, S. Proctor, G. Ritchie & T. Sarkar
Scotland and Newcastle Lymphoma Group (SNLG),
Edinburgh EH8 9AG, UK.
1,130 patients (pts) with working formulation high or inter-
mediate grade NHL, treated with conventional chemo-
therapy and/or radiotherapy were registered with the SNLG
between 1979 and 1987. With median available follow-up of
4.5 years, detailed analysis was performed on all patients
<70 years with the aim of identifying poor and good
prognostic groups for future therapy studies. The prognostic
model was developed using clinical, haematological and
pathological data. One test group (202 Edinburgh pts ages
<70 years) was excluded to provide a test group for the
subsequent model. Using Cox's proportional hazard model
best survival was seen in young pts of performance status
(PS) 0 with clinical stage I or II disease without liver
involvement or weight loss, and with histology other than
DUL. Relative risk of death at any time was increased by a
factor of 3.0-fold for PS 3-4; 1.9-fold for liver +ve; 1.9-fold
for DUL; 1.8-fold for PS 1-2; 1.7-fold for white cell count
<4 x 109 1-; 1.4-fold for stage II, III, IV; 1.4-fold for
weight loss; 1.22-fold for every decade. Knowing pathology,
weight loss and liver status, simple multiples of PS, stage,
age and WBC enable the physician to assign a patient to 1
of 3 distinct prognostic groups. The best cohort (25%) have
plateau survival of 66% at 5 years in the test group, the
worst 25% <5% survival at 5 years (median survival 12
months). Apart from being valuable in future selection of
patients for novel therapies these data imply that patient
selection may have been very important in determining long
term results of previous therapeutic studies in HIG NHL.
A randomised comparison of low and high dose dexamethasone
in combination with haloperidol and lorazepam for control of
chemotherapy-induced vomiting
R. Coleman, Z. Doran, J. Clarke, E. Black, C. Twelves,
S. O'Reilly, L. Fleming, M. Richards, R. Rubens
& P. Harper
ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.
Combination antiemetic regimens have resulted in improve-
ments in chemotherapy-induced nausea and. vomiting even
though the contributions of individual drugs are often poorly
defined. However, most studies focus on cisplatin (DDP)
induced vomiting and antiemetic management of non-DDP
chemotherapy, particularly in the outpatient setting, has
been somewhat neglected.
61 patients received the antiemetic combination halo-
peridol (S) 3 mg p.o., lorazepam (A) 2 mg p.o. and
dexamethasone (D) 5 mg or 20 mg i.v. (double-blind
randomisation, parallel design). SAD was given immediately
prior to chemotherapy except for DTIC or mustine contain-
ing regimens (given > 1 hours before) and outpatient treat-
ments (A taken on reaching home). The doses of S and A
were reduced in patients >70 years and/or <50 kg, 14
patients received DDP-based regimens and 47 non-DDP
based chemotherapy but including highly emetogenic agents.
Assessment of efficacy was by a patient-completed diary
recording nausea (N), vomiting (V), appetite, drowsiness and
acceptability of treatment.
Severity of nausea
None A little A lot Continuous
Non-DDP n=47 (%n) 40 30 19 11
DDP n=14 (%n) 0 29 14 57
D 5mg n=28 (%n) 29 32 7 32
D 20mg n=33 (%n) 33 27 27 12
Episodes of vomiting
None 1-2 2-4 >4
Non-DDP n=47 (%n) 49 34 6 11
DDP n=14 (%n) 0 43 7 50
D 5mg n=28 (%n) 36 32 4 29
D 20mg n=33 (%n) 39 39 9 12
The SAD combination was a safe, practical and effective
antiemetic regimen for emetogenic outpatient chemotherapy.
It was inadequate for DDP-based chemotherapy. There was
no clear difference in efficacy between patients receiving 5
and 20 mg of D although severe nausea and/or vomiting
were more common with the lower dose (P<0.05). Drowsi-
ness occurred in 92% of patients but only 10% found this
unacceptable. Efficacy in non-DDP based chemotherapy was
maintained during subsequent courses.
A single injection of the 5HT3 antagonist BRL43694A
protects against emesis and would be ideal for outpatient
chemotherapy
D. Cunningham, A. Turner, S. Isles, C. Coulter, H. Thomas,
D. Rosin, G. Glazer, R. Witherow & M. Snell
Ludwig Institute for Cancer Research, St Mary's Hospital
Medical School and St Mary's Hospital, London W2, UK.
This is a report of the use of single injection of BRL43694A
at 40 ig kg-1 i.v. over 30 minutes as an anti-emetic in
patients naive to chemotherapy. The dose scheduling was
selected on the basis of the long plasma half-life (10 hours)
and preliminary information showing that the compound
may have a clinical effect for up to 24 hours as demon-
strated by the flare inhibition model. The patients consisted
of 11 males and 6 females, mean age 64 years. Ten were
receiving combinations which included cisplatin at a dose of
>50 mg m-2 and the remainder were receiving emetogenic
combinations including Doxorubicin and cyclophosphamide.
Assessment of emesis control was performed on an inpatient
basis for the 24 hours after chemotherapy. During this time,
11 patients experienced no nausea, vomiting or retching and
received no additional anti-emetic therapy (7/10 receiving
cisplatin regimens and 4/7 receiving rton-cisplatin regimens).
The remaining 6 patients developed nausea or vomiting
between 2.5 and 14 hours after chemotherapy. In no case did
the number of episodes of vomiting exceed 4 in the first 24
hours. There were no adverse events reported. In particular,
patients did not experience sedation headache or extrapyra-
midal side-effects. BRL43694A is a well tolerated effective
anti-emetic against cytotoxic drug-induced emesis including
regimens which contain cisplatin. The very favourable side-
effect profile and the 24 hour protection after a single
injection indicates it will be of particular value in outpatient
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Analysis of prognostic factors for response and survival in
advanced breast cancer patients receiving first line
chemotherapy (CT)
A. Bowman, S.G. Allan, G. White & R.C.F. Leonard
Imperial Cancer Research Fund Medical Oncology Unit; and
Scottish Cancer Trials Office, Western General Hospital,
Edinburgh EH4 2XU, UK.
This paper is an analyis of potential prognostic factors for
response and survival in patients (pts) receiving 1st-line CT
for relapsed or metastatic breast cancer. 237 pts were
studied, median age 50 (26-80), 48% premenopausal, distri-
bution of disease at CT: soft tissue alone 32%, bone + soft
tissue 14%, visceral + any other site 54%. 14 pts remained
alive at analysis. Prognostic factors analysed were age,
menopausal status, ER status of primary, disease-free inter-
val (DFI), response to prior endocrine therapy, distribution
of disease and number of sites involved at CT. Overall
response rate to CT was 44%; factors predictive of response
were age (45-64 vs <45 or >64, P=0.05) and use of
doxorubicin-containing CT vs other CT (P=0.006). Median
survival from CT was 10.03 months (0.25-104 months).
Survival was significantly shorter in pts with visceral disease
(lung, liver, marrow, CNS) vs non-visceral (P=0.006), and in
those with multiple vs one site of involvement (P=0.0004).
Within these categories, long DFI (>20 months) signifi-
cantly improved survival. No other factors influenced survi-
val from CT. Only patients with 1 site of disease (usually
soft tissue) and DFI >20 months are likely to have relatively
long survival from CT (median 22.5 months vs 9.4-10.7
months for all other categories).
A phase I/II evaluation of a novel oral formulation of APD
for the treatment of bone metastases
R.E. Coleman, P.J. Woll & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.
The bisphosphonate APD (Pamidronate) is a potent inhibi-
tor of osteolysis. It is the most effective agent for the
treatment of hypercalcaemia of malignancy and repeated
intravenous administration may promote bone healing and
reduce the morbidity of skeletal metastases (Coleman et al.,
Br. J. Cancer, 1988, 58, 621). In the past the use of oral
APD has been limited by upper GI intolerance due to the
drug's corrosive properties. We have tested a novel effer-
vescent formulation of oral APD (provided by Ciba-Geigy
Pharmaceuticals).
Eleven patients (pts) with bone metastases from breast
cancer have been studied. Ten pts had evidence of increased
osteolysis (urinary calcium excretion >0.4mmolmmol creat-
inine-1). The first four pts were treated with 150mg daily
for 4 weeks. Subsequent cohorts of 4 pts received 300mg
and 450 mg daily. Dose escalation within pts was allowed
only after completion of four weeks treatment at a constant
dose. Pts were assessed weekly for toxicity and biochemical
response.
APD was tolerated without toxicity up to a dose of
450mg a day. In two pts dose escalation to 600mg a day
resulted in unacceptable nausea, vomiting and indigestion.
All pts showed a fall in urinary calcium excretion to within
the normal range during the first two weeks of treatment
indicating adequate absorption of APD and inhibition of
bone resorption at all dosages. Serum calcium fell signifi-
cantly but remained within the normal range.
Effervescent oral APD inhibits bone resorption secondary
to breast cancer at doses which are non-toxic. Studies of
long-term tolerance of oral APD and its use as an adjunct to
sytemic treatment are now indicated.
The importance of serum aspartate aminotransferase (AST)
in breast cancer patients with liver metastases
S.M. O'Reilly, C.J. Twelves, M.A. Richards & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London
SE] 9RT, UK.
We have studied the significance of AST-measurements in
breast cancer patients with liver metastases. The relationship
between AST at diagnosis of liver metastases and subsequent
survival was investigated retrospectively in 312 patients.
Changes in AST occurring during chemotherapy were stu-
died prospectively in 36 patients receiving weekly epirubicin.
263/312 (84%) patients had an elevated AST at diagnosis
of liver metastases. There was no difference in survival
between patients with normal AST and those whose AST
was 1-2 x normal (P=0.23). Marked elevation (>2 xnormal)
of AST was, however, an adverse feature (P<0.001) and,
within this group, further elevation of AST was strongly
associated with a progressively worse prognosis (P<0.001
trend test). Multivariate analysis of clinical and biochemical
features at diagnosis of liver metastases showed AST to be
the most significant variable predicting survival.
Serial measurements of AST from patients receiving
weekly epirubicin 25 mg m-2 were analysed. All patients
had a pretreatment AST >2xnormal. In the 11 patients
who had an objective response to treatment, two patterns of
change in AST were observed: (a) 7/11 showed steady
improvement in AST while (b) 4/11 showed an initial
deterioration of >25% in AST during the first month of
treatment, with subsequent improvement as chemotherapy
continued. In all, 4/20 patients whose AST deteriorated
during the first month of treatment subsequently had an
objective response.
We have found AST at diagnosis to be the most signifi-
cant single predictor of survival in patients with breast
cancer and liver metastases. An initial deterioration in AST
during chemotherapy does not preclude a subsequent
response.
Toxicity of intra-arterial doxorubicin (DOX) in patients with
locally advanced breast cancer (LABC)
C.J. Twelves, M. Chaudary, J. Reidy, R.D. Rubens &
M.A. Richards
ICRF Clinical Oncology Unit and Dept of Radiology, Guy's
Hospital, London SE 9RT, UK.
In patients (pts) with LABC chemotherapy reduces, but does
not eliminate, local recurrence. Intra-arterial (i.a.) chemo-
therapy may increase local drug delivery and enhance cell
kill making subsequent local treatment more effective.
We have studied i.a. DOX in pts with inoperable LABC.
Under local anaesthetic a catheter was introduced percutan-
eously via the femoral artery and positioned in the internal
mammary artery. The area to be perfused was imaged by a
radionucleide perfusion scan. Treatment was with DOX 30
mg m-2 by 6 h i.a. infusion on 2 successive days. A second
course of i.a. DOX and 2 intravenous (i.v.) courses were
planned after which pts were to be graded as operable or
inoperable.
Four pts were treated. In each pt the catheter was
positioned without complications. Within 48 h of starting i.a.
DOX, all 4 developed extensive erythema (WHO grade 1)
over the chest wall corresponding to the area shown by the
perfusion scan. In 1 pt this progressed to superficial ulcer-
ation (grade 3). Erythema resolved in the remaining 3 pts
over 1-2 weeks, but 1 pt had a persistent area of increased
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radiotherapy. 2 pts developed a raised hemidiaphragm and
phrenic nerve paralysis. The incidence of systemic side-effects
was similar to that expected after i.v. administration. No pt
received more than I course of i.a. DOX because of the
unacceptable local toxicity. After 3 further courses of i.v.
DOX, 2 pts were operable, but 2 were not.
We conclude that although pts with LABC can be treated
with i.a. DOX, the toxicity of this schedule is unacceptable.
The study closed prematurely, and therefore we cannot
assess the activity of DOX given in this way. If this
approach to local control is to be studied further in LABC,
lower DOX doses of different drugs should be used.
Mitozantrone (M) and prednimustine (P) in advanced breast
cancer (BC)
M.E.R. O'Brien, D.M. Eccles, S.G. Allen, G. Knight,
A. Rodger, J.F. Smyth & R.C.F. Leonard
Imperial Cancer Research Fund Medical Oncology Unit and
Radiation Oncology Unit, University Department of Clinical
Oncology, Western General Hospital, Edinburgh; Scottish
Cancer Trials Office; University Department of Clinical
Surgery, Longmore Hospital, Edinburgh, UK.
Two phase II studies of M+P reported response rates of
around 50% in patients with advanced BC. In this trial
either 3 or 9 courses of M+P were given to patients with
advanced BC (no prior chemotherapy). M was given as
12mgm2 on day 1 with P orally 130mgm 2 days 1-5
repeated 4 weekly. Thirty-four patients were treated. The
median age was 58 years (range 34-73). Performance status
was 0-1 in 26 patients and 2 in 4. Locoregional disease only
was present in 13. Nine had lung involvement, 8 liver, 3
bone and 1 stomach. Nine patients had received no prior
hormone therapy. Median disease free interval from initial
diagnosis was 24 months (range 0-144). 14/23 patients had
an oestrogen receptor level of >20ffmol. Two patients are
non-evaluable for toxicity or response (disease related
deaths). Three others are non-evaluable for response due to
progressive disease (PD) after one course. 25/34 patients
received >3 courses. Nine patients had grade 2 or more
neutropenia with 2 major infections and 1 minor. There was
1 grade 1 thrombocytopenia. Only 6/29 patients had no
nausea or vomiting, 14 had grade 1 and 8 patients had grade
2-3. Four patients had grade 2 alopecia. 29 are assessible for
response. There was 1 CR and 2 PR both in soft tissue and 1
PR in soft tissue and lung. There were 4 minor responses:
one in stomach, 2 PR in soft tissue with SD in liver and lung
and 1 SD in soft tissue and an improved bone scan. 14
patients had stable disease after 3 courses, 6 of these lasting
>5 months. 11 patients had PD.
The low response rate (14%, 95% confidence intervals
6-35%) is not accounted for by patient selection. One
possibility is the relatively low dose - intensity of M
compared to the usual dose of 14 mg m-2 3-weekly (i.e.
64% of the usual dose).
Mitomycin C and vincristine in advanced pre-treated breast
cancer
M.J. Millward, A. Hendrick & B.M.J. Cantwell
University Department of Clinical Oncology, Newcastle
General Hospital, Westgate Road, Newcastle-upon-Tyne
*NE4 6BE, UK
We have treated 30 heavily pre-treated patients with
advanced breast cancer (median prior chemotherapy regi-
mens 2; median prior hormone therapies 2) with mitomycin
C 10 mg total and vincristine 2 mg total every 3 weeks to a
maximum of 4 cycles. Objective responses were seen in 4
patients (complete response (CR) 2, partial response (PR) 2),
9 patients had static disease (SD) and 14 progressive disease
(PD). Three patients are not evaluable for response. The
overall response rate was 15% (95% CI 4-33%). Three
responding patients had CR, PR and SD respectively to
prior doxorubicin therapy, but none had responded to
previous mitoxantrone. Response durations were CR -15
weeks and 16+ weeks, PR -26 weeks and 29 weeks and 4
patients with SD had progression free intervals of >24
weeks. The overall median survival was 35 weeks. Haemato-
logical toxicity consisted of 5 patients requiring dose
reductions and/or delays because of WHO grade 1 or 2
myelosuppression. One patient was withdrawn because of
persisting thrombocytopenia after one cycle of therapy and
another patient had persisting thrombocytopenia after 4
cycles of therapy. No grade 3 or 4 haematological toxicity
and no renal or hepatic toxicity was seen. Five patients had
peripheral and/or autonomic neuropathy requiring cessation
of vincristine. Treatment was stopped in one patient because
of grade 3 vomiting and in another because of generalised
herpes zoster in the absence of myelosuppression.
Low dose, short course mitomycin C and vincristine is a
well tolerated regime with moderate activity in this poor
prognosis group of patients.
Phase 1 trial of GR63178A
J. Cassidy, C. Lewis, A. Setanoians, L. Adams, D.J. Kerr,
A.H. Calvert, G.W. Brown, A.J. Pateman, E.M. Rankin &
S.B. Kaye
CRC Dept of Medical Oncology, Glasgow University, UK;
Royal Marsden Hospital, Sutton, UK; Glaxo Group Research,
Greenford, UK.
GR63178A is a water-soluble analogue of mitoquidone, the
first of a new group of pentacyclic pyrroloquinones deve-
loped as potential antitumour agents. It has preclinical
activity in a range of solid tumours, but not in P388 or
L1210 leukaemia. Preclinical toxicology indicated no signs of
significant delayed toxicity, and the i.v. LD10 in mice was
reached at 191mgkg-1 (600mgm 2). The starting dose for
this phase 1 study was therefore chosen as 70mgm 2. The
drug is given once weekly for 3 weeks as a 20 minute
infusion in 5% dextrose (final concentration not less than
0.5mg GR63178A per ml). A total of 18 patients (8 male, 10
female) have been entered to date. The mean age is 45.9
years, 5 had colorectal tumours, and 4/18 had received no
prior chemotherapy. Five patients received a total of 23
doses at 70mgm 2, with minor symptoms of headache,
nausea and back pain. Three patients received a total of 13
doses at 90mgm-2, and three received a total of 12 doses at
110mgm-2. Similar symptoms occurred with some but not
all doses at both levels. Seven patients have received a total
of 24 doses at 140mgm 2. At the highest dose level,
potentially dose-limiting side-effects were observed in 2
patients; these comprised severe headache, generalised pain
(particularly back pain) and nausea and vomiting.
An HPLC assay has been developed for GR63178A and
GR54374 (an active metabolite) with a sensitivity of
lOngml-1 and 2ngml-1 respectively. Preliminary
pharmacokinetics suggest that peak plasma levels and AUCs
achievable in patients are close to the levels associated with
activity in murine tumour models. This study is continuing
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The stability of the intravenous preparation of etoposide in
isotonic fluids
S.P. Joel, P.I. Clark, M.C. Maclean & M.L. Slevin
Imperial Cancer Research Fund Department of Medical
Oncology, St Bartholomew's and Homerton Hospitals,
London ECIA 7BE, UK.
Etoposide has limited stability in solution but the reported
data show a wide variation in results. The stability of
etoposide has therefore been re-examined in 2 studies. In the
first study solutions of etoposide at a range of concent-
rations were regularly inspected for precipitation and sam-
pled for HPLC analysis to determine the time at which
concentration fell by > 10%.
Study I
Etoposide Time of Time of >10% Minimum
(mgml-') precipitate fall in conc. stability
0.25 >8 days >8 days >8 days
0.5 30 hours 30 hours 24 hours
0.75 10 hours 10 hours 8 hours
1.0 6 hours 8 hours 5 hours
Study 2
Etoposide Time of Minimum
(mgml-) precipitate stability
0.25 >3 weeks >3 weeks
0.5 11 days 10 days
1.0 24 hours 18 hours
2.0 10 hours 8 hours
The stability of etoposide was identical in saline 0.9%/
dextrose 5%, and saline 0.15%/dextrose 4% (all in Viaflex
infusion bags). No picro etoposide was detected. This study
has demonstrated that etoposide stability is concentration-
dependent and that the visual detection of precipitate is as
sensitive as HPLC in detecting loss of stability. In addition
etoposide at a concentration of 0.5mgm-1 was stable for
10 days if unsampled, compared with 36 hours if sampled
regularly. In a second study the stability of etoposide at
20-23°C in unsampled infusion bags has been determined
according to appearance of precipitate. These data show that
the stability of etoposide is dependent on concentration but
is much greater than previously thought. The appearance of
precipitate indicates loss of stability. Considerable saving of
etoposide is possible as a whole course of infusions can be
prepared at the start of treatment. Previous estimates of
etoposide stability have failed to realise the loss of stability
that occurs with sampling.
A pharmacokinetic hypothesis for the clinical efficacy of
etoposide in small cell lung cancer
P.I. Clark, S.P. Joel & M.L. Slevin
Imperial Cancer Research Fund Department of Medical
Oncology, St Bartholomew's and Homerton Hospitals,
London ECJA 7BE, UK.
Etoposide is a phase-specific and schedule-dependent drug.
In 2 sequential phase III randomised trials investigating the
role of scheduling of etoposide, 3 schedules have been
compared. Single-agent etoposide has been given intra-
venously to patients with untreated extensive small cell lung
cancer (SCLC) at the same total dose of 500 mg m2 per
course (every 3 weeks) for a maximum of 6 cycles. In the
first study a 24-hour infusion was compared with 5 consecu-
tive daily 2-hour infusions. In the second study 5 consecutive
daily 2-hour infusions were compared with 8 consecutive
daily 75-minute infusions. The pharmacokinetics of etopo-
side were studied in patients on several occasions. The times
over which plasma concentrations of etoposide exceeded 1, 5
and 10 Mg ml-' per course of therapy have been calculated.
Median patient and pharmacokinetic data are presented
below.
Study I Study 2
24-hour 5-day 5-day 8-day
No. patients 20 19 25 25
Response rate 10%(P<0.05) 90% 72% 80%
Remission (months) - 4.5 4.7 5.6
Drug AUC
(pgml-l h-1) 483 472 512 492
>1I0 gmgm (hours) 24 (P<0.05) 12 12 (P<0.05) 3
>5pgml 1 (hours) 32 34 33 (P<0.05) 26
>Iugml- (hours) 49 (P<0.05) 97 101 106
No. etoposide peaks 1 5 5 8
The results of study 1 suggested that the superiority of the
5-day schedule was either due to the presence of 5 separate
daily exposures to etoposide or to the greater duration of
plasma etoposide >1 g ml-1. The 8 daily exposures in
study 2 failed to increase the duration of remission, but
provided a similar duration of plasma etoposide >1 Mg
ml-1. This data suggests that the cytotoxicity of etoposide in
man, at least in SCLC, is related to maintenance of low
plasma concentrations of drug.
Intraperitoneal cisplatin - a new approach to the adjuvant
treatment of gastric cancer
D. Cunningham, P. Sauven, M. Parker, G. Glazer,
D. Coleman, C. Coulter, D. Cunningham, M. Lennox,
J. Hermon-Taylor, R.C. Coombes, J.S. Kirkham &
R.D. Rosin
St Mary's Hospital, London; St Georges Hospital, London;
QEII Hospital, Welwyn Garden City, UK.
The five year survival for patients with gastric cancer is
5-10%. Although 30-40% of patients have a potentially
'curative resection' only one-third of these patients remain
disease free. Serosal penetration is one of the best predictors
of relapse and in Japan has been shown to be associated
with malignant cells in peritoneal washings taken at the time
of surgery. In view of this we initiated a pilot study to
evaluate the feasibility of giving intraperitoneal cisplatin. 14
patients have entered the study. All patients had a curative
resection. 12/14 had serosal involvement with tumour. 9/14
had lymph node involvement. Peritoneal lavage with 1 litre
of N-saline was performed pre-operatively, immediately
postoperatively and before each course of chemotherapy.
Cisplatin 60 mg m 2 was given intraperitoneally in 2 litres
of N-saline via a Tenckhoff catheter (7 patients) or peritoneal
catheter (7 patients) every 3 weeks for 4 courses beginning
within 6 weeks of surgery. Four of 14 patients had malig-
nant cells in the peritoneal washings taken before chemo-
therapy. Chemotherapy was generally well tolerated. There
were 2 episodes of Tenckhoff catheter sepsis and the cath-
eters were replaced. Technicium was given intraperitoneally
before chemotherapy and after 4 courses of chemotherapy in
5 patients and in each case there was good distribution of
the fluid in the abdominal cavity. Four of 14 patients
experienced nausea and vomiting. There was no renal toxi-
city. Three of 14 patients have relapsed and 1 has died. One
had +ve peritoneal washings. This pilot study demonstrates
the safety and feasibility of administering cisplatin 60 mg
m-2 intraperitoneally following surgery for gastric cancer.THIRTIETH BACR AND FOURTH ACP MEETINGS 459
A phase II study of epirubicin and mitoxantrone in advanced
hepatobiliary and pancreatic carcinoma
C.M. Barton, G.R.P. Blackledge, M. O'Brien &
J. Neoptolomos
West Midlands CRC Clinical Trials Unit, Queen Elizabeth
Medical Centre, Birmingham B15 2TH, UK.
Surgery may cure localised hepatoma and carcinomas of the
pancreas and biliary tract but the prognosis of advanced
disease is poor even with chemotherapy and radiotherapy.
Chemotherapy response rates rarely exceed 20% with res-
ponses of short duration. The best results have been reported
with doxorubicin or doxorubicin containing chemotherapy.
Epirubicin and mitoxantrone have also been shown to be
effective and there is in vitro evidence of a synergistic effect
between doxorubicin and mitoxantrone (Alberts et al., J.
Drug Dev., 1988, 1, 15). A combination of the less cardiotoxic
analogue, epirubicin, and mitoxantrone may have the same
synergy with fewer side effects. Sixteen patients with locally
advanced, recurrent or metastatic hepatoma (8), cholangio-
carcinoma (1) and pancreatic carcinoma (7) have been
treated with a combination of mitoxantrone, 8-12 mg m-2
day-1 as a bolus on day 1, and epirubicin 15-25 mg m-2
day - on days 1 to 3, given as a continuous infusion at
three weekly intervals, with dose modifications according to
the degree of myelosuppression. A total of 52 courses have
been administered with 14 patients receiving at least 2
courses and 2 patients completing a maximum of 6 courses.
One patient awaits assessment; 9 patients ceased chemo-
therapy due to disease progression (4 hepatoma, 3 pancreatic
carcinoma); 4 had static disease (2 hepatoma, 2 pancreatic
carcinoma) and 2 complete responses were seen. Both res-
ponders remain in complete remission more than 6 months
(pancreas) and 2 years (cholangiocarcinoma) after starting
treatment. Myelosuppression, particularly leucopenia, was
the most frequent and serious side effect with 25 of the 52
courses complicated by grade 3 or 4 neutropenia, and 17
courses by pyrexia or frank infection. Myelosuppression was
more common with doses of epirubicin greater than 20 mg
m-2 day-1. One patient with coincidental septicaemia and
steatorrhoea experienced symptomatic hypokalaemia and
hypomagnesaemia after her third course of treatment. Alope-
cia occurred in most patients but other side effects were mild
and infrequent and no cardiotoxicity was seen. These data
suggest that double intercalating therapy can be administered
with myelosuppression being the major toxicity. Responses
were seen in tumours generally insensitive to chemotherapy.
Comparative pharmacokinetics of doxorubicin (DOX) given by
bolus injection or 4 day infusion
C.J. Twelves, N.A. Dobbs, M. Aldhous, S. O'Reilly,
M.A. Richards, P.G. Harper & R.D. Rubens
Clinical Oncology Unit, Guy's Hospital, London SEI 9RT,
UK.
Although there has been much interest in dose intensity,
drug scheduling has been studied less widely. We have
compared the pharmacokinetics of DOX given by i.v. bolus
or 4-day infusion in 11 patients (pts) with advanced breast
cancer, normal liver biochemistry and no evidence of liver
metastases. Six pts were treated with DOX 70-75 mg m-2
i.v. bolus on day 1 and blood samples collected at timed
intervals for 72 hours after injection. Five pts received DOX
60-75 mg m-2 by continuous i.v. infusion days 1-4 via a
Hickman indwelling catheter using a Travenol infusor. Blood
samples were collected during the infusion and for 48 hours
after its completion.
Plasma levels of DOX and its metabolite doxorubicinol
(DOXol) were assayed by high performance liquid
chromatography (HPLC) with fluorimetric detection. Peak
plasma concentrations (PPC) of DOX and DOXol were
measured, areas under the concentration-time curves (AUC)
derived by the trapezoidal method and clearance (Cl) calcu-
lated; the white blood count (WBC) was checked on day 10-
12. Results are shown below as mean values and the groups
compared using Wilcoxon's rank sum test.
PPC AUC Cl WBC
(ngml 1) (ngml 1h1) (m-2h-1) (x 109 1-1)
DOX DOXol DOX DOXol DOX DOXol dJO-12
Bolus 4,278 39.1 2,787 1,006 28.1 79.1 2.1
Infusion 107 28.3 5,617 2,260 12.5 38.3 3.7
P value <0.01 NS <0.01 NS <0.01 <0.05 NS
Despite a similar dose intensity, 4-day infusion signifi-
cantly reduced peak DOX levels, but increased total drug
exposure. Drug scheduling may have an important effect on
the efficacy and toxicity of doxorubicin.
Quantitative distribution of 1311 labelled monoclonal
antibodies administered by the intra-ventricular route
D.B. Smith, R.H.J. Begent, M. Glaser, S. Dewhurst &
A. Kelly
Cancer Research Campaign Laboratories and Dept of
Radiotherapy, Charing Cross Hospital, London, UK.
Tumours of the CNS often remain confined to the neuraxis
throughout their natural history and thus intra-cavity radio-
labelled monoclonal antibody treatment represents an
attractive therapeutic option. In order for such therapy to be
effective there must be distribution of the antibody complex
throughout the CSF and in this study we make a quantit-
ative assessment of distribution in 3 patients following
administration via the intra-ventricular route. The patients
were (1) a 34-year-old man with CNS relapse from a
teratoma (SB10 xW14 monoclonals raised against HCG
were used), (2) a six-year-old with a relapsed primitive
neuro-ectodermal tumour (antibody used was UJ13A), (3) a
22-year-old with a recurrent medulloblastoma (antibody used
MEL14). The antibodies were labelled with 20-50 mCi 131I
and were administered in each case via an Ommaya reser-
voir. Patients were scanned using an IGE Gemini 700
gamma camera at intervals up to 10 days post injection.
Counts were assessed over the head, upper half spine and
lower half spine. In all 3 patients there was distribution of
radiolabel throughout the neuraxis reaching the three study
areas within 24 hours. In the first 2 patients 41-56% of the
counts at each time point remained in the head with 18-39%
in each of the upper and lower spine areas. Similar results
were achieved in the third patient despite a partial block to
the flow of CSF although distribution took 12-24 hours
longer. The T112 for total neuraxis counts was 31.5 h in
patient 1, 19.8 h in patient 2 and 15.5 h in patient 3. There
was no evidence of antibody binding to known sites of
tumour.
The data indicate that adequate distribution of radio-
labelled monoclonal antibodies can be achieved using the
intra-ventricular route even in the presence of partial CSF
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Peritoneal lavage fluid (PLF) CA125: a tumour marker and
independent prognostic factor in epithelial ovarian cancer
(EOC)
C.W.E. Redman, D.M. Luesley, G. Blackledge, E.J. Buxton
& K.K. Chan
West Midlands CRC Clinical Trials Unit, Queen Elizabeth
Medical Centre, Birmingham B15 2TH, UK.
The monitoring and assessment of response in EOC can be
difficult, especially when the disease burden is small. Serum
CA125 is more sensitive than clinical and radiological modes
of assessment and its levels have an excellent correlation
with disease burden. Unfortunately there is a significant false
negative rate when the amount of residual disease is small.
As EOC is largely an intraperitoneal disease, theoretically
intraperitoneal CA125 levels may be a more sensitive index
of disease status. Following peritoneal lavage with 1 1 of
0.9% saline, CA125 levels in peritoneal lavage fluid were
measured 40 healthy controls and 67 EOC patients with
residual disease prior to treatment. There was a highly
significant difference in both serum (t105 =8.0; P<0.001)
and PLF CA125 (t105 =5.6; P<0.001) levels between the
two groups of patients. The presence of ascites and amount
of residual disease had a significant association with serum
and PLF CA125 levels but there was no significant associa-
tion with histological type and grade of differentiation. Cut-
off point for serum and PLF CA125, that achieved the
maximum discrimination between cancer and control
patients were 30 and 60 U ml-1 respectively. On the basis of
these values the sensitivity for serum and PLF CA125 were
89.5 and 64.2%, and overall predictive value 91.5 and 77.6%
(Mcnemar x2=9.0; P=0.003). Although not as sensitive as
its serum counterpart, PLF CA125 was better than clinical
findings, ultrasound, CT scan and peritoneal cytology in
detecting residual disease. In 59 evaluable EOC patients
changes in serial PLF CA125 levels corresponded with
observed response in 71% of cases compared to 84% for
serum CA125. PLF CA125 was a poor marker of response
when initial levels were negative. To assess the prognostic
significance of PLF CA125 levels at the start of treatment in
conjunction with other prognostic parameters, including
serum CA125, an initial univariate and subsequent multi-
variate analysis was performed. Stage, size of residual dis-
ease, positive peritoneal cytology, the -presence of ascites,
serum and PLF CA125 levels were identified as important
prognostic variables on the basis of univariate log-rank
analysis. Because of the interaction between these factors,
and as neither serum nor PLF CA125 conformed to the
proportional hazards model, a multivariate stepwise discrimi-
nant analysis was performed, using survival at 12 months
after primary surgery as the end point. The presence of
ascites and PLF CA125 levels prior to treatment achieved
the greatest discrimination correctly predicting the outcome
at 12 months in 81% of patients. These findings indicate
that whilst PLF CA125 is not a more sensitive tumour
marker than its serum counterpart its pre-treatment levels
have an independent prognostic value.
Analysis of survival in epithelial ovarian carcinoma
D.M. Eccles, S.G. Allan & R.C.F. Leonard
Department of Clinical Oncology, Western General Hospital,
Edinburgh EH4 2XU, UK.
Survival from epithelial ovarian carcinoma has not improved
significantly over the past 5-10 years (yr) and it is now the
leading cause of death from gynaecological cancer. Several
factors have been identified as having some prognostic
significance including FIGO stage, age, performance status,
ascites adhesions, extent of debulking surgery and histo-
logical type and grade. In the present series of 320 patients
presenting to the Department within the years 1975-88, 109
had FIGO stage I and II (limited stage) disease and 205 had
stage III and IV (advanced stage) disease. The mean age of
all patients was 57.8yr (range 28-82). Stage IV mean age
64yr, stage III mean age 58.6yr (23-82), stage II mean age
60.9yr (45-78), stage I mean age 53.6yr (31-79). In
advanced stage disease 30% had good debulking surgery
(maximum dimension of residual tumour <2cm), mean
survival (MS) was 18.8 months (m) (median 16m); 30% of
advanced stage disease was partially debulked (residual
tumour <5cm maximum dimension), MS was 16.2 m
(median 12m); 34% had no debulking of advanced disease
and MS was 12.2m (median 8m). In 6% surgical debulking
was not assessable. Only 4 patients with advanced disease
were still alive at 5yr. Chemotherapy used in advanced
disease was a single alkylating agent regimen, 54 patients,
MS 15.4m (median 9m); single agent cisplatinum, 22
patients, MS 16m (median 12m); or a cisplatinum combi-
nation regimen, 66 patients, MS 16.5m (median 15m). Data
on haematological and biochemical parameters recorded
within 8 weeks of operation will be included in the multi-
variate analysis of prognostic factors.
Phase I and pharmacokinetic study of thiotepa (T)
administered intraperitoneally (i.p.) to patients with ovarian
cancer
C.R. Lewis, N. Lawson, E.M. Rankin, G. Morrison,
J. Cassidy, D. Kerr, A. MacLean, J. Cordiner & S.B. Kaye
Dept ofMedical Oncology & Dept ofGynaecology, University
of Glasgow, UK.
Fifteen patients with ovarian cancer, all of whom had
previously received first line systemic chemotherapy with
platinum analogues or cisplatin, were given T via a Tenck-
hoff peritoneal dialysis catheter in 21 of normal saline with a
4h dwell time. Doses ranged from 30mgm2 to 80mgm2.
Dose limiting toxicity was myelosuppression, which occurred
at 80mgm-2 and was frequently prolonged (white cell count
WHO grade 3, 5pt; grade 4, lpt; platelets WHO grade 3,
3pt; grade 4, ipt). Short lived nausea and vomiting (WHO
grade 2 or less) was easily controlled, and there was no local
toxicity. Five patients remain free from disease progression 2
to 7 months after commencing intraperitoneal T, and 3
patients had temporary reduction in ascites formation.
Thiotepa concentrations were measured by gas chromato-
graphy. Peritoneal fluid concentrations declined in a first
order fashion with a half-life of 1.1 h. A mean of 90% of
the drug was absorbed during the 4h dwell time. Plasma
levels peaked -1 I h after drug instillation and were substan-
tially lower than corresponding peritoneal levels. Maximum
peak level peritoneal/plasma pharmacological advantage was
30 (mean 25), and mean AUC advantage was 9.
This study demonstrates a selective pharmacological
advantage for the i.p. delivery of T, and the treatment is well
tolerated. The recommended dose for i.p. T is 60mgm-2
every 3-4 weeks.
High dose intensity combination chemotherapy with cisplatin
and cyclophosphamide for advanced epithelial ovarian
carcinoma - results of a pilot study
J.W. Sweetenham & C.J. Williams
CRC Wessex Medical Oncology Unit, Southampton General
Hospital, Southampton S09 4XY, UK.
The influence of dose intensity on outcome for patients (pts)
with advanced ovarian carcinoma treated with chemotherapyTHIRTIETH BACR AND FOURTH ACP MEETINGS 461
has been the subject of a large retrospective study by Levin
and Hrynuik (J. Clin. Oncol., 1987, 5, 756). A significant
correlation was demonstrated between average relative dose
intensity (ARDI), response rates and survival. As part of a
proposed randomised trial to assess the effect of dose
intensity on outcome in this disease, we undertook a pilot
study to determine the toxicity and tolerability of the high
intensity therapy. Eligibility: histologically confirmed epithe-
lial ovarian cancer, age 16-75, KPS>50%, FIGO stage II
with >2cm res. disease, FIGO stage III or IV, normal FBC,
creatinine clearance >701/24h. Chemotherapy: cisplatin
120 mgm2 i.v. dl., cyclophosphamide 1000mgm-2 i.v. dl.
q=21 days. No. of cycles=6. ARDI= 1.14 (using CHAP
regimen (Greco et al., Obstet. Gynecol., 1981, 58, 200) as
standard ARDI of 1). Patient characteristics: 16 entered,
median age=62 years (34-72). FIGO stage II, 3; III, <11;
IV, <2; >2 res. dis., <11; <2cm res. dis., <5. 87 courses
of chemo have been given. 42 courses have been delayed or
given at reduced dose because of leucopenia (14) or renal
impairment (28). Only 1 pt has received the total planned
dosage of chemotherapy at an ARDI of 1.14. Median
received dose intensity =0.93 (0.61-1.14). Toxicity: all pts
had WHO grade 2 or 3 nausea and vomiting and alopecia.
Treatment was discontinued in 2 pts because of severe
ototoxicity. Nine pts had peripheral neuropathy which was
disabling in 4. Clinical response: CR, <9; PR, <4; PD,
<2; inev., < 1. Conclusion: Prospective randomised trials of
dose intensity are essential. An initial step is to test whether
the projected high intensity arm can be delivered. In this
study we were only able to administer chemotherapy of an
ARDI of 0.93. Although this is considerably less than the
projected dose, it still approaches that of the standard
regimen (CHAP). A regimen of such a dose intensity may be
suitable for a randomised trial.
Educating the public about testicular cancer - experience with
university students
S.M. Crawford, G.B. Littlejohn & P.G.O. Kamill
Clinical Oncology Unit, Dept of Social Analysis, Student
Health Service, Bradford University, Bradford BD7 JDP, UK.
The treatment of testicular cancer carries a higher morbidity,
and its success may be compromised, when patients present
with very advanced disease. Such presentation is usually
associated with delay on the part of the patient or his
doctors. The delay might be reduced by educating patients
about the significance of gonadal abnormalities.
Male students at this University were offered a leaflet at
the time they collected their grants in April and October
1988, which described testicular self examination (TSE).
Consultations for scrotal lesions at the Health Centre were
monitored and in January 1989 students were interviewed
about the leaflet.
Nine consultations occurred, none with findings indicative
of tumours. Further consultations took place during the
period of the survey. Preliminary analysis of the survey
based on 171 interviews shows that only 21.6% male stu-
dents recalled seeing the leaflet. Of these 70.2% knew that
TSE was to detect cancer compared with 27.6% of those did
not remember the leaflet (P<0.001). Half of those who had
seen the leaflet had performed TSE compared with 3% of
those who had not seen it.
The TSE leaflet is a useful method of educating the public
but a more positive method of drawing it to people's
attention is needed.
BACR - oral presentations
Cerebral metastases in small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC) treated by chemotherapy
C. Twelves, R. Souhami, P. Harper, J. Tobias, S. Spiro,
D. Geddes, C. Ash & J. Drake
Clinical Oncology Unit Guy's, University College & Middlesex
Medical Schools, Brompton & London Chest Hospitals,
London, UK.
Cerebral metastases are conventionally treated by cranial
irradiation even when the primary tumour may be chemo-
sensitive because it is assumed they are protected by the
blood brain barrier (BBB). We have assessed response in
SCLC and NSCLC patients with symptomatic, CT proven
cerebral metastases at presentation treated by chemotherapy
alone. Patients did not receive cranial irradiation; steroids
were given where clinically indicated but were reduced or
withdrawn during chemotherapy.
In 25 SCLC patients treatment was with cyclophos-
phamide gm-2 i.v. day 1, vincristine 2mg i.v. day 1 and
etoposide either 100mg p.o. tds days 1-3 or 120mg i.v. day
1 and 100mg p.o. bd days 2 and 3 on a 21-day cycle. On
repeat brain scan 10 of 17 patients responded. In responders
who were scanned after only 1 course of chemotherapy,
response was detectable at this early stage. Eight patients
were assessed only clinically and 3 responded. All cranial
responders improved on chest X-ray. Overall NSCLC cranial
response rate was 2/6 (33%).
We conclude that symptomatic SCLC and NSCLC cere-
bral metastases are not protected from chemotherapy by the
BBB. Indeed, the 'blood-tumour barrier' may be the same in
these metastases as other sites of metastatic disease. Chemo-
therapy has the advantage of treating both cerebral metas-
tases and extra-cranial tumour.
Investigations of the mechanisms of epithelial carcinogenesis
using XB2 keratinocytes
S.D. Hewitt, P.A. Duffy, R.C. Garner & T.C. Orton
Cancer Research Unit, University of York, Heslington, York
YOJ SDD; ICI Pharmaceuticals, Mereside, Alderley Park,
Macclesfield, Cheshire SKJO 4TG, UK.
XB2 keratinocytes, derived from Rheinwald and Green's
teratoma line are routinely cultured in our laboratory in a
low calcium medium (0.03mM) and used in the study of
mechanisms of epithelial carcinogenesis. When cultured at
low density (50cm-2), cells begin to differentiate and this
process can be affected by certain carcinogenic agents. At
high density (5000cm-2), there is less tendency to different-
iate and the process will be perturbed by only the strongest
carcinogens, e.g. DMBA. The degree of differentiation can
be assessed by measurement of keratin production and
stratification; cell numbers are used as an index of prolifer-
ation.
Using this system, we have found that the strong stage I
and II promoters TPA, teleocidin and okadaic acid all
greatly increase parameters of proliferation and differen-
tiation but, whereas okadaic acid achieves this at low density
only, the protein kinase C-mediated promoters also exert an
effect at high density. The stage II promoter mezerein
affected stratification only. BHA, the non-mutagenic carci-
nogen of rodent forestomach, had opposite effects to its non-
carcinogenic partner BHT. BHT increased proliferation only
and BHA increased only the parameters of differentiation.
These data suggest that the mechanism of carcinogenesis
by BHA does not involve protein kinase C but is possibly
similar to the mechanism of action of mezerein. This system
of low/high density culture also seems to provide a method
whereby non-mutagenic carcinogens may be recognised as a
group distinct from promoters.462 THIRTIETH BACR AND FOURTH ACP MEETINGS
Amplification of specific DNA sequences in C127 mouse cells
transformed by bovine papillomavirus type 4
K.T. Smith & M.S. Campo
The Beatson Institute for Cancer Research, Garscube Estate,
Bearsden, Glasgow G61 IBD, UK.
The mode of malignant transformation of cells by BPV-4 is
the result of a 'hit and run' mechanism: viral DNA is always
found in oesophageal papillomas whereas the viral genome is
rarely detected in carcinomas arising from those papillomas.
Furthermore, BPV-4 DNA can transform C127 mouse fibro-
blasts in vitro but again the viral genome is often absent
from the transformed cells, indicating that the viral DNA is
not involved in the maintenance of the transformed state. As
an initial attempt to characterise the event(s) initiated by the
virus, leading to the stably transformed phenotype, we have
used high molecular weight DNA from the BPV-4-
transformed cells to re-transfect C127 cells. This resulted in
morphological transformation of the C127 cells in the
absence of any BPV-4 DNA, thus the virus has activated a
dominant oncogene. Southern blot analysis of DNA from
these secondary transformants demonstrated that there was
amplification of a specific DNA sequence, previously iso-
lated from a BPV-4-transformed cell line where it was linked
to a rearranged viral genome. Amplification of this, or a
related sequence, was also observed in a chemically induced
mouse skin carcinoma. Therefore, we have identified an
oncogene that is activated by BPV-4 resulting in malignant
transformation of cells. We are currently investigating the
mechanism of this activation.
This research was supported by the Cancer Research
Campaign.
What is the role of c-erbB-2 protein in Paget's disease of the
nipple?
therefore, that c-erbB-2 amplification is related to this
architectural and cytological pattern of ductal carcinoma and
may play a role in the manner of local spread of tumour
cells seen in Paget's disease of the nipple.
Biochemical characterisation and localisation of normal ber
gene products
S. Dhut, T.S. Ganesan, T. Chaplin & B.D. Young
ICRF, Department of Medical Oncology, St Bartholomew's
Hospital, West Smithfield, London ECIA 7BE, UK.
A monoclonal antibody (7C6) derived against a synthetic bcr
peptide was used to study normal bcr gene products. In 35S-
methionine labelled KGI cells, a bcr phosphoprotein of
130kDa was demonstrated in addition to the previously
identified bcr phosphoproteins of 160kDa. Sequential
immunoprecipitation demonstrated both p130 and p160 had
determinants from two separate regions of the putative bcr
translated sequence. The rate of synthesis of normal bcr
products as estimated by metabolic labelling was comparable
with that of p210 bcr-abl in BV173 and K562 cells. In K562
cells, the in vivo phosphorylation of p160 exceeded that of
p130 and both normal products were unaffected by the
increased phosphorylation of p210 bcr-abl. The half-life of
both normal bcr products was estimated to be more than 48
hours by pulse-chase experiments. Immunofluorescence
analysis by conventional and confocal microscopy estab-
lished that both normal bcr products were located predomi-
nantly in the cytoplasm. This was confirmed by subcellular
fractionation of 35S-methionine labelled cells and immuno-
precipitation with 7C6 antibody. In conclusion, there are two
normal bcr gene products, p160 and pl30, both phospho-
proteins located in the cytosol, and the level of expression of
p210 bcr-abl and the normal bcr products are similar in cell
lines K562 and BV173.
D. M. Barnes, G.A. Lammie, R.R. Millis & W.J. Gullick
ICRF Clinical Oncology Units, Guy's Hospital, London
SE] 9RT, and Hammersmith Hospital, London W12 OHS,
UK.
Amplification of the c-erbB-2 oncogene in mammary carci-
noma has been proposed as an indicator of poor prognosis.
Antibodies are now available and comparative studies have
found a close relationship between positive immunohisto-
chemical staining of sections of human breast tumours and
amplification of the gene. Retrospective studies on archival
material from patients with extended follow up are therefore
possible. We have carried out two such studies using anti-
body 21N (Gullick et al., Int. J. Cancer, 1987, 46, 246) with
a peroxidase conjugated avidin-biotin technique. We have
examined the presence of c-erbB-2 protein in 195 infiltrating
carcinomas and in tissue from 45 patients with Paget's
disease of the nipple. When the staining patterns of the 195
patients, who had a 10-year follow-up, were evaluated,
strongly positive membrane staining was found in 9% of the
tumours. An association between positive staining and histo-
logical grade III tumours (P=0.04) was the only significant
finding. Although log rank analysis did reveal a tendency for
patients with unstained tumours to have a slightly better
prognosis, this trend disappeared in a multivariate Cox
regression analysis. When we examined the tissue from the
45 patients with Paget's disease of the nipple we found 90%
positivity, both in the Paget cells and in the underlying
carcinoma. In 35% of the cases the underlying carcinoma
was purely in situ and in 65% infiltrating tumour was also
present. In the majority of cases the malignant cells in both
components were large and pleomorphic and the in situ
ductal carcinoma was of the comedo type. It is suggested
Association of an abnormal c-raf-1 gene, a radioresistant
phenotype and aberrant topoisomerase II activity in a
cancer-prone family
J.M. Cunningham, K. Pirollo, E. Chang & G.E. Francis
Molecular Cell Pathology Unit and Department of
Haematology, The Royal Free Hospital, London NW3;
and Dept of Pathology, Uniformed Services University of
the Health Sciences, Bethesda MD 20814 USA.
Susceptibility to mutation at many sites in the genome is
consistent with the behaviour of malfunctioning DNA
topoisomerases in vitro. Studies of the Li-Fraumeni cancer
family syndrome show an association between susceptibility
to a wide variety of neoplasms, inheritance (in non-
cancerous cells) of the c-raf-l oncogene and a radioresistant
phenotype. This association, and the fact that topoiso-
merases are known to be activated in vitro by serine/
threonine kinases similar to raf, prompted investigation of
DNA topoisomerase activity in non-cancerous fibroblasts
from a cancer-prone family. Since radioresistance is trans-
ferred to HIH-3T3 cells when the family's aberrant c-raf-l
gene is transfected, we also examined transformants contain-
ing this and other oncogenes (c-myc and EJ-ras). The latter
were examined because myc is amplified 3-8-fold in lines
derived from this family, but does not appear to convey the
radioresistant phenotype and because radioresistance can
also be conveyed by several other oncogenes including ras.
All three family members cell lines and three transfected
mouse lines containing either the abnormal c-raf-1 or ras
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perturbation of a spermidine and ATP dependent DNA
catenation activity typical of DNA topoisomerase II. Relaxa-
tion of DNA supercoiling (DNA topoisomerase I activity
and other DNA nicking enzymes) was not abnormal. Since
topoisomerases are error prone, particularly when their
activity is disturbed, these findings may be relevant to the
mechanisms of oncogenesis and related radioresistance in
this family.
A new in vitro colony assay for multipotential progenitors in
human bone marrow peripheral blood
I.B. Pragnell, M. Freshney, A. Sproul, D. Kerr,
D.G. Wright, N. Lucie, N. Wilkie & G. Konwalinka
Beatson Institute, Glasgow; MRC Radiobiology, Didcot;
Western Infirmary, Glasgow; University ofInnsbruck, Austria.
The physiology of human hematopoietic stem cells can be
studied in normal and diseased states by clonal in vitro
cultures in which the primitive progenitor cells proliferate
and differentiate into different lineages to form mixed col-
onies. For many applications it is essential that such assays
detect a high proportion of primitive progenitor cells. We
describe an in vitro assay for human pluripotent progenitor
cells which detects a considerable proportion of the primitive
progenitor compartment. Mononuclear cells from bone
marrow were plated at low cell concentrations in semisolid
agar cultures with recombinant human granulocyte-
macrophage colony-stimulating factor. These culture con-
ditions support the formation of macroscopic multilineage
colonies at an average incidence of 137+85 (mean+s.d.) per
105 mononuclear bone marrow cells. The colony forming
cells, (CFR-A, colony forming unit, type A) detected in
normal bone marrow give rise to colonies displaying a
marked heterogeneity, a variable cycling status and a high
replating efficiency. These observations are consistent with
the CFU-A being primitive progenitor (stem) cells. Colonies
with similar properties could also be detected upon culture
of mononuclear cells from peripheral blood at a 10-
20-fold lower incidence. The demonstration of fluctuatary
levels of CFU-A in peripheral blood after cytotoxic drug
treatment suggests that the assay could be exploited for
clinical use. The application of this technique to the analysis
of neoplastic haemopoietic cells will be discussed. The stu-
dies are supported by grants from the Cancer Research
Campaign.
Onco-suppressor action of the normal human H-rasl gene
D.A. Spandidos & N.M. Wilkie
The Beatson Institute for Cancer Research, Garscube Estate,
Bearsden, Glasgow G61 IBD, UK; and Biological Research
Center, National Hellenic Research Foundation, Athens,
Greece.
The transformed phenotype of rat 208F cells transfected with
the T24 H-rasl oncogene is suppressed by simultaneous or
subsequent transfection with the normal H-rasl gene. The
suppressed cells express both the normal and mutant forms
of ras p21 but the normal form predominates. Rare trans-
formed cells obtained after simultaneous transfection express
mainly the T24 p21. Some suppressed cells induce tumours
in nude mice after a long lag period and these tumour cell
lines have much reduced expression of normal p21. The
normal H-rasl gene also suppresses the transformed pheno-
type induced by mutant N-ras, albeit less effectively. The
tumorigenicity of the EJ bladder carcinoma cell line, which
contains only the T24 mutant allele of H-rasl, is also
suppressed following transfection with the normal H-rasl
gene. The results suggest that transforming alleles of ras
genes do not behave in a truly dominant manner and that
expression of the normal allele at elevated levels can lead to
suppression of the transformed and tumorigenic phenotypes.
The effect of H-ras and c-myc oncogene transfection on
response of epithelial cells to growth factors and cytotoxic
drugs
D.J. Kerr, J. Plumb, M. Khan, R.I. Freshney &
D.A. Spandidos
CRC Dept Medical Oncology & Beatson Institutefor Cancer
Research, Glasgow, UK.
Mink lung epithelial cells were transfected with c-myc and
activated H-ras genes. The transfected sublines formed
colonies in soft agar and were tumorigenic when injected
subcutaneously into athymic nude mice. DNA synthesis was
measured in each of the cell lines by 3H-thymidine incorpor-
ation and in the parent line there was dose related stimul-
ation of DNA synthesis by epidermal growth factor [EGF: 6
fold stimulation at 1 ng ml-') and inhibition by transform-
ing growth factor-# (TGF-fl: ID50=310pgml1). The c-myc
transfected line had a reduced inhibitory response to TGF-f
(ID50 =3,880pgml-1) and an exaggerated stimulatory res-
ponse to EGF (8.5-fold increase at 1 ngml1) whereas the
activated H-rasl transfected line did not respond to TGF-#
and EGF. Cellular sensitivity to cytotoxic drugs was assessed
using a colorometric assay based on the ability of living cells
to reduce a tetrazolium dye. The activated H-rasl transfected
line' was significantly more resistant to doxorubicin (ID5O
2.4nM) than the parent mink lung epithlial cell line (ID5O
1.4nM). Incubation of the different cell lines with TGF-fl
and EGF for 24 hours before and during drug exposure did
not alter their sensitivity to doxorubicin. It would appear
that oncogene transfection can alter the sensitivity of mink
lung epithelial cells to both exogenous growth factors and
cytotoxic drugs.
Carboplatin dose determination using a simple formula: single
agent, combination and high-dose studies
D.R. Newell, L.A. Gumbrell, F.E. Boxall, R.A. Eeles,
A. Horwich & A.H. Calvert
Institute of Cancer Research and Royal Marsden Hospital,
Sutton, Surrey, UK.
Carboplatin is an active platinum complex with reduced
non-haematological toxicities. However, the full therapeutic
potential of the drug may not have been realised because of
inadequate dosing. Carboplatin is cleared primarily by urin-
ary excretion (about 70% dose in patients with normal renal
function), so that patients with impaired or higher than
average renal function may experience over or under dosing,
respectively. We have developed (Newell et al., Br. J. Cancer,
1987, 56, 233) a carboplatin dosage formula which compen-
sates for variations in glomerular filtration rate (GFR) and
gives doses which result in far more consistent drug exposure
than doses calculated on the basis of surface area, i.e. dose
(mg) = target AUC x (GFR+25). In the equation AUC is the
required area under the 0-24h free carboplatin plasma
concentration vs time curve and GFR is the absolute value
(mlmin-1) as measured by 51CrEDTA, not creatinine, clear-
ance. In previously treated patients given single agent carbo-
platin, an AUC of 4-6mgml-1 was well tolerated (platelet
count at week 3, 36-83% pretreatment) while in previously
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associated with manageable thrombocytopenia (3 week count
36-73% pretreatment). In combination studies with other
myelosuppressive agents the target AUC should be reduced
and with carboplatin, etoposide (120mgm 2 x 3) and bleo-
mycin (30mg weekly), for the treatment of testicular tera-
toma, the formula has been used with a target AUC of
4.5mgml-1min- . In a crossover study in 4 patients (8
courses of carboplatin, 16 courses of etoposide) there was no
interaction between carboplatin and etoposide pharmaco-
kinetics and the schedule was well tolerated. The formula
accurately predicted the carboplatin dose required to achieve
the desired AUC (observed AUC 4.8+0.6mgml-1min-1).
Retrospective analysis of pharmacokinetics following high-
dose carboplatin (800-1600mgm 2) also indicated that the
formula is predictive (AUC range 10-28mgml-1min-1,
observed/predicted ratio 1.01+0.15). To simplify future stu-
dies, the relationship between AUC and the 24h total
plasma platinum level was investigated. After 58 courses
(AUC range 0.1-28 mgml- 1 min-1) there was a highly signi-
ficant correlation (r=0.96, P<0.00001) and hence the
AUC achieved can be determined by a single plasma plati-
num determination. Thus the dose formula provides a simple
and consistent method of determining carboplatin doses for
single agent, combination and high dose studies. Its appli-
cation should allow the full therapeutic potential of carbo-
platin to be determined and exploited.
Preclinical and clinical pharmacokinetic studies with
1-(4-carboxyphenyl)-3, 3-dimethyl triazene (CB10-277)
B.J. Foster, D.R. Newell, J. Carmichael, A.L. Harris,
L.A. Gumbrell, D.E.V. Wilman & A.H. Calvert
Inst. Cancer Res., Sutton, Surrey; Newcastle General
Hospital, Newcastle-upon-Tyne, UK.
CB10-277 is an analogue of dacarbazine (DTIC) which is
being evaluated in early clinical trials. DTIC and CB10-277
require metabolic activation (N-demethylation) to a mono-
methyl (MM) metabolite and in preclinical experimental
systems possess equivalent antitumour efficacy. As part of
the preclinical and phase I evaluation of CB10-277 the
pharmacokinetics in patients and mice have been compared.
In mice treated with an i.v. maximum tolerated dose (MTD)
of 750mgm 2, GB10-277 was cleared monophasically from
plasma (25 ml min- m-2), t =32 min. One major and two
minor metabolites were found in mouse plasma using HPLC
analysis. The major metabolite was sensitive to hydrolysis by
glucuronidase yielding CB10-277. One of the minor meta-
bolites was identified by HPLC as the MM derivative of
CB1O-277 with levels up to 50 uM at the MTD. Urinary
excretion of CB10-277 and the glucuronide metabolite at the
MTD was 0.3 +0.3% and 38 +9% (mean+s.d.), respectively.
Thirty-six patients with various tumour histologies have
received 80 courses of CB10-277 by short i.v. infusion over a
dose range of 80-6000 mg m 2. Pharmacokinetic analyses
have been performed on 46 courses. CB10-277 plasma
clearance in patients (61 +25mlmin1 m 2) was biphasic
with infusion times of <10min (ti, = 13+7min t = 86+
40min). Three metabolites have been identified in plasma:
CB1O-277 glycine conjugate, CB1O-277 glucuronide conju-
gate and the MM. The highest MM levels were detected at
the MTD where the range was 18-32 UM. The two conju-
gates were the major metabolites identified in the urine.
Urinary excretion of CB10-277, glycine and glucuronide
conjugates was 0.9+2.5%, 19+11% and 31 + 15%, respecti-
vely. Nausea and vomiting were observed at all levels
>900mgm-2 and became dose limiting (WHO grade 3) at
the human MTD of 6000mgm-2. The only other significant
toxicity observed was flushing without haemodynamic conse-
quences in 76% of patients treated with >2000mg m
Responses occurred in patients with melanoma (1 complete,
2 pattial, 1 mixed/11 patients) and sarcoma (1 mixed/6
patients). These pharmacokinetic results support the conclu-
sion that there are qualitative metabolic similarities between
mice and patients following CB10-277 i.v. administration. In
addition, the clinical CB10-277 antitumour spectrum appears
similar to DTIC; whether it will be more useful should be
determined by further trials in a DTIC sensitive tumour.
Pharmacokinetic aspects of plasma drug concentration
monitoring for prediction of etanidazole (SR 2508) toxicity
P. Workman, R. Ward, T.S. Maughan, H.F.V. Newman
& N.M. Bleehen
MRC and University Department of Clinical Oncology and
Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH,
UK.
Although considerably less neurotoxic than misonidazole
because of its hydrophilic character leading to rapid renal
clearance and partial exclusion from the nervous system,
peripheral neuropathy remains dose-limiting for the develop-
mental hypoxic cell sensitiser etanidazole. Monitoring
plasma drug concentrations by HPLC to determine the area
under the curve (AUCOG ) provides a quantitative method
of predicting patients at risk. We have analysed data for 18
patients receiving multiple doses of 2gm-2 etanidazole to
identify the optimum time-points for accurate estimation of
AUC. Kinetic analysis was first carried out using time-points
at 0, 15 and 30 min and 1, 2, 4, 8, 12 and 24 h. Data fitted
the 2-compartment model, with mean tq, and t+ values of
24.3min and 5.67h respectively, with CVs of 40 and 18%.
AUC was estimated from the rate equation as A/cx+B/A. The
average AUC was 503Mgml-I h with a CV of 30%. Omit-
ting either the 0 or 24h time points gave quite small average
errors (2.5%) but individual patient errors of up to 16 and
7% respectively were seen. Leaving out both the 8 and 12h
points together gave a similar low mean error of 2.9% and a
highest value of 7%. Omitting all points after 4h gave an
average error of 25% and 15/18 patients had errors greater
than 10%. Failure to correct for infusion time results in an
average underestimation of AUC by 5%. We conclude that
omitting the 8 and 12h points only combines maximum staff
and patient convenience with accurate estimation of AUC
for toxicity prediction.
The effect of ifosfamide and its metabolites on intracellular
glutathione levels in vitro and in vivo
A.T. McGown, M.J. Lind, D.G. Poppitt, J.A. Hadfield,
N. Thatcher, D. Crowther & B.W. Fox
Paterson Institute for Cancer Research, Dept of Medical
Oncology, Christie Hospital, Manchester M20 9BX, UK.
The technique of flow cytometry and the glutathione-specific
fluorochrome monochlorobimane have been used to study
the effect of ifosfamide and its metabolites on P388 cells in
vitro, and also on the glutathione levels in lymphocytes of a
patient undergoing an 8h infusion with ifosfamide. Of all
metabolites only 4-hydroperoxyifosfamide and chloroacetal-
dehyde are capable of reducing intracellular GSH. However
the concentration of 4-hydroperoxyifosfamide required to
reduce GSH by 50% (1mM) was far in excess of that
achievable in' patients receiving the drug. In contrast
chloroacetaldehyde was found to reduce GSH at levels
known to be reached in patients receiving ifosfamide
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The glutathione levels in the lymphocytes isolated from a
patient undergoing an 8 hour infusion of ifosfamide show a
marked decrease to about 30% of their original values. It is
concluded that ifosfamide causes glutathione depletion in
vivo, the majority of which can be accounted for by the
production of chloroacetaldehyde.
Pharmacokinetics of pyridoglutethimide, a new aromatase
inhibitor
B.P. Haynes, L.J. Griggs, M. Jarman, R.C. Coombes,
P.E. L0nning & T.J. Powles
Institute of Cancer Research, Sutton, Surrey SM2 5NG;
St George's Hospital, Cranmer Terrace, London SW17; and
Royal Marsden Hospital, Sutton, Surrey, UK.
Pyridoglutethimide (PG) is an analogue of aminoglute-
thimide, an aromatase inhibitor currently in use for the
treatment of hormone-dependent metastatic breast cancer.
PG is a selective aromatase inhibitor which, unlike its parent
compound, does not inhibit the desmolase enzyme complex
(Foster et al., J. Med. Chem., 1985, 28, 200). Furthermore,
PG lacks the CNS side-effects associated with aminoglute-
thimide (sedation, ataxia, anticonvulsant activity) in standard
tests in mice. As part of a phase I trial the pharmacokinetics
of PG have been studied in postmenopausal patients with
metastatic breast cancer. Each patient received a single oral
dose of PG (1000 mg) on day 0 and plasma samples were
obtained at 0, 0.5, 1, 2, 4, 6, 8, 12, 15, 24, 28, 32, 36 and 48
hours after this. Further oral doses of PG (1000 mg) were
then given daily for 5 days (days 2-6). After the last dose of
PG plasma samples were taken at the same time-points as
they were following the first dose of PG on day 0. Plasma
concentrations of PG and its principal metabolite, the n-
oxide, were measured by reversed-phase HPLC with UV
detection at 254nm.
Curvilinear plasma concentration-time profiles for PG
were obtained in all patients. Fitting of these curves to the
integrated Michaelis-Menten equation yielded excellent para-
meter estimates for C., Km and Vmax as indicated by small
standard errors of determination. The mean CO, Km and Vmax
values after a single dose of PG were 24.74Mg l-', 1.88MgI-1
and 0.80jigI-1 h- I respectively. After repeat dosing both the
Km and Vmax were found to be increased (3.96 igI-1 and
1.89 jgI 1 1 h- 1 respectively) while there was no change in Co
(24.85 ugI1-). It was also observed that the AUC of PG was
over 30% less and the AUC of PG N-oxide over 50%
greater after repeat dosing compared to that after a single
dose. The data obtained indicate that the pharmacokinetics
of PG are best described by a non-linear system with
Michaelis-Menten elimination kinetics. It would also appear
that PG induces its own metabolism, a phenomenon
observed with aminoglutethimide (Murray et al., J. Clin.
Pharmacol., 1979, 19, 704), and that the site of induction
may be the N-oxidation process.
Non-renal clearance of methotrexate (MTX) in patients with
bladder cancer
S. Harland & J. Hartley
Institute of Urology and Department of Oncology, University
Collge, London, UK.
There is very little information on the non-renal clearance of
MTX in adult patients - a matter which may be a determi-
nant of toxicity in patients with poor renal function. Nine-
teen patients with incurable bladder cancer were treated with
carboplatin in combination with MTX.
MTX was given in a dose determined by body weight and
glomerular filtration rate (GFR) (range: 330-680mg) infused
over 24 hours. Sampling of plasma and urine at steady state,
towards the end of the infusion, permitted calculation of
total and renal clearance, and by subtraction, non-renal
clearance.
Mean MTX concentration at steady state was 3.0+0.4
(s.e.) gM. Mean total clearance was 240 ml min-'. 50% of
this was renal and 50% non-renal. The renal clearance was
2.3 +0.3 fold greater than the GFR. Large variations in the
non-renal clearance were seen (range 14-94% of total clear-
ance). Non-renal clearance correlated very strongly with
body weight. Thus for patients whose weight was >70kg
this value was 191 +42mlmin-1 (n=6); weight <70kg,
86+ 18mlmin- I (n=8). Repeated estimations in a patient
who recovered his weight loss on chemotherapy showed
improvement from 91 to 192mlmin-1. Four patients with
grade 3 performance status had a mean value of
56+28mlmin1. for PS 0 and 1 it was 140+23mlmin1
(n= 15).
Patients with low body weight and poor performance
status in addition to a low GFR may have a compounded
susceptibility to methotrexate toxicity.
Potentiation of the anti-tumour effect of melphalan by the
calcium antagonist nifedipine
J. Godden, I.J. Stratford, J. Bremner & G.E. Adams
MRC Radiobiology Unit, Chilton, Oxon OXJJ ORD, UK.
It has been shown that the vasoactive agent hydralazine can
substantially increase the anti-tumour effect of melphalan
(Br. J. Cancer, 1988, 58, 122). Hydralazine is an anti-
hypertensive agent effecting the peripheral vascular supply
causing reduced blood flow to tumours. We report here a
study on nifedipine, another clinically used vasoactive agent,
for its ability to alter tumour blood flow in mice and to
modulate tumour and tissue damage caused by melphalan.
the KHT sarcoma implanted either s.c. or i.m. requires a
dose of 6mgkg-1 melphalan to reduce surviving fraction of
tumour cells to 0.1. In contrast when 10mgkg-1 nifedipine
is given 15min after melphalan the dose required to reduce
survival to this level is 2mgkg-1. In poorly vascularised
pulmonary metastases the drug combination is less effective,
suggesting that nifedipine induced vascular changes asso-
ciated with the larger tumours may contribute to the
increased efficiency of the alkylating agent. This contention
is supported by measurements of changes in tumour blood
flow caused by nifedipine. However, blood flow changes by
this dose of nifedipine are not sufficient to cause induction
of close to 100% tumour hypoxia, which contrasts with our
previous results with hydralazine, nor is there any increase in
hypoxia related binding of 3H-misonidazole to tumour
tissue. Further, nifedipine also acts by increasing melphalan
induced damage to the mouse intestine. However, the DMF
for this normal tissue damage is less than the increased
efficacy of melphalan against the s.c. or i.m. tumours.
Monitoring drug-induced hypoxia in murine tumours by
31p NMR
J.F. Dunn, N. Howells, I.J. Stratford, G.E. Adams &
G.K. Radda
MRC Clinical and Biochemical Spectroscopy Unit, Dept of
Biochem., Oxford and MRC Radiobiol. Unit, Chilton, Didcot,
Oxon., UK.
A knowledge of the oxidative status of tumours is important
since hypoxic cells in tumours are resistant to radiation and
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can be refractory to a number of commonly used cytotoxic
drugs. Experiments have been carried out to manipulate
tumour oxygenation in mice using either the vasoactive agent
hydralazine or BW12C, an agent which shifts the oxyhaemo-
globin curve to the left. Changes in tumour oxygenation
were measured by determining the proportion of hypoxic
cells using an in vitro-in vivo assay of tumour response to
radiation (the radiobiological hypoxic fraction). Tumour
NMR spectra were measured using a vertical bore 4.2T
magnet with a Bruker spectrometer, or a horizontal bore
4.7T magnet with a Varian spectrometer. Mice were anaes-
thetised, placed in the magnet for control spectra, removed
for i.v. administration of the drug, and placed back in the
magnet to follow the time-course of alteration in phosphorus
containing metabolites. After administration of the vaso-
dilator hydralazine (on KHT, RIF-l and 16C murine
tumours), we have shown that the ratios of inorganic
phosphate (Pi) to ATP increase with a time course which is
tumour specific. Further, the time course is similar to that
observed for the radiobiological hypoxic fraction. KHT
tumours in mice given BW12C show variable NMR spectra.
However, in those tumours where changes are observed, the
Pi/ATP ratio increases by 1.5-3 times that of the control
value and the time course of the change is similar to that
seen in the radiobiological hypoxic fraction. These obser-
vations indicate that substantial changes in oxidative meta-
bolism can result from administration of BW12C and hydra-
lazine.
The hepatic asialoglycoprotein receptor as a target for drug
delivery
L. Seymour, P. Flanagan, K. Ulbrich & R. Duncan
Cancer Research Campaign Laboratory, University of Keele,
Staffs. ST5 5BG; Institute of Macromolecular Chemistry,
Prague 6, Czechoslovakia.
A soluble synthetic polymer (N-(2-hydroxypropyl)-
methacrylamide), developed as a lysosomotropic drug car-
rier, has been tailored to interact with the hepatocyte
asialoglycoprotein receptor by incorporation of galactose
(5.5wt%). Doxorubicin (DOX, 7.3wt%) was covalently
attached to the polymer carrier via a tetrapeptide spacer
designed for intracellular cleavage by a lysosomal enzymes.
When administered intravenously a single dose of this conju-
gate (containing 5mg DOXkg-1) shows therapeutic activity
against L1210 (i.p.). The mechanism of action is unknown.
At low doses (0.05mg DOXkg-1) up to 48% of adminis-
tered radiolabelled conjugate was taken into the liver, the
amount of DOX deposited increasing (up to 23,ugg-1) as a
function of the dose administered (up to 20mgkg-1). At a
dose of 5mgkg-1, 7Mg of DOX was captured per g liver
tissue (60min) but at this time 24% of the dose remained in
the circulation due to saturation of the receptor. Circulating
material is rapidly excreted in the urine, however, and repeat
administration of drug conjugate after 24h produced an
identical profile of blood clearance, suggesting that receptors
were again fully available. In addition there was little or no
IgG response against the drug conjugate (5mgkg-1 DOX
administered thrice in adjuvants).
Although the concept of a liver depot slowly releasing
drug to treat peripheral disease is still not established, we
feel that this route of targeting should be clinically useful in
the treatment of malignant disorders of the liver.
Comparative toxicity of HPMA copolymer-adriamycin
conjugates and free adriamycin in the rat
T.K. Yeung, R.H. Simmonds, J.W. Hopewell,
L.W. Seymour, R. Duncan & K. Ulbrich
CRC Radiobiology Research Group, Churchill Hospital,
Oxford, UK and CRC Polymer Controlled Drugs Delivery
Group, University of Keele, Keele, UK.
A rat model has been used to evaluate the general toxicity
and the late cardiotoxicity of 4mgkg-1 adriamycin (free
drug) and N-(2-hydroxypropyl)-methacrylamide (HPMA)
copolymer conjugates containing 4mgkg-1 adriamycin.
These were bound to the copolymer via peptide linkages
which were either (i) non-biodegradable (Gly-Gly) or (ii)
biodegradable (Gly-Phe-Leu-Gly) or as (ii) but with the
incorporation of galactosamine into the copolymer. After i.v.
administration of the drugs all animals showed a transient
reduction in body weight in the first two weeks. The average
maximum reductions in body weight in the three groups of
animals receiving HPMA-copolymer conjugates were not
significantly different from each other and were significantly
less than those measured in animals receiving free adria-
mycin (P<0.01). Over the 12-week period of this study,
deaths were only observed in animals receiving free adria-
mycin. Cardiac output (COP) was measured using an exter-
nal counting technique. In all animals receiving the conju-
gates the COP was not significantly different from that
measured in age-matched control animals (P>0.05). How-
ever, these animals did show a slight (-9%) but significant
increase in heart rate from 8 weeks after drug administration
(P<0.01). The COP measured in surviving animals receiving
free adriamycin showed a -70% reduction, with a reduced
heart rate, after 4 weeks. This study demonstrated that
conjugates of adriamycin HPMA-copolymer significantly
reduced its general toxicity and increased animal survival.
The present results suggest a greater than 4-fold reduction in
cardiotoxicity when adriamycin was administered as a
HPMA-copolymer conjugate. Further studies are planned to
evaluate the dose-related cardiotoxicity of the agents.
Antitumour activity of N-(2-hydroxypropyl)Methacrylamide
copolymers containing anthracyclines
R. Duncan, I.C. Hume, K.B. O'Hare, J. Strohalm,
J. Kopecek & K. Ulbrich
Cancer Research Campaign Laboratory, University of Keele
and Institute of Macromol. Chem., Prague, Czechoslovakia.
Biocompatible soluble synthetic polymers show excellent
potential as carriers of anticancer agents for controlled and
targeted drug delivery. HPMA copolymer conjugates have
been synthesized to contain daunorubicin (DNR) and
doxorubicin (DOX), the drugs being bound to the polymer
by lysosomally degradable peptide side-chains. The conju-
gates have a Mw-20,000, Mw/Mn 1.2 and drug
loading 6-10wt%. The antitumour activity of such conju-
gates has been evaluated against L1210 leukaemia and B16
melanoma in DBA2 or C57/6J mice (i.p. or s.c.) and Walker
sarcoma in rats. Conjugates were administered i.p. or i.v.
(range 5-100mgkg-1 in respect of drug bound). When
tested against L1210, free drug (DNR, DOX) always showed
lower activity than polymeric derivative over a wide concent-
ration range and using a variety of protocols for administ-
ration. Conjugates were substantially less toxic (LD50 50-
75mgkg-1) and always more active (up to 4/5 surviving at
50 days) than free drug (no survivors). Preliminary experi-
ments against a solid tumour model (Walker) showed
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day 1, 5mgkg-', i.p.) at day 14 giving a 70% reduction in
tumour size. The above conjugates show superior activity
due to controlled delivery of drug and perhaps by passive
tumouritropism. Conjugates have also been synthesised to
contain carbohydrates, sugars or peptides/proteins to pro-
mote tumour-specific capture. For example, conjugates con-
taining melanocyte stimulating hormone (MSH) and DOX
were administered (5mgkg-1 i.p.) to mice bearing B16
melanoma (i.p. or s.c.). The conjugate containing MSH was
more active than than without (3/5 bf survivors at day 50: 0/
5 survivors), but in this case free drug at equivalent dose
also displayed activity against this tumour model (2/5
survivors).
Activity of HPMA copolymers containing daunomycin (DNM)
against a rat tumour model
J. Cassidy, R. Duncan, G.J. Morrison, J. Strohalm,
D. Plocova, J. Kopecek & S.B. Kaye
CRC Dept of Medical Oncology, Glasgow, UK;
CRC Polymer Controlled Drug Delivery Group, Univ. of
Keele, UK; and Institute of Macromolecular Chemistry,
Prague, Czechoslovakia.
Polymeric drug carriers based on water soluble non-
immunogenic copolymers of N-(2-hydroxypropyl)methacry-
lamide (HPMA) have been developed in recent years by
Duncan et al. This group have shown that it is possible
covalently to bind drugs to these carriers in such a way as to
be stable in the bloodstream, but then to be cleaved inside
the cell by lysosomal cysteine proteinases. We present data
to show modification of pharmacokinetics and a degree of
'targeting' in a rat tumour model, using HPMA copolymers
containing DNM.
5mgkg-1 of free DNM or HPMA bound DNM was
administered i.v. to Wistar rats bearing subcutaneous
implants of Walker 256 tumour. At various times up to 24
hours later animals were killed and tissues removed for
determination of free DNM by means of an HPLC assay.
The polymer bound drug was found in the tumour at greater
concentration than the free drug at all time points. Tumour
AUC was increased approximately 4-fold.
Five animals in four groups were given; saline as control,
5mgkg-1 of free DNM, the same dose of DNM bound to
HPMA via a biodegradable 'spacer' or the same dose of
DNM bound to HPMA by a non-biodegradable linkage.
The injections were performed on the same day as subcut-
aneous implantation of 0.5cm cubes of Walker tumour.
Subsequent tumour growth was measured by calipers every
2-3 days. The only group with a significant growth delay
were the animals given the biodegradable polymer prepar-
ation. In fact 4/5 animals in this group were long-term
survivors (>180 days), compared with only 1/5 with free
DNM. In summary, this carrier favourably influences
pharmacokinetics and efficacy in this model system. Further
studies are planned with other models before clinical trials.
Will biodegradable emboli enhance regional chemotherapy for
hepatic metastases?
D. Chang, S.A. Jenkins, D.M. Nott & T. Cooke
Department of Surgery, University of Liverpool, Royal
Liverpool Hospital, Liverpool, UK.
Embolisation by degradable starch microspheres (DSM) with
regional chemotherapy to treat hepatic metastases is thought
to result in intra-tumour vascular stasis. As the true mecha-
nism is unknown we have studied this using a hypovascular
hepatic tumour derived from the intraportal injection of SN
fibrosarcoma cells.
Intrahepatic distribution of 99Tc methylene diphosphonate
(MDP), representing a cytotoxic drug, injected via the
liepatic artery was measured before and after hepatic artery
clamping or mixed with DSM with and without portal vein
clamping. The distribution of 15pm "'Co microspheres was
also measured with or without co-administration with DSM.
Administration of MDP alone resulted in a tumour to
liver ratio of 0.79+0.07: 0.61+0.04. Co-injection with DSM
significantly increased this 14 fold to 11.11 + 1.08:
-0.69+0.08 (P<0.001, Mann-Whitney) but hepatic arterial
clamping had minimal effect on MDP retention with a
tumour to liver ratio of 1.19+0.34: 0.53+0.35. Following
portal vein occlusion DSM increased retention in liver but
less so in tumour (4.35+3.63: 2.21 + 1.16). The tumour to
liver ratio of 1:2 with 57Co microspheres was reversed using
DSM.
These results demonstrate that DSM enhances the reten-
tion of a low molecular weight marker in hepatic tumour, not
by causing intratumour stasis, but by reducing arterial flow
to normal liver thereby allowing selective uptake by tumour.
The effects of vasopressin on hepatic and tumour
haemodynamics in an experimental model of liver tumour
D. Hemingway, D.M. Nott, D. Chang, S.A. Jenkins,
S. Grime & T. Cooke
Department of Surgery, University of Liverpool, Royal
Liverpool Hospital, Liverpool, UK.
The ineffectiveness of regional chemotherapy in potentiating
the delivery of cytotoxic drugs to hepatic metastases may be
related to the avascular nature of most liver tumours. Since
vasopressin (AVP) is known to alter extra- and intra-hepatic
haemodynamics, the aim of this study was to investigate its
effects on blood flow to normal liver tissue and hepatic
metastases. Systemic, splanchnic, hepatic and tumour haemo-
dynamics were measured before and after a 10 minute
infusion of 0.1 mUkg-1 min-1 AVP in rats with liver
tumour derived from intraportal administration of HSN
sarcoma cells using a dual microsphere technique. AVP
infusion was associated with significant increase in arterial
blood pressure, portal venous inflow (mean+s.e.m. 2.03 +0.3
to 6.07+1.17mlmin1; P<0.01 Student's t test) and the
tumour to liver blood flow ratio. (0.62:1 +0.24 to 1.31:1 +0.3;
P<0.05). Heart rate was reduced but hepatic arterial flow
was not significantly changed by AVP administration. These
results indicate that the alterations in hepatic haemo-
dynamics effected by low dose AVP infusion increase blood
flow to liver tumour and suggest that the drug may poten-
tiate the delivery of cytotoxics to hepatic metastases.
Immunogold visualisation of adriamycin in a human breast
cancer cell line (2R 75)
W. Aherne, H. Henneberry & S. Stallard
Dept of Biochemistry, University of Surrey, Guildford
GU2 5XH; and Dept of Medical Oncology, University of
Glasgow, Glasgow, UK.
The mechanism by which anthracyclines exert their effects
on normal and neoplastic cells is still largely undefined.
Information on their cellular distribution at different con-
centrations may provide important evidence on sites and468 THIRTIETH BACR AND FOURTH ACP MEETINGS
mechanisms of action. Silver enhanced immunogold (IGSS)
techniques have been used to visualise the distribution of
adriamycin (ADR) in a human breast carcinoma cell line
(2R75). Cells were cultured until almost confluent and
treated with 0-1 Igml-I ADR for 24 hours. The cells were
resuspended in drug free medium for 24 hours, trypsinised
and harvested. Aliquots of each cell suspension were pipetted
onto albumin-coated slides, air dried and freeze permea-
bilised on dry ice. A rabbit polyclonal antibody, produced
against an ADR-BSA conjugate was purified on a controlled
pore glass column to which BSA had been coupled. This
procedure eliminated nonspecific binding to proteins. The
slides were incubated with ADR antibody overnight, stained
with gold labelled second antibody (Intense M, Janssen Life
Sciences) and counterstained with eosin. The intensity and
extent of immunostaining corresponded to ADR concent-
ration in the cells measured with a specific ADR radio-
immunoassay (0-721 pg jg-1 protein). At low concentrations
staining was confined to the cell membrane but at higher
concentrations both the cell membranes and intracellular
components were stained. Using IGSS immunocytochemistry
it is possible to visualise the distribution of ADR in cells
grown in culture and the technique has the potential of being
used with electron microscopy for subcellular investigations.
Supported by the CRC.
Concentration and time-independent factors in the
determination of cytotoxicity?
S.M. Crawford, R.M. Phillips, J.A. Double & M.C. Bibby
Clinical Oncology Unit, University of Bradford, BD7 JDP,
West Yorkshire, UK.
The anti-tumour effect of a cytotoxic agent is accepted as
being determined by the area under the plasma concent-
ration curve in in vivo studies, represented by the product of
concentration (C) and exposure time (t) in in vitro work.
Antimetabolites are regarded as potential exceptions to this
because enzyme inhibition by drugs used clinically is usually
reversible. The aim of this study was to assess in vitro
whether or not long exposures to low drug concentrations
were more toxic than short exposures to high drug concent-
rations whilst maintaining the same overall drug C x t expo-
sure. The cell line used in this study was derived from an
ascitic murine adenocarcinoma of the colon (MAC 15A)
tumour and chemosensitivity in vitro was assessed using a
modified clonogenic assay. ThioTEPA caused little variation
in cell survival following a 3, 6 and 24 hour exposure with
ID70 values ranging from 20 to 15,ughml- '. One hour
exposure proved to be less active (ID70=25 pghml-1).
Methotrexate was ineffective at all drug concentrations
following a 1 hour drug exposure. A 3, 6 and 24 hour
exposure produced dose-response curves with an initial
exponential phase followed by a distinct plateau phase.
Cell kill was strongly related to the duration of drug
exposure. Flavone acetic acid induced exponential dose
response curves. Long exposures to low drug concentrations
were more toxic with ID70 values for 1, 6, 24, 48 and 72
hour drug exposures of 8, 10, 7, 2.5 and 1.25mghml-1
respectively. Preliminary data suggest that adriamycin shows
a similar but much smaller time-dependent effect against
MAC 26 cells. This suggests that for drugs other than
alkylating agents clinical schedules ensuring prolonged expo-
sure should be investigated and that studies of tumour
penetration by cytotoxics should address the dynamics of
this process.
Blood transfusion, recurrence of laryngeal carcinoma and
AgNORs
T. Alun-Jones, P.J. Clarke & J. Hill
Department of Otolaryngology, Radcliffe Infirmary,
Oxford and Nuffield Department Surgery, Oxford, UK.
Blood transfusion induced immunosuppression may have a
detrimental effect on prognosis in patients undergoing sur-
gery for malignant disease but retrospective clinical trials
have yielded conflicting results. In those studies which have
found a positive correlation between transfusion and progno-
sis, it is possible that transfusion is only an epiphenomenon,
and is a marker of patients with an intrinsically bad
prognosis. In order to investigate this possibility, 69 patients
who had a laryngectomy for carcinoma of the larynx were
studied. Patients were excluded if they had metastatic disease
at the time of surgery (either local or distant). 38 had
received a peroperative transfusion and 31 had not. The
groups were comparable for age, sex, site of tumour, stage,
operating time and preoperative haemoglobin. At 5 years,
survival in the transfused group was 44.7% compared with
90.3% in those patients who were not transfused (P<0.001,
x2 test). Blood transfusion was found to be the only factor
of importance in determining outcome when prognostic
factors were included as covariates in a multiple regression
analysis (P<0.01). the paraffin sections of the tumours were
then stained for the presence of AgNOR bodies. These are
extranuclear collections of DNA, and the number of
AgNORs per cell has recently been postulated as a measure
of biological tumour aggression. In a preliminary study of
the laryngeal tumours from our study there was no differ-
ence in AgNOR scores between transfused and nontrans-
fused patients. This implied that the deleterious effect of
transfusion in this study could not be explained by a
difference in either known prognostic variables or by a
marker of tumour aggression.
Pregnancy outcomes in childhood cancer survivors:
probable effects of abdominal irradiation
R.A. Smith & M.M. Hawkins
Childhood Cancer Research Group, Radcliffe Infirmary,
Woodstock Road, Oxford, UK.
A postal survey of 2,083 general practitioners of childhood
cancer survivors of reproductive age has revealed that
females who were directly abdominally irradiated (exposed),
particularly for Wilm's tumour, have an increased risk of
several untoward pregnancy outcomes as compared with
female survivors of the same types of tumour not directly
abdominally irradiated (unexposed). Among female survivors
22% and 41% of those exposed and unexposed, respectively,
have children. The corresponding percentages of first preg-
nancies reported as ending in spontaneous abortion were
9/40=22% and 11/174=6%. The mean birthweight of first
singleton children born to exposed mothers was over 300 g
less than the corresponding value for unexposed mothers.
We conclude that radiation is probably involved in the
mechanism producing these effects but how it does so is
uncertain. There are four hypotheses to explain this associa-
tion: (a) radiation induced genetic damage; (b) uterine
abnormalities; (c) lack of uterine distensibility; (d) late effects
of radiation on the vasculature of the uterus. With the aid of
modern ultrasound and pathological techniques it should
prove possible to test these hypotheses. A register of such
women is to be set up with the aim of appropriately
monitoring these women and their pregnancies and to obtain
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for histological examination. The findings have implications
for counselling survivors, monitoring their pregnancies and
treating future patients.
Which smokers develop lung cancer?
D.J. Hole, C.R. Gillis & V.M. Hawthorne
West ofScotland Cancer Surveillance Unit, Glasgow, UK and
Department of Epidemiology, Univ. of Michigan, USA.
Cigarette smoking is a major risk factor for both lung cancer
and ischaemic heart disease. What is not clear is whether
other characteristics differentiate between these two diseases.
This paper examines the role of respiratory symptoms,
cholesterol and body mass index using data collected in a
prospective general population cohort study of 15,399 men
and women aged 45-64 resident in urban West of Scotland,
an area with the highest lung cancer incidence in the world.
2,397 deaths and 1,594 cancer cases have occurred in the 12
years of follow-up. Low cholesterol, low body mass index
and the presence of respiratory symptoms are all significant
independent factors in identifying a high risk group for lung
cancer. The relationship between low cholesterol and high
lung cancer risk is steepest for heavy smokers (>15 cigar-
ettes per day), less steep for light and ex-smokers and non-
significant for those who have never smoked. In addition, a
similar relationship holds for low cholesterol and other
smoking-related cancers. These relationships remain even
when cancer cases diagnosed within the first four years
following screening are excluded. Further, there is no evi-
dence to suggest that the findings are a result of individuals
with high cholesterol and high body mass index dying first
from ischaemic heart disease.
Cancer of the stomach: is it declining?
J. Powell & C.C. McConkey
Regional Cancer Registry, Q.E. Medical Centre, Birmingham
B15 2TH, UK.
The precise reasons for the well documented and world-wide
decline in stomach cancer have never been proven. More
recently a few centres have reported an increase.
Data in the West Midlands Regional Cancer Registry
include details of both subsite and histology. An analysis of
the period 1962-1981 was undertaken as part of a much
larger study. Age standardised incidence rates were used to
allow for the ageing population. The overall decrease in
stomach cancer was confirmed, but focusing on specified
sites within the stomach showed a considerable increase in
adenocarcinoma of the cardia (from 0.75 to 2.01 per
100,000) and smaller increases in the other sites with the
exception of the pyloric antrum which remained relatively
constant (at about 2.6). Unspecified sites have decreased in
number but more precise localisation is unlikely to be the
main reason for the changes observed since increases were
also observed in adenocarcinoma of the oesophagus.
The aetiological implications are intriguing but there are
also implications for patient management since lesions of the
cardia have the worst prognosis. Further, the above oppos-
ing trends could not be demonstrated if only mortality data
is studied.
Stage II melanoma in the West of Scotland: prognostic
indicators for survival and effects of adjuvant chemotherapy
D.M. Tillman, T.C. Aitchison & R.M. MacKie
Departments of Dermatology & Statistics, University of
Glasgow, UK.
We have carried out a retrospective analysis of patients
undergoing therapeutic lymph node dissection for stage IIA
melanoma at the regional plastic surgery centre between
1976 and 1985. There were 142 patients (68 M, 74 F), mean
age 52yr (range 18-87). Features of the primary tumour
were as follows. (1) Site: head and neck 15.5%, trunk 20.4%,
lower limb 47.9%, upper limb 16.2%. (2) Histogenetic type
(n= 120): nodular 35.9%, superficial spreading 47.5%, acral
lentiginous 8.3%, lentigo maligna melanoma 5%, unclassi-
fiable 3.3%. (3) Breslow thickness (n= 110): 0-1.49mm 11%,
1.5-3.49mm 44.5%, >3.5mm 44.5%. (4) Clark level
(n=118): II 2.5%, III 15.3%, IV 67.8%, V 14.4%.
The disease-free interval between excision of the primary
tumour and Stage II disease was 0 in 15%, <1 yr in 41.5%,
<2yr in 23.2%, 2-4yr in 9.1% and >4yr in 11.2%. In
35.3% 1 node, 21.8% 2 nodes, 16.8% 3 nodes, and 26.1% 4
or more nodes were involved (n=119).
91 patients (64.1%) received no adjuvant therapy, 24
(16.9%) had 2 courses of adjuvant BELD (bleomycin,
vindesine, lomustine, DTIC) and 27 patients (19%) other
adjuvant monotherapy. The overall 5-year survival after
lymphadenectomy (life table analysis) was 26%. Although
there was a trend towards improved survival in both groups
receiving adjuvant therapy, this was not significant. Using a
proportional hazards model with stepwise variable selection,
overall survival was significantly related to the number of
involved nodes and the age of the patient.
This study confirms the poor prognosis of patients with
stage II melanoma and that the extent of nodal metastatic
disease is the main determinant of survival. It also demon-
strates the limited value of systemic adjuvant therapy and
provides a database for the design of new treatment
strategies.
Analysis of prognostic factors for survival in soft tissue
sarcomata
J.N. El-Jabbour, K.M. McLaren, G.R. Kerr, S.S. Akhtar,
A. Rodger, J.F. Smyth & R.C.F. Leonard
University Department of Pathology, Teviot Place, Edinburgh
EH8 9AG; and Clinical Oncology Department, Western
General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.
Histological review of 223 cases referred to the Clinical
Oncology Department, Edinburgh in a 10 year period with a
diagnosis of sarcoma or Mullerian tumour confirmed the
diagnosis of sarcoma in 163 patients. Since 33 of these were
not referred at initial diagnosis but presented to us as local
recurrence (21), metastases (5) or both (7), they were
excluded from the survival analysis to minimise the effect of
referral bias. Uni- and multivariate analyses were performed
to detect significant prognostic factors on the remaining 130
patients.
The five-year survival was 21.7%. By univariate analysis,
the following factors were of prognostic significance: radio-
therapy (P<0.0001), surgical treatment (P<0.0001), site
(P=0.001), mitotic activity (P=0.001), grade (P=0.005) and
histological type (P=0.039). Necrosis (P=0.354), size
(P=0.409), age (P=0.58) and sex (P=0.17) were not.
The multivariate analysis on 68/130 patients with known
size revealed the following independent prognostic factors:
surgical treatment (P=0.0001), radiotherapy (P=0.0031)470 THIRTIETH BACR AND FOURTH ACP MEETINGS
and necrosis (P =0.0090). When size was not among the
variables analysed (105/130 cases) the independent prognos-
tic parameters were: surgical treatment (P<0.0001), necrosis
(P=0.0006), radiotherapy (P=0.0096) and mitotic activity
(P<0.0337).
These data will be compared with those from other major
series.
Determination of prognosis in advanced colorectal cancer
K. Moran, T. Cooke, G. Forster, P. Gillen, S. Sheehan,
P. Dervan & J.M. Fitzpatrick
Departments of Surgery and Pathology, Mater Hospital,
Dublin, Ireland, and Royal Liverpool Hospital, Liverpool, UK.
Conventional clinical and pathological prognostic parameters
are inaccurate in colorectal cancer. One-third of patients
with Dukes' B die with 1/3 of those with Dukes' C surviving
long-term, irrespective of histological differentiation. We
studied the prognostic value of NORs and ploidy status and
their correlation with established prognostic parameters in
advanced colorectal cancer. Fifty-one patients aged 35-81
(mean 61.6 years) with Dukes' C tumours (8 with liver
metastases) were studied. All were followed for a minimum
of 5 years. Sections from primary tumours (10) and lymph
node metastases (LN) were stained for NORs. Ploidy status
was determined for primary tumours in 40 patients using
flow cytometry. NOR and ploidy status were correlated with
age, sex, histological differentiation, presence of liver meta-
stases and survival time and the independent significance of
prognostic variables was determined using Cox's multivariate
regression analysis. NORs and ploidy values did not corre-
late with age or sex. Sixteen patients who survived 5 years
had lower NOR counts than non-survivors (P<0.05) Mann-
Whitney U test. Survivors had a lower percentage of aneu-
ploid tumours. NORs were the most important individual
variable for predicting survival (P<0.05). Ploidy values
correlated with histological differentiation and liver metas-
tases.
Survivors (J°LN) Non-survivors (J°LN)
NOR
(median, range) 12 (8-15) 11 (8-15) 17 (14-25) 18 (13-25)
Ploidy
(% aneuploid) 40% 57%
In conclusion, NORs were more accurate and ploidy
values were as accurate as conventional clinical and patho-
logical parameters in predicting 5-year survival in advanced
colorectal cancer.
Will DNA ploidy predict response to chemotherapr in
end-stage squamous carcinoma of the head and neck?
L.D. Cooke, T.G. Cooke, G. Forster, T.R. Helliwell,
D. Spiller & P.M. Stell
Departments of Otorhinolaryngology, Surgery, Pathology and
Radiation Biology, Univ. of Liverpool, UK.
In two phase III trials we have shown that cisplatinum
significantly prolongs survival in patients with end stage
squamous carcinoma of the head and neck region. Factors
such as performance status, age, site, nodal status and serum
albumin are prognostic but are not significantly clear cut to
define which patient should be treated. In an attempt to
improve on this we have measured tumour cellular DNA in
this same group.
We studied tumours from 41 untreated and 52 patients
receiving cisplatinum as part of a prospectively randomised
trial. 50pm sections of tumour were enzymatically disaggre-
gated, treated with RNAase, and the DNA stained with
propidium iodide. Following analysis by flow cytometry they
were classified as diploid or aneuploid.
Fifty-four per cent of all tumours were aneuploid and
46% diploid, with similar proportions in both treated (57-
43%) and untreated patients (51-49%). Survival for
untreated patients with diploid tumours of 68 days was
increased to 128 days after chemotherapy; this difference was
not significant (X2=1.91). However, the survival of aneu-
ploid tumours increased four-fold from 55 to 224 days
(X2=10.29 P<0.001).
This study suggests that cisplatinum chemotherapy in end
stage head and neck cancer should be restricted to patients
with aneuploid tumours.
Steroid receptors and enzyme activity in human
breast carcinoma
V. Ramalingam & P. Govindarajulu
Dept of Endocrinology, P.G. Institute of Basic Medical
Sciences, Madras 600 113, Dept. Zoology, Tagore Arts
College, Pondicherry 605 008, India.
The potential markers of oestrogen action in breast cancer is
of greatest importance to improve the selection of patients
for hormonal therapy. Since the activities of lactate dehydro-
genase (LDH) and glucose-6-phosphate dehydrogenase
(G6PDH) have been reported to be oestrogen responsive in
reproductive tissues, an attempt has been made to evaluate
oestrogen receptor (ER), progesterone receptor (PR), LDH
and G6PDH in the cytosol of 160 human breast cancer
tissues. 71% and 64% of the subjects were found to be ER
positive and PR positive (>5 fmol mg protein-1) respec-
tively. More than 80% of the cases showed increased
activities of LDH and G6PDH when compared to the
normal tissues. The enzyme activities were similar in ER
positive cases and ER negative cases though they were
observed with elevated activity. However, both the enzyme
activities were significantly higher in the PR positive cases
when compared to PR negative cases. PR has been shown as
a post-nuclear marker of oestrogen action. From the results
of this study, it may be suggested that LDH and G6PDH
could be considered as sensitive markers of functional ER
sites and it may provide a better monitor for the selection of
hormone dependent cancer.
The relationship between myeloma-mediated inhibition of
osteoblast-like cells and TNF
C.E. Evans, C.S.B. Galasko & C. Ward
University ofManchester, Dept ofOrthopaedic Surgery, Hope
Hospital, Eccles Old Road, Salford M6 8HD, UK.
We have previously reported that the bone-resorbing tumour
myeloma will inhibit the proliferation and DNA synthesis of
human osteoblast-like cells (BDC) in vitro. Further experi-
ments have demonstrated that myeloma cells from other
sources also have this effect. Thus, having established that
this is a reproducible effect and common feature of this
tumour, we are now attempting to find the substances
responsible. We report here preliminary results for this
project. Using the cytotoxicity test for TNF, we have found
this cytokine to be present in medium conditioned by the
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then incubated our BDC with pure TNF-# at the same
concentration as that in MCM. Proliferation of the BDC
was inhibited by a mean of 39%. Incubation of the BDC
with TNF-fl at a range of concentrations showed that this
effect was dose-dependent. As the cytokine concentration
increased, the inhibition of the BDC growth increased. These
results confirm those found with MCM itself. A plateau was
reached at 35U/ml, after which there was no further increase
in inhibition. TNF-,B also had a dose-dependent effect on
DNA synthesis, as with increasing concentrations of TNF-fl,
increasing stimulation was seen. No plateau was reached,
however. These results are dissimilar to those seen with
MCM. We are now attempting to isolate TNF-j from the
MCM. Initial purification work has yielded some fractions
with similar effects to TNF-,B. Our results suggest that more
than one factor is involved in myeloma mediated osteoblast
inhibition.
Comparative effects of two gastrin receptor (GR) antagonists
on the growth of gastrin responsive gut tumours
sis. Most tumours (70%) had both high (mean KD
3.1 nmol1-1; range 0.3-9.9) and low (mean KD 136nmolI;
range 16-500) affinity binding sites, although 15 tumours
had a single binding site (mean KD 5.7 nmol 1-1; range 1.1-
13.7). Binding capacity expressed as fmol per mg membrane
protein was 1.9 (range 0.4-5.9), 10 (range 0.8-34) and 3.2
(range 0.7-10.8) respectively: expressed as fmol per pg DNA
the values were 7.5 (range 1-23), 48 (range 5-288) and 10.3
(range 2-28). There was no apparent association between the
binding capacity of the high affinity or sole receptor and
tumour stage. The majority (78%) of tumours were oestro-
gen receptor negative (<20fmol per mg protein) and
although this group included tumours with the highest levels
of high affinity receptor, the mean values were similar (2.33
vs 2.3fmol per mg membrane protein; 8.83 vs 6.6fmol per Mg
DNA). Thus the inverse relationship between oestrogen and
EGF receptors reported in breast cancer is not evident in
cervical carcinoma. Median follow up is 12 months and 4 pts
have died: there is no correlation, as yet, between survival
and EGFR.
S.A. Watson, L.G. Durrant & D.L. Morris
Cancer Research Campaign Laboratories, University of
Nottingham, NG7 2RD, and Dept of Surgery, University
Hospital, Nottingham NG7 2UH, UK.
The effect of 2 GR antagonists (Proglumide and CR1409,
Rotta) on the growth and gastrin response of gut tumour
cells was investigated.
For a comparison of GR binding, a GR positive tumour
cell line was used (AR42J, rata pancreatic). The concent-
rations inducing 50% inhibition of binding (IC50) of 1251-
gastrin-17 (G-17) to GR was 5 x 10-10M for G-17 alone,
3 x 10-6M for CR1409 and > 10-4M for proglumide.
Basal growth of a human gastric tumour cell line,
MKN45G which produces its own gastrin (30 ngI1 day-
as measured by an RIA) was inhibited by CR1409 to 30%
of control values as measured by 75Se-selenomethionine
uptake at a concentration 10 times the IC50' The compound
had no effect on cell viability. Proglumide (up to 10-3M)
had no effect on basal growth.
AR42J cell growth is increased by G-17 (as measured by
75Se-selenomethionine uptake). Proglumide (3 x 10-4M)
reduced the growth response to gastrin at 5 x 10-11M. G-17
(150-100% of control) but not at 10-10M G-17 (280% of
control). GR1409 (3 x 1O-6M) reduced the growth response
at both G-17 concentrations; 5xlO-11, 150-100% control,
10-10M, 280-130% of control.
Antagonists of GR can reduce both gastrin-stimulated gut
tumour growth and basal growth (if gastrin is involved in
autocrine/paracrine growth stimulation) and may therefore
be of great therapeutic benefit.
Epidermal growth factor receptors in cervical cancer
M. Harding, J. McIntosh, F. Rinaldi, R.P. Symonds,
N. Reed, T. Habeshaw & R. Leake
Departments of Oncology and Biochemistry, University of
Glasgow, UK.
Epidermal growth factor receptor (EGFR), a transmembrane
glycoprotein is present in large amounts on many squamous
carcinomas and a cervical cancer cell line (A431). EGFR has
been measured in 50 non-pretreated cervical tumours (FIGO
stages I, n=9, II n= 15, III n= 19 and IV n=7) by
radioligand binding alone and in the presence of an excess of
non-labelled ligand, and data subjected to Scatchard analy-
Nature of mitogenic activity in extracts of colon carcinoma
J. Sweetenham, A. Richter, D. Davies & P. Alexander
CRC Medical Oncology Unit, Centre Block CF99,
Southampton General Hospital, Southampton S09 4XY, UK.
Ten of ten surgical specimens of carcinoma were found to
stain in frozen section with monoclonal antibodies directed
against either human EGF or TGFca. In the majority both
the carcinoma cells (identified by staining for cytokeratin)
and the macrophages (identified with a monoclonal antibody
directed against CDlIC) stained for either hEGF or TGFai
or both. Acid as well as detergent extracts from these
tumours were prepared and fractionated by anion chromato-
graphy. The fractions were analysed for mitogenic activity of
density inhibited human fibroblasts and by ELISA for
hEGF. An antibody against the EGF receptor blocked
mitogenic activity induced by either EGF or TGFa and was
used to identify TGFa activity after removal of hEGF by
immunoabsorption. Evidence was found that the mito-
genicity in some fractions was produced by very low con-
centrations of hEGF which were below detection by ELISA,
due to potentiation by TGFf. However, the principal mito-
genic activity was not due either to hEGF or TGFx, but was
fibroblast growth factor-like as it was absorbed by heparin.
We cannot determine if this FGF-like activity within the
tumour is produced by the cancer cells, by stromal compo-
nents or by infiltrating leukocytes.
Effects of bryostatins (BRYOs) on protein kinase C (PKC) in
A549 human lung carcinoma cells
T.D. Bradshaw, I.L. Dale, A. Gescher & G.R. Pettit
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET,
UK; and Cancer Research Institute, Arizona State
University, Tempe, USA.
BRYOs are macrocyclic lactones isolated from the marine
bryozoan Bugula neritina which possess antineoplastic
activity against the murine P388 lymphoma. Like the tumour
promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), the
BRYOs are activators of PKC. At nanomolar concentrations
the BRYOs mimic some effects of TPA, for example inhibi-
tion of growth of A549 cells, but at higher concentrations472 THIRTIETH BACR AND FOURTH ACP MEETINGS
BRYOs 1 and 2 antagonise TPA. We have tested the
hypothesis that the concentration-dependent biphasic effect
of the BRYOs is correlated with their ability to interact with
PKC. BRYOs 1, 2, 4 and 5 competed with 3H-labelled
phorbol dibutyrate (3H-PDBu) for specific receptor sites in
intact cells. On incubation for 30min at 37°C BRYOs 1, 2, 4
and 5 at lnM inhibited 3H-PDBu binding by 28+2%,
18+7%, 29 +7% and 62+10% respectively, and at 100 nm by
74+3%, 46+6%, 73+3% and 78+4% respectively
(mean+s.d., n=8). PKC activity in the cytosolic and particu-
late fractions of the cells was quantified after partial purifi-
cation by non-denaturing PAGE. On incubation for 1 h,
10nM BRYO 1 induced translocation of 31% of PKC
activity from the cytosol to the membrane. After 5 h, 47%
of enzyme activity was down-regulated. Treatment with 1gM
BRYO 1 caused a more rapid down-regulation; after 1 h,
65% (n=2) of PKC activity had disappeared. The results
show that 'the BRYOs possess high affinity for the phorbol
receptor and modulate PKC location and activity in a
manner similar to TPA, which suggests that their ability to
antagonise TPA-induced growth inhibition does not involve
PKC or is mediated by a PKC isoform insensitive to TPA.
Specific biochemical or less-specific biophysical action of ether
lipid SRI 62-834 on tumour cell membranes in vitro?
C. Dive, M.G. Thompson, J.A. Hickman, J.V. Watson
& P. Workman
Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, and MRC Clinical Oncology Unit,
Cambridge, UK.
SRI 62-834 is a novel analogue of the phospholipid platelet
activating factor currently undergoing preclinical evaluation
as a membrane-directed antitumour agent. We previously
showed that it modulates membrane permeability to a
fluorescein derivative BCECF and propidium (P) by flow
cytometry (FCM), and causes non-toxic elevation of cellular
calcium (Ca2+i) by fluorimetry using fluorescent probe
Quin-2. FCM offers unique advantages of both twin-probe
analysis and individual subpopulation identification. Here we
report simultaneous measurement of Ca2'i and permeability
to P in drug-treated EMT6 mouse mammary tumour cells by
FCM. Cells (106ml- 1 in medium) were preloaded with
Quin-2 for I h via its lipophilic ester (20 pM), washed and
resuspended in Ca2 + buffer (pH 7.2) before addition of
propidium iodide (20ygml-1) and SRI 62-834 (1-80,pM).
UV laser excitation was used and blue (460-510nm, Quin-2)
and red fluorescence (>630nm, P) were immediately ana-
lysed together with light scatter and time. After 8 min the %
of cells permeable to P increased from 2% at 1gM to 80% at
80gM SRI 62-834. Blue fluorescence in this subpopulation
was minimal. For P-impermeable cells a time- and
concentration-dependent rise in blue fluorescence was
followed by a decrease. Importantly, at only 1 M drug,
Ca2+i was elevated for 20min before falling to control levels
at 35 min. At this concentration no cytotoxicity was seen by
MTT assay. These results indicate a specific effect on cell
membranes resulting in Ca2. i elevation at low drug concent-
rations (<15uM), with more dramatic, possibly biophysical
damage allowing influx of large charged molecules at higher
doses. They also support the possibility of a selective thera-
peutic effect against particular cell types.
Investigation of DNA/topoisomerase II interactions during
retinoic acid induced neutrophil-granulocyte differentiation:
evidence for DNA site-specificity
R.J. Anderson, J.M. Cunningham, D. Fisher & G.E. Francis
Molecular Cell Pathology Unit, Royal Free Hospital School of
Medicine, London NW3 2PF, UK.
We have shown that DNA breakage/reunion events,
mediated by topoisomerase II, are necessary and very early
changes during retinoic acid induced differentiation of
haemopoietic cells (Francis et al., Leukaemia, 1987, 1, 653).
Although a method (Trask et al., EMBO J., 1984, 3, 671)
exists for purifying DNA/topoisomerase complexes, this is
most efficient for DNA sites where many enzyme molecules
are attached and thus favours the recovery of replication
fork DNA (where topoisomerase II operates, possible to
separate daughter chromatids). DNA cleavage sites in the
regulatory sequences of known genes are isolated or in small
clusters, implying that this method may be unsuitable for
examination of differentiation-associated topoisomerase
binding sites. We have therefore devised a novel strategy to
purify covalently bound DNA/protein complexes (hence
topoisomerase II bound DNA), using liquid-liquid phase
partitioning. A significant increase in recovered protein-
bound DNA was achieved in HL60 cells with the addition of
10-9 to 10-5M VP16-213 (etoposide) which is known to
stabilise the DNA-Topoisomerase II complexes. Using the
new technique, we obtained highly purified topoisomerase II-
associated DNA from retinoic acid induced differentiating
cells. Hybridisation of this DNA with DNA enriched for, or
depleted of, protein-bound DNA from undifferentiated
HL60 cells and cells induced to differentiate by phorbol ester
or retinoic acid, demonstrated that the isolated DNA is
enriched for specific sequences (since significant differences
in hybridisation were obtained). This is, as far as we are
aware, the first demonstration that topoisomerase II inter-
acts at specific (or limited) sites in the genome during the
induction of differentiation. Break-site DNA is currently
being cloned for further evaluation of topoisomerase II's role
in differentiation.
Expression of mdrl and gst-pi in breast tumours, compared
with the chemosensitivity of the same breast tumour cells
in vitro
S. Stallard, R. Brown, N. Keith & S.B. Kaye
CRC Dept of Medical Oncology, University of Glasgow, UK.
Breast cell lines resistant to adriamycin have been shown to
express elevated levels of mdrl and/or gst-pi mRNA. How-
ever, it is still to be demonstrated that these genes have a
role in chemoresponsiveness of breast tumours in vivo. We
have measured the mRNA levels of mdrl and gst-pi in more
than 41 freshly excised human primary breast cancers by dot
blot filter hybridisation, and in some cases Northern hybridi-
sation. Relative levels of mRNA have been standardised by
hybridisation of the same filter to a probe for a ubiquitously
expressed gene, B2-microglobulin, and to poly d(T) for total
mRNA levels. Detectable, if low, levels of mdrl expression
were observed in 70% of the tumours, however in 30% there
was considerably higher levels of expression (up to 100-fold
higher). A range of gst-pi expression has also been observed
in these tumours, but not with as large a fold variation.
Chemosensitivity of cells grown in short-term culture from
these tumours has been measured by an in vitro colony
forming assay in the presence of adriamycin. The dose of
adriamycin causing 50% inhibition of growth (ID50) shows
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relations between ID50 and gene expression levels did not
reach significance; however, all the sensitive tumours in vitro
had low mdrl expression levels. Similarly the resistant
tumours tended to show high levels of mdrl expression.
These data would support the hypothesis that the mdrl gene
may play a role in determining the response of breast cancer
cells, and in some tumours it may play a role in conjunction
with other mechanisms of resistance.
Are established small-cell lung cancer (SCLC) cell lines an
appropriate model for clinical resistance?
R. Milroy, J.A. Plumb, S.W. Banham & S.B. Kaye
CRC Dept of Medical Oncology, University of Glasgow and
Dept ofRespiratory Medicine, Royal Infirmary, Glasgow, UK.
Many studies of drug resistance concentrate on cell lines
made resistant by exposure to drug in vitro but the relevance
of these lines to clinical resistance is not known. We have
established a number of SCLC cell lines from biopsies from
both untreated and treated patients and have demonstrated a
30-fold range in sensitivity to doxorubicin (DOX). In one
case, an apparently resistant line, LS274 (ID50 220nM), was
established from an untreated patient. The patient showed a
partial response to chemotherapy but later relapsed. A
second cell line established from relapse tumour from the
same patient was 4-fold more resistant to DOX (LS3 10,
ID50 1050nM) than LS274. In contrast, an apparently
sensitive cell line (LCPH3, ID50 39nM) was obtained from
tumour taken from a patient at relapse. All the lines express
L-dopa decarboxylase (DDC) and creatine kinase BB isoen-
zyme (CKBB) activities. The highest DDC activities
(LS274= 14, LS310 = 12mIUmg- 1 protein) are observed in
the two most resistant lines. Activities of CKBB do not
relate to chemosensitivity in vitro. Furthermore, apparent
resistance could not be explained by the growth character-
istics of the cells since LS1 11 which grows as tight aggregates
was of intermediate sensitivity (ID50 105nM) while LS263
which grows as loose easily disaggregated clusters was more
resistant (ID50 147nM). The resistance modifier Verapamil
(V) increased the drug sensitivity of a number of the cell
lines by 2-3-fold but there was no relationship betv-een
either sensitivity in vitro or patient history and the activit of
V. Thus, in one case chemosensitivities of two lines obta ned
from the same patient do reflect the patient history. 3w-
ever, the absolute chemosensitivity of an individual cell line
does not reflect the clinical history of the tumour from
which it was derived.
Is there a role for resistance modifiers in cancer
chemotherapy?
J.A. Plumb, R. Milroy & S.B. Kaye
CRC Dept of Medical Oncology, University of Glasgow,
Glasgow,
UK.
Activity of resistance modifiers is concentration dependent
and for many, maximal activity is observed at a concent-
ration of about 6.6pM. Thus for the resistant small-cell lung
cancer (SCLC) cell line H69LXIO, derived from NCIH69 by
chronic exposure to doxorubicin (DOX), drug sensitivity is
increased 10-fold at 6.6 pM Verapamil (V) but only 3-fold at
2 pM (which is the maximum plasma concentration achiev-
able clinically). We have shown that at similar concent-
rations the D-isomer of V (DV), thought to be less cardio-
toxic than the L-isomer, is an effective resistance modifier in
H69LXIO. Further clinical studies will determine the role of
DV based on achievable plasma levels. We have also deter-
mined the activity of a number of other resistance modifiers
in H69LXIO which we have shown to express P-glyco-
protein. Both Quinidine (Q, 6.6pM) and Bepridil (B, 4pM)
increased the sensitivity to DOX, by 10 and 8-fold respecti-
vely, and these concentrations can be achieved in pat'-nts.
All the modifiers stimulate the rate of lactate production by
the cells and the increase correlates with the degree of
resistance modification achieved with DOX. These obser-
vations are consistent with the theory that the modifiers act
on the efflux pump protein, P170, possibly by inhibition of
the energy supply. However, preliminary observations with
intrinsically resistant non-SCLC cell lines indicate that V can
increase DOX sensitivity to an extent which other modifiers,
including DV, may not achieve; hence V may have more
than one mechanism of action. Thus Q or B are better
candidates for modification of the MDR phenotype, but V
may still have a role through other undefined mechanisms.
Resistance modification by cyclosporins in mouse
multidrug-resistant (MDR) cell lines
P.R. Twentyman, K.A. Wright & J.G. Reeve
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
We have previously reported that the non-immunosuppressive
cyclosporin, B3-243 (Sandoz), is a more potent resistance
modifier (RM) than cyclosporin A (CsA) in the human small
cell lung cancer MDR subline H69/LX4. These two com-
pounds have now been examined for their RM properties in
the EMT6 mouse tumour cell line and three MDR sublines
(ARL.0, VRL.0, CR0.2) derived in vitro by exposure to
adriamycin (ADM), vincristine (VCR) and colchicine (COL)
respectively. Dose-response curves to cytotoxic drugs were
obtained using a 3 day MTT assay in the presence or
absence of the RM agent. Doses of RM used were 2.5 and
5.Opgml-1 for CsA and 0.5, 1.0 and 2.5pgml-1 for B3-243.
Sensitisation ratios (SR=ratio of ID50s in absence/presence
of RM) are shown in the table for 2.5pgml-I of the RMs.
Expression of SR (CsA/B3-243)
Cell line P-170 Sorcin ADM VCR COL
EMT6 parent + - 9.4/9.2 4.6/2.4 6.6/7.8
AR1.0 + + + + 29.0/5.0 38.0/3.5 36.0/3.0
+'R1.0 + + + + 29.0/6.9 53.0/6.3 50.0/7.8
CR0.2 + + + + 22.2/9.6 34.0/20.0 26.0/16.2
It is clear that, at 2.5pgml-1, CsA is generally a much
more effective RM than B3-243 in sublines ARL.0 and
VR1.0 where high level expression of P-170 is observed.
However, the relative efficiency of B3-243 is much greater in
CR0.2 (which has a lower level of MDR than ARL.0 and
VRL.0).
Measurement of individual cell glutathione content in human
cancer biopsies using flow cytometry
D.W. Hedley, A.R. Hallahan & E.H. Tripp
Ludwig Institute for Cancer Research, University of Sydney,
NSW 2006, Australia.
Glutathione (GSH) is the principal thiol-containing free
radical scavenger in mammalian cells. Elevated levels may be
an important cause of clinical resistance to agents which act
through radical generation, and GSH depletion using buth-474 THIRTIETH BACR AND FOURTH ACP MEETINGS
ionine sulphoximine (BSO) can improve the therapeutic
index of alkylating agents used to treat human tumour
xenografts. Rice et al., (Cancer Res., 1986, 46, 6105) have
described a flow cytometric (FCM) method in which the
non-fluorescent probe monochlorobimane (MBCI) forms a
fluorescent adduct with GSH under the action of GSH-S-
transferase. We have confirmed that >99% of fluorescence
is found in a low molecular weight cytoplasmic fraction of
MBC1-stained EMT6 carcinosarcoma cells. By variably dep-
leting these cells of GSH using BSO, and then performing
simultaneous FCM and biochemical (Eyer & Podhradsky,
Anal. Biochem., 1986, 153, 57) analyses we were able to show
an excellent correlation between the two (n = l1, r = 0.969).
Fluorescent calibration beads were run immediately prior to
the FCM GSH samples, and were assigned a fluorescence
value equivalent to a known cellular GSH content. Sub-
sequent FCM measurements were quantitated by reference
to this fluorescence standard. To date we have examined 4
non-Hodgkin's lymphomas and 8 carcinomas. Six samples
were obtained by fine needle aspiration biopsy (FNAB) and
6 were surgical specimens. Mean GSH content was
0.24+0.12 for the lymphomas and 0.99+0.39fmolcell- for
the carcinomas. The carcinomas showed a wide range in
individual cell values, which was not simply related to cell
size. Because it is rapid (<30 min), quantitative and can be
performed using FNAB samples, FCM measurement of
GSH content should be particularly useful for monitoring
the effects of agents such as BSO which are intended to
overcome GSH-mediated resistance.
Mechanisms associated with differential cisplatin sensitivity
expressed by three human ovarian carcinoma cell lines
S.A. Shellard, L.K. Hosking & B.T. Hill
Cellular Chemotherapy Lab., Imperial Cancer Research Fund,
Lincoln's Inn Fields, London WC2A 3PX, UK.
Certain in vitro characteristics of two recently established
human ovarian carcinoma cell lines (TR170 and TR175)
(Hill et al., Int. J. Cancer, 1987, 39, 219) have been
compared with those of the well established SK-OV-3 cell
line of similar origin. Drug concentrations reducing cell
survival by 50%, obtained from colony forming assay data,
indicated a 10-fold and 26-fold hypersensitivity to cisplatin
in the TRI70 and TR175 cells respectively, when compared
to the SK-OV-3 cell line. However, no significant differences
in cellular uptake and DNA binding of drug were observed
in these three cell lines. One possible explanation for the
hypersensitivity of TR170 and TR175 cell lines to cisplatin
may be attributed to their reduced levels of total glutathione
content, glutathione reductase and glutathione peroxidase
activities. In contrast a two-fold elevation in glutathione S-
transferase activity (GST) was observed in the TRI70 cells,
whereas GST activities were comparable in the TR175 and
SK-OV-3 cell lines. Preliminary data obtained from alkaline
elution studies suggest that at equimolar concentrations of
cisplatin less DNA damage is induced in the TR175 cells
than in the more resistant SK-OV-3 cells. Furthermore both
cell lines appear proficient in the repair of interstrand cross-
links. In order to more clearly define the mechanisms of
differential cisplatin sensitivities observed in these cell lines it
is now proposed to quantitate the induction and removal of
cisplatin adducts using polyclonal antisera, according to the
procedure described earlier (Bedford et al., Cancer Res.,
1988, 48, 3019).
Mitomycin C resistance: association with decreased NADPH
cytochrome P450 reductase activity in Chinese hamster
ovary (CHO) cells in vitro
M.I. Walton, P.R. Hoban, C.N. Robson, P. Workman,
A.L. Harris & I.D. Hickson
MRC Clinical Oncology Unit, Cambridge CB2 2QH and Dept
Clinical Oncology, Newcastle NE2 4HH and Oxford
OX3 7LJ, UK.
Mitomycin C (MMC) is the prototype bioreductive alky-
lating drug in clinical use. To investigate the mechanism of
resistance, a MMC resistant cell line (MMCr) was derived by
exposing normal CHO (KI) cells to increasing drug concent-
rations in air. MMCr exhibited a 16-fold resistance to MMC
but only a 2-fold resistance to the more readily activated
MMC analogue BMY 25282. We examined the rates of
MMC and BMY 25282 reduction in CHO-Kl and MMCr
cells under aerobic (air) and anoxic (N2) conditions. In
addition we characterised some of the reductases present in
these cells. MMC and BMY 25282 loss were monitored by
reverse-phase HPLC. Reactions were carried out under N2
using cell sonicates in the presence of NADH, NADPH and
drug (50pM). Rates of reduction of MMC and BMY 25282
were at least 30-fold greater under N2 than air. Under N2,
MMC reduction was 2-3-fold lower in MMCr compared to
K1 cells, e.g. 0.0782+0.018 and 0.238+0.054nmol-
min- 1 mg-1 protein, respectively (mean+2 s.e., n=4,
P<0.01). Aerobic MMC reduction rates were too low to be
assayed. By contrast rates of BMY 25282 reduction in
MMCr and KI cells were comparable in either air or N2 and
10-20-fold faster than for MMC, e.g. - 3.0nmol
min-1mg - protein in N2. The activity of NADPH cyto-
chrome P-450 reductase, an enzyme implicated in MMC
bioactivation, was 3-4-fold lower in MMCr compared to KI
cells, e.g. 0.582+0.11 versus 2.43+0.033nmol cytochrome c
reduced min 1 mg- protein, respectively (mean+2 s.e.,
n=3, P<0.001). No DT-diaphorase activity was detectable
in MMCr cells. These results clearly implicate decreased P-
450 reductase activity in the mechanism of increased resis-
tance to MMC in MMCr CHO cells in vitro. Similar
mechanisms may operate in vivo, and more readily activated
derivatives might potentially overcome such resistance.
Sensitivity of a methotrexate-resistant tumour cell line to a
methotrexate-albumin-monoclonal antibody conjugate
K. Affleck & M.J. Embleton
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
An osteogenic sarcoma cell line, 791T, was rendered resistant
to methotrexate (MTX) by growth in increasing concent-
rations of MTX at consecutive passages, in the continuous
presence of 12-O-tetradecanoylphorbol 13-acetate. A subline
designated 791T-R120 was derived which required approxim-
ately 50 times more MTX than the parental line to achieve
an IC in a 75Se-selenomethionine incorporation cyto-
toxicity assay. Studies on the uptake of 3H-MTX suggested
that resistance in this subline was predominantly due to
diminished MTX transport.
A conjugate constructed by linking a monoclonal antibody
against 791T (79IT/36) to MTX via human serum albumin
as a carrier was provided by Dr M.C. Garnett. This was
tested for cytotoxicity against both parental and resistant cell
lines in comparison with free MTX. 791T-R120 showed
sensitivity to the conjugate equal to that of parental 791T,
the respective IC50s being 11 and 14 ng ml-1 for the
conjugate and 756 and 18 ng ml - I for MTX. It thusTHIRTIETH BACR AND FOURTH ACP MEETINGS 475
appeared that the altered (i.e. antibody-mediated) mechanism
of uptake of MTX in conjugate form overcame the transport
deficiency in the resistant cell line. it is suggested that drug-
antibody conjugates might be useful in overcoming some
clinical cases of drug resistance if administered in the
appropriate form and by a suitable route.
Enhancing the effectiveness of bioreductive drugs in vivo
J.C.M. Bremner, I.J. Stratford, L. Ding & G.E. Adams
MRC Radiobiology Unit, Chilton, Oxon OXJJ ORD, UK.
Increasing tumour hypoxia to 100% can substantially
enhance the effect of bioreductive drugs such as RSU1069
and SR4233. We have demonstrated this using a growth
delay assay in KHT, RIF-l and 16/C tumours. An in vitro
cell survival assay of tumour cells treated in vivo 24 h
previously, shows that when KHT tumours are treated with
80 mg kg - RSU1069 followed 15 min later by clamping for
90min, the surviving fraction is reduced to 5 x 10-. This is
wholly consistent with the growth delay data. Other means
of inducing hypoxia, such as using hydralazine, are less
effective than clamping in enhancing the effect of bio-
reductive drugs both for growth delay and cell survival
assays. A feature of tumours which could affect bioreductive
drug therapy is the state of the tumour vascular bed. An
aspect of this has been studied by implanting KHT and
RIF-1 tumours into previously irradiated sites (15Gy).
Tumour growth rate is reduced and there is evidence that the
number of hypoxic cells increases. When treated with
RSU1069 and clamping, the growth delay induced is sub-
stantial. However, when the slower growth rate of the
untreated controls is considered, the overall response is no
different from that of tumours in unirradiated sites.
In vitro studies show that an 80% reduction of (control)
GSH, by BSO, produces a marked increase in the effect of
RSU1069. However when tumour GSH levels are reduced to
this level in vivo the enhancement of RSU1069 toxicity in
clamped and unclamped tumours is only slight.
Comparative effects of BW12C, hydralazine (HDZ) and
nicotinamide (NCT) on relative perfusion of RIF-1 tumour
and normal murine tissues
D.J. Honess & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
The haemoglobin (Hb) modifier BW12C at 70mgkg-1
(Wellcome) and the vasodilator HDZ at 5mgkg-1 both
increase tumour hypoxia; NCT at 1000mgkg-1 can radio-
sensitise some murine tumours. BW12C is thought to act
primarily by inhibiting 02 release from Hb; HDZ and NCT
by reducing or increasing tumour blood flow respectively.
All 3 drugs are potential modifiers of tumour response to
chemotherapy. To improve our understanding of the syste-
mic effects of the agents we have measured their effects on
relative tissue perfusion (RTP) assayed by 86Rb uptake





Leg tumour 400mm3 64a 26a 101
Leg tumour 800mm3 n.a. 12a n.a.
Flank tumour 400mm3 34a ga 104
Leg muscle 90 107 66a
Kidney 127a 64a 1Soa
aValue different from 100, bp<0.05; time after injection.
Tumour RTP is unaffected by NCT and reduced by
BW12C and HDZ, HDZ being more effective, and the
changes are size and site dependent. Hence reduction in RTP
may contribute to BW12C-induced tumour hypoxia. BW12C
and NCT increase kidney perfusion while HDZ reduces it,
suggesting that the half life of any renally cleared cytotoxic
agent may be changed by these drugs. The variation between
tissues indicates that tumour perfusion modifiers for combin-
ation with cytotoxic agents should be selected on the basis of
their effects in normal tissues at risk.
Biodistribution and molecular enzymology of SR 4233
reductive metabolism in mice
M.I. Walton & P. Workman
MRC Clinical Oncology Unit, Hills Rd, Cambridge
CB2 2QH, UK.
SR 4233 is the prototype of a novel class of benzotriazine di-
N-oxide bioreductive agents which show high selective cyto-
toxicity towards hypoxic cells. This probably results from
reductive bioactivation to toxic species. We have studied the
pharmacokinetics of SR4233 in mouse plasma, tumour, liver
and brain using an HPLC assay for SR4233 and its reduced
metabolites SR 4317 (2e) and SR 4330 (4e). A dose of
0.2mmolkg-1 i.v. (35.6pgg-1) produced peak plasma con-
centrations of about 20pgml-1. Elimination was biphasic
with a tl/23<2min and a t1/2p of 26.5+ 1.4min (mean+2 s.e.;
n=3). The AUCO was 13.6pgml -1h. Peak plasma con-
centrations of SR4317 were between 6-8pgml-'. The
apparent t1/2 was 43.3+12min and the AUC0 was
12.1 pgml 1h. Very similar results were produced after i.p.
administration. SR 4233 tumour/plasma ratios in im KHT
tumours were low at 34+12% (n=21) compared to
174+42% and 196+51% for SR 4317 and SR 4330 respec-
tively. Results for s.c. KHT, 16C, and RIF-1 tumours were
similar but SR4233 ratios were significantly reduced in s.c.
EMT6 tumours at 6.6+2.5% (P<0.01). Brain/plasma ratios
were similar to those in im KHT tumours. With time, SR
4233 liver/plasma ratios increased from 5-100% and SR
4330 ratios decreased from 1850-540%. Mouse liver micro-
somes readily reduced SR 4233 to SR 4317 under N2 in the
presence of NADH and particylarly NADPH. SR 4233
reduction was rapid, e.g. 266nmolmin-1 mg-1 protein at
2mM. SR 4233 was reduced predominantly by cyt P-450
with a more minor role for cyt P-450 reduetase. Buttermilk
xanthine oxidase catalysed this reaction but cytotosolic alde-
hyde oxidase did not. These results show that SR 4233 is
readily bioactivated via reduction in vivo and in vitro, and
are consistent with the expectation of extensive hypoxic
tumour cell killing.
The effects of bioreductive drugs on radiation sensitive cell
lines in vitro
A. Keohane, J. Godden, M.A. Stephens, L. Ding,
I. Stratford & G.E. Adams
MRC Radiobiology Unit, Chilton, Didcot, Oxon, OXJJ ORD,
UK.
We have used a group of cell lines (irs) selected for their
sensitivity to ionising radiation and assessed the effects of
Mitomycin C, RSU-1069 and SR-4233 under both aerobic
and hypoxic conditions. The cells were cloned from V79
fibroblasts (Jones et al., Mutat. Res., 1987, 183, 279) and
exhibit a range of sensitivity to ionising radiation in air.
Treatment of cells with RSU-1069 and SR-4233 resulted in
selective toxicity towards hypoxic cells. Hypoxic toxicities to
the irs cells were similar to those of V79's indicating that the476 THIRTIETH BACR AND FOURTH ACP MEETINGS
radiation sensitive cells have not lost their capacity to reduce
the drugs under anaerobic conditions. In air the mutant cells
are 10 x more sensitive than V79's which may be relat6d to
the hypersensitivity of these cells to radiation in air.
Levels of intracellular GSH can profoundly alter sensi-
tivity to drugs and radiation. The concentration of GSH in
the irs cells is 3 x lower than in V79. However, if this is
important it would also be expected to affect sensitivity to
the bioreductive drugs under N2 and is clearly not the case.
To further characterise these cell lines we have measured
radiosensitivity in N2 and radiosensitisation by misonidazole.
The OER is 3 and 1.7 in wild type and irsi cells respectively.
ImM misonidazole gives an ER of 1.7 in both cell lines.
Similar experiments are being carried out with RSU 1069 to
determine if the irs cells are also hypersensitive to the
radiosensitising action of this drug. (Supported by NCI grant
No. ROI CA44 126-01).
Comparison of uptake, free radical generation and cytotoxicity
of C1941 with doxorubicin in MCF-7 human breast cancer
cells
G.R. Fisher & L.H. Patterson
Dept ofPharmacy, Leicester Polytechnic, Leicester LEJ 9BH,
UK.
C1941 is an anthrapyrazole DNA complexing agent broadly
based on doxorubicin (DOX) and is currently undergoing
phase 1 clinical trials. The NAD(P)H dependent metabolic
reduction of DOX to an anthraquinone free radical inter-
mediate which concomitantly generates reactive oxygen spe-
cies from dioxygen (termed redox cycling) has long been
implicated in the cytotoxicity of this agent. This study
compares redox cycling by C1941 with doxorubicin in MCF-
7 cells and its relationship to cytotoxicity. Drug induced
redox cycling in MCF-7 S9 cell fraction was monitored by
X-band ESR spectroscopy, NADPH oxidation at 340 nm
and superoxide anion (2-) generation as Superoxide Dis-
mutase inhibitable reduction of acetylated cytochrome c.
Cytotoxicity was measured after 24h drug treatment of 105
exponentially growing cells and a subsequent 96h drug free
incubation. To measure drug uptake, MCF-7 cells were
incubated with drug (15 pM) for between 1-90min, the cells
centrifuged and the remaining supernatant analysed by
HPLC. The results show that the basal rate NADPH
oxidation (72+ 18pmolmin I mg protein-1) was stimulated
by DOX (11.5-fold) but was unaffected by CI 941. Basal rate
02- formation was undetectable in MCF-7 S9 but in the
presence of DOX (100yM) was 7.5nmolmin-1 mg protein-l
while C1941 showed no effect on 02- formation. Doxoru-
bicin produced a broad singlet ESR spectrum in both MCF-
7 S9 fraction and intact cells under anaerobic conditions.
However, C1941 did not generate an ESR signal under such
conditions. The cytotoxic concentration of C1941
(ED5= 1 nM) was considerably less than DOX (>40 nM)
while cell uptake after 90min for both drugs was between
45-50%. The results indicate that C1941 does not redox
cycle in MCF-7 cells although it is more cytotoxic than
doxorubicin in this cell line. It appears that although free
radical generation may be important in the mechanism of
cytotoxicity of DOX it is not related to the MCF-7 cell-kill
activity of C1941.
In vivo uptake of 1311-5-iodo-2-deoxyuridine by malignant
tumours in man
P.A. Philip, K.D. Bagshawe, F. Searle, R.H.J. Begent,
A. Green, E.S. Newlands & G.J.S. Rustin
Cancer Research Campaign Laboratories, Charing Cross
Hospital, London W6 8RF, UK.
5-Iodo-2-deoxyuridine (IUdR) is a synthetic analogue of
thymidine which is taken up by cells in the S-phase of the
cell cycle, being incorporated into newly synthesised DNA.
Labelled DNA (with IUdR) confers upon the cell reduced
viability and increased sensitivity to ionising irradiation and
UV light. IUdR uptake by normal cells results in many side
effects precluding its effective use in therapy. It has been
shown recently that selective uptake can be significantly
enhanced when mice bearing xenografts were pretreated with
hydroxyurea (HU) and antemetabolites. The former arrests
DNA synthesis in the normal cells (and sensitive tumour
cells) and the latter inhibits de novo thymidine synthesis
(Bagshawe et al., Br. J. Cancer, 1987, 55, 299).
26 patients with various malignancies, judged to be resist-
ant to conventional therapy, were investigated. HU 2.0g
twice weekly p.o. was given for 2-3 weeks to enhance
resistance of tumour cells. 5-Fluorouracil 200mgm 2 was
given i.v. at time Omin, followed by 600mgm-2 at time
30min. HU 3.0gm-2 was given i.v. at time 35min. 10-
15min later 131I labelled IUdR (5-lOmCi) was given i.v.
over 10 min. Planar imaging with a gamma-camera was
performed approximately 24 and 48 hours from administ-
ration of the radiolabelled IUdR. Thyroid blockade was with
KI 120mgtds for 7 days and KCl03 was given 200mgtds (4
days) to reduce secretion of iodide into the stomach.
13 (50%) patients showed positive uptake in at least one
disease site. Of the 43 known active disease sites only 15
(34.9%) exhibited uptake of radioactivity. Three out of 4
brain tumours showed significant uptake. Other sites of
uptake include liver, lung and pelvis, and a subcutaneous
nodule. No false positive images were encountered.
Enhancement of 1--p-D-arabinofuranosylcytosine (ARA-C)
metabolism and toxicity by pre-treatment with gallium
D.W. Hedley & E.H. Tripp
Ludwig Institute for Cancer Research, University of Sydney,
NSW 2006, Australia.
Gallium nitrate (NSC15200) has significant activity against
refractory lymphomas in man, while sparing normal prolifer-
ating tissues. We recently identified ribonucleotide reductase
as the probable main enzyme target (Hedley et al., Cancer
Res., 1988, 48, 3014). It has been previously shown that
inhibitors of this enzyme can enhance the metabolism and
toxicity of ARA-C, and we therefore examined the inter-
action of gallium and ARA-C in CCRF-CEM human T-
lymphoblasts. Pre-treatment for 24 h with a cytostatic
(480pm) concentration of gallium increased the percentage
of cells in S-phase from 44 to 66%, as determined by DNA
flow cytometry. There was a fall in the size of the dCTP
pool from 27 to l9pmol 10-6 cells, and the activity of the
salvage enzyme deoxycytidine kinase (which is feedback
inhibited by dCTP) increased from 29.8 to 62.4pmolh-1
10-6 cells. Uptake of 5pM 3H-labelled ARA-C was mea-
sured using the method -of Plagemann et al. (Cancer Res.,
1978, 38, 978). Pre-treatment with gallium approximately
doubled the rate of isotope incorporation. Separation of 3H-
ARA-C metabolites using thin layer chromatography showed
that 86% was present as ARA-CTP with gallium pre-
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incubation of cells with cytostatic concentrations of gallium
and ARA-C showed that the combination was more toxic
than either agent alone. These results are further evidence
that gallium acts primarily as a ribonucleotide reductase
inhibitor, and suggest that a gallium/ARA-C combination be
tested in patients with refractory lymphomas.
Cisplatin induced mutation frequencies in human tumour
cell lines
C.N. Parris & J.R.W. Masters
Institute of Urology, University College London, St Paul's
Hospital, London WC2H 9AE, UK.
Drug resistance rarely develops in testicular tumours
(TGCT) and 80-90% of metastatic TCGT are cured. How-
ever chemotherapy is mutagenic and can induce drug resis-
tance (Kerbel & Davies, Lancet, 1982, ii, 977). Therefore one
explanation for the curability of TGCT is that they are less
mutable than other solid tumours, such as bladder cancer.
We compared spontaneous and cisplatin-induced mutation
frequencies (MF) at the hypoxanthine guanine phosphori-
bosyl transferase (HGPRT) locus in two bladder (RT4,
RTI 12) and two testicular (833K, SuSa) cancer cell lines.
Following a 1 h exposure to an equimolar concentration of
cisplatin (4/ugml-1) and concentrations reducing survival by
50% in all cell lines (IC5,,), MF were compared (see table).
Mutation frequency x 10- 6
surviving cells
Spontaneous Induced MF induced MF
Cell type MF @ 4ygml-' @ IC50
RT112 11.5+5.5 55+35 55+35
RT4 4.3+0.3 4.3+0.2 5.2+1.4
833K 3.8+0.5 13.2+1.5 6.0+1.2
SuSa 4.6+0.3 9.5+1.5 4.5+0.3
P=0.462 P=0.546 P=0.462
These data indicate that MF are similar in testicular and
bladder cancer cells, and do not account for differential
sensitivity between these tumour types. However, following
the same dose of cisplatin, fewer testicular tumour cells
survive so fewer mutants develop, perhaps indicating why
testicular tumours rarely develop resistance.
A bispecific monoclonal antibody against methotrexate and
a human tumour associated antigen: antibody production
purification and characterisation
M.V. Pimm, R.A. Robins, E. Jacobs, A.J. Markham,
A.D. Curran & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, NG7 2RD, UK.
The development of monoclonal antibodies reactive with
human tumour-associated antigens has led to interest in their
use as targeting agents to deliver therapeutic agents to
tumour sites. One approach is to produce hybrid bispecific
antibodies, one combining site of which reacts with tumour
associated target antigen and the other with the therapeutic
agent. In the present study a bispecific monoclonal antibody,
reactive with methotrexate (MTX) and a tumour associated
gp72 antigen has been produced by fusing spleen cells from
MTX-HSA immunised mice with the existing 791T/36
hybridoma.
The hybrid antibody had gamma-1 and gamma-2b heavy
chains from the parent anti-MTX splenocyte and 791T/36
hybridoma respectively. It was purified from anti-MTX and
anti-gp72 antibodies in the hybridoma culture supernatant
by combinations of affinity chromatography on MTX-
agarose and step-wise acid elution from Sepharose-protein
A. In competitive ELISA assays, binding to MTX-HSA was
inhibited by excess MTX-HSA but not by HSA. Free MTX
and aminopterin inhibited binding, but much less efficiently
than the equivalent amount of MTX as MTX-HSA conju-
gate. In reaction against tumour cells, hybrid antibody, but
not the anti-MTX, reacted with gp72 positive 791T cells and
not with antigen negative (Colo-205) cells as detected by
subsequent reaction with fluorescein labelled anti-mouse
IgG. Simultaneous dual binding between tumour cell surface
antigen and MTX was demonstrated by the ability of hybrid
antibody to bridge between 791T tumour cells and MTX as
MTX-HSA conjugate, reaction here being detected with
fluorescein labelled anti-HSA antiserum.
These studies indicate the potential of this bispecific
antibody for improving therapeutic efficacy of MTX. The
reaction with conjugated rather than free MTX could be an
advantage since targeting of conjugates would be expected to
increase many fold the number of molecules of drug carried
by or localizing in pre-targeted antibody. The effect of the
hybrid antibody on the cytotoxicity of MTX and MTX-HSA
for gp72 positive tumour cells is now being investigated
(Embleton et al., next abstract).
Selective cytotoxicity against tumour cell lines mediated by
a bispecific monoclonal antibody and a methotrexate albumin
conjugate
M.J. Embleton, M.V. Pimm, R.A. Robins, A.J. Markham,
A. Charleston & E. Jacobs
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
A bispecific monoclonal antibody reactive with methotrexate
(MTX) and a tumour-associated gp72 antigen was tested for
ability to modify the cytotoxic effects of MTX and MTX-
human serum albumin conjugate (MTX-HSA) against gp72-
positive and gp72-negative tumour cell lines using a 75Se-
selenomethionine incorporation cytotoxicity assay. In some
tests the drug or conjugate was titrated against a fixed
concentration of antibody, and in others the antibody was
titrated against a single concentration of the cytotoxic agent.
The bispecific antibody did not influence the cytotoxic
effect of free MTX at high or low doses on either antigenic
or non-antigenic cell lines. However, it enhanced the cyto-
toxicity of MTX-HSA (normally much lower than MTX)
against gp72-positive cell lines. At low antibody and high
MTX-HSA concentrations augmentation was weak, but anti-
body at saturating levels produced significant cytotoxicity
using MTX-HSA at a concentration too low to be cytotoxic
in its own right. Monoclonal antibodies against MTX or
gp72 alone had no consistent effect, and bispecific antibody
was inactive in the absence of MTX-HSA. The combination
of bispecific antibody and MTX-HSA appeared to result in
capture and delivery of an optimum number of MTX
molecules, consistent with the greater affinity of antibody
with conjugated rather than free drug and the large number
of drug residues per molecule of conjugate. Targeting of
relatively non-toxic conjugates by pre-localised bispecific
antibody might be a valid approach for anti-tumour therapy.478 THIRTIETH BACR AND FOURTH ACP MEETINGS
Tumour localisation of 791T/36 Fab/c fragment compared to
whole antibody
venous blood. Colorectal cancer may down regulate function
of T lymphocytes circulating through the tumour.
S. Demignot, M.C. Garnett & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
Fab/c, a monovalent antibody fragment containing Fab and
Fc regions, was shown to have a similar half life to whole
antibody (BACR, Dec. 1988), but it showed a faster equili-
bration and greater extravasation. The maximum binding of
the Fab/c fragment was 10-30% compared to 70% for
whole antibody as measured by assay of immunoreactivity at
infinite antigen excess. We now report an experiment to
determine the tumour localisation of this fragment in nude
mice bearing 791T (antigen positive) and Colo 205 (antigen
negative) xenografts. At 72 hours the tumour to blood ratio
for antibody was 1.7 and for Fab/c fragment 1.2 in the 791T
xenograft compared to 0.6 in the Colo 205 xenograft.
Expressed as % injected dose per g tumour, both antibody
and Fab/c showed a similar uptake with a maximum at
about 5-6%. In tumour bearing mice the serum half life of
the whole antibody was slightly less than the Fab/c fragment
and there was some uptake of whole antibody, but not
Fab/c, to liver and spleen (antibody tissue to blood ratios of
0.5 and 1.5 respectively). These differences between antibody
and Fab/c distribution may be due to a small amount of
circulating antigen causing some antibody but not Fab/c
uptake to liver and spleen. Despite its lower affinity Fab/c
shows good tumour localisation. The lower molecular weight
and monovalency of this fragment may be an advantage for
antibody targeting by permitting better tumour penetration
than whole antibody.
The effect of colorectal carcinoma on T-lymphocytes
circulating through the tumour
K.M. Rigg, B.K. Shenton, R.M.R. Taylor &
T.W.J. Lennard
University Department of Surgery, The Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Malignancy is known to depress the host immu
To determine if passage of lymphocytes through
affected their number and function, 11 patients
curative resection for colorectal cancer were
operation blood was taken from the artery su
vein draining the tumour. Separated lymphocyti
artery and vein were stimulated with the T-c
phytohaemagglutanin (PHA) for 72 hours,
lymphocyte transformation (LT) was measured I
tritiated thymidine. Using monoclonal antibodi
cytometry, the percentages of CD3(T), CD8(T
cytotoxic) and CD4(T helper) cells in the tota
lymphocyte population, along with basal an(
interleukin-2 receptor (I1-2R) were enumerated
are expressed as median (range).







aP<0.04 (paired t test).
There was a significant decrease in lymphocyl
ation following passage of lymphocytes through
but there was no significant difference in T




The role of oligosaccharide side-chains in the blood clearance
of antibody-toxin conjugates
A.J. Cumber, G.D. Parnell, R.V. Henry, J.A. Forrester &
E.J. Wawrzynczak
Institute of Cancer Research, Sutton, Surrey SM2 5NG,
UK.
The rate of blood clearance of a panel of antibody-toxin
conjugates made by linking different ribosome-inactivating
proteins to the monoclonal antibody Fib75 was monitored
after intravenous administration to rats. Fib75-ricin A was
rapidly lost from the circulation because of the preferential
uptake of a proportion of molecules bearing oligomannose
side-chains by the liver. In contrast, a Fib75 conjugate made
with the purified Al-chain of ricin, which contains a single
complex-type oligosaccharide side-chain, was not rapidly
cleared and persisted in the bloodstream for a prolonged
period of time (A.J. Cumber et al., Biochem. Soc. Trans.,
1989, 17, 137).
The clearance rates ofFib75 conjugates made with ricin Al-
chain, gelonin and momordin, each containing a single
oligosaccharide side-chain, were similar. However, these
conjugates disappeared from the circulation more rapidly
than a Fib75 conjugate made with abrin A-chain which is
not glycosylated. A Fib75 conjugate made with gelonin which
had been chemically treated to destroy carbohydrate residues
persisted in the bloodstream longer than Fib75-gelonin sug-
gesting that recognition of oligosaccharide side-chains of a
type other than the oligomannose type may accelerate
clearance.
Human small cell lung cancer antigen recognised by
monoclonal antibody SWAll mediates immunotoxin
cytotoxicity
E.J. Wawrzynczak, R.V. Henry, G.D. Parnell &
E.J. Derbyshire
Institute of Cancer Research, Sutton, Surrey SM2 SNG,
UK.
studied. At The potential of mouse monoclonal antibodies raised against spplying and human small cell lung cancer (SCLC) to form cytotoxic
es from both conjugates with ricin A-chain was tested using an indirect
well mitogen assay. The classic SCLC line HC12 was first treated with a
after which saturating concentration of anti-SCLC monoclonal antibody,
by uptake of washed to remove unbound antibody and then incubated
ies and flow with goat anti-mouse immunoglobulin (GAMIg) Fab' frag-
suppressor/ ment linked by a disulphide bond to a single molecule of
l circulating ricin A-chain. At a non-toxic concentration of GAMIg Fab'-
d stimulated ricin A, protein synthesis by HC12 cells pretreated with the
The results SWAI1 monoclonal antibody (Smith et al., Lung Cancer,
1988, 4, suppl., A12; Smith et al., Br. J. Cancer, 1989, 59, in
the press) was decreased to less than 20% of that in
untreated cell cultures. In contrast, there was no significant
rim. I-2R (%) inhibition of protein synthesis in cells exposed to SWAl1
73 (39-91) alone or in cells pretreated with isotype-matched antibodies
70 (28-88) (binding to antigens other than that recognised by SWAl1)
and then incubated with GAMIg Fab'-ricin A. Our experi-
ments indicate that the SCLC antigen recognised by SWAl1
te transform- mediates the internalisation of ricin A-chain via a route
the tumour, leading to cell intoxication and is a suitable target for the
lymphocyte development of ricin A-chain immunotoxins with selective
arterial and cytotoxicity to human SCLC.THIRTIETH BACR AND FOURTH ACP MEETINGS 479
Theoretical studies on combined mIBG/TBI therapy of
neuroblastoma micrometastases
J.A. O'Donoghue, T.E. Wheldon, A. Barrett, J.W. Babich,
J. Moyes & S. Meller
Beatson Oncology Centre, Belvidere Hospital, Glasgow
G31 4PG; and The Royal Marsden Hospital, Sutton,
Surrey SM2 5PT, UK.
Measurements of M125IBG uptake in surgically excised
samples of neuroblastoma from 6 patients were used to
assess absorbed dose to micrometastases. Doses to achieve a
50% probability of cure were calculated using a simple
analysis. Two categories were examined: (a) absorbed dose
greater than 50% cure dose; (b) absorbed dose less than
50% cure dose. The number of patients falling into each
category depends on the tumour size and on the radionuclide
half-life in the tumour. For a 1 mm diameter tumour the
number of category (a) patients increases from 0 (t1/2 = 1.2
days) to 4 (t1/2=8 days). MIBG is less effective for smaller
tumours due to the reduced absorption of the beta-energy
from 1311. For a 0.2mm diameter tumour the number of
category (a) patients increases from 0 (t1/2=1.2 days) to 2
01/2=8 days). The use of mIBG in combination with total
body irradiation (TBI) and autologous bone marrow rescue
was investigated. For a 1 mm tumour the number in category
(a) increases from 3 (t1/2= 1.2 days) to 5 (t1/2=8 days). For a
0.2mm tumour all 6 patients remain in category (a) for the
full range of tumour half-times considered. Tumour doses
with combined mIBG/TBI are significantly higher than
achievable with either modality alone. Additionally, the two
modalities complement each other as TBI is relatively more
effective at eliminating small (<1 mm) micrometastases and
single cells whereas in mIBG is better for larger (>, 1mm)
micrometastases.
Radioimmunoimaging and CT in malignant melanoma
A.T. Elliott, R.M. MacKie, T. Murray, V.R. Doherty,
G. Gillen & F.G. Adams
Depts of Clinical Physics, Dermatology and Radiology,
Western Infirmary, Glasgow Gil 6NT, UK.
A monoclonal antibody raised against the high molecular
weight melanoma antigen was labelled with indium-111 and
injected intravenously into 25 patients with malignant mela-
noma. The results obtained from images at 24 and 96 hours
post i.v. administration of the antibody were compared with
results obtained from computerised tomography studies with
regard to detection of previously unrecognised sites of
metastatic disease and apparent false positive localisation.
Detailed study of the patients' clinical condition and detec-
tion rates using the two methods suggests that both methods
detect approximately 80% of clinically and pathologically
confirmed metastases. Of 62 known metastases, the antibody
detected 60 (81%), with 17 false positive results. False
negatives were most common in the lung. In 8 patients the
two methods were considered of equal value, in 10 the
monoclonal gave a greater amount of clinically relevant
information, and in 7 the CT was superior. In three patients
clinically significant metastatic lesions were detected by the
radiolabelled monoclonal which had not been previously
recognised either by CT scanning or on clinical grounds.
No patients had any adverse reaction to the antibody and
in the course of our study the dose of antibody was reduced
from 20mg to 200mg with no apparent loss of sensitivity. In
at least 2 patients uptake of the labelled monoclonal into
tumour sites would have been adequate for effective targeted
radiotherapy.
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The interaction of cellular factors with the NCR of HPV16
G.J. Sibbet & M.S. Campo
Beatson Institute, Glasgow, UK.
The progression of human papillomavirus 16 associated
cervical intraepithelial neoplasia (CIN) to cancer is fre-
quently accompanied by chromosomal integration of the
viral genome. The cell line SiHa, derived from a cervical
squamous cell carcinoma, contains a single integrated copy
of HPV16.
We have mapped a complex pattern of nuclease hyper-
sensitive sites (HSS), covering -500bp, at high resolution in
SiHa chromatin to the tissue specific enhancer within the
HPV16 non coding region (NCR). DNase footprinting (FP)
of cloned DNA in vitro confirms the presence of cellular
transacting factors (CTAFs) in SiHa nuclear extract with
binding specificity for at least 13 sites in the HPV16
enhancer. The majority of FPs contain the consensus
T/AGGCT/A, which is analogous to both the specific cyto-
keratin and ubiquitous CCAAT box motifs. However, the
bound CTAFs found in nuclear extracts of SiHa as well as
CaSki and HeLa are also found in non-epithelial K562 and
MRC5 cells and appear to be related to the CCAAT box
binding C/EBP but not to NFI/CTF, NFY or NFY*/CRF.
One of the nuclear HSS in the HPV16 enhancer in SiHa
contains overlapping DNA motif binding sites for API,
C/EBP and glucocorticoid receptor (GR).
We are currently determining how these factors compete
for their overlapping binding sites and how this effects the
regulation of HPV16 in SiHa and cervical neoplasia.
This work was funded by the Cancer Research Campaign.
The Harvey ras gene is activated in
papillomavirus-associated carcinomas of the upper
alimentary canal in cattle
M.S. Campo, I. Doherty, R. McCaffery, L.W. Coggins &
I.M. Kennedy
The Beatson Institute for Cancer Research, Garscube Estate,
Switchback Road, Bearsden, Glasgow G61 IBD, UK; and
The Institute of Virology, The University of Glasgow,
Church Street, Glasgow G12, UK.
The possible activation of ras sequences in papillomavirus-
associated carcinomas of the upper alimentary canal of cattle
was investigated by restriction enzyme and hybridisation
analysis, and by DNA-mediated transformation of NIH 3T3
cells. The DNA from three cancers, two squamous cell
carcinomas of the palate and the rumen, and one transitional
cell carcinoma of the urinary bladder, showed anomalous
restriction patterns for the c-Ha-ras sequences, indicating
rearrangements and, in the case of the palate cancer, amplifi-
cation. Cancer DNA was capable of inducing focus forma-
tion in the NIH 3T3 test. DNA from primary transformants
was used in a second round of transformation and secondary
transformants were analysed. Bovine Ha-ras sequences were
detected in all transformants. In addition, high levels of ras
transcripts were observed in several cancers. It is concluded
that the Ha-ras gene is activated in alimentary canal carci-
nomas and the possible relationship between papillomavirus
infection and activation of the ras gene is discussed.
This research was funded by the Cancer Research
Campaign.